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Zusammenfassung 
Myxobakterien sind außergewöhnliche Bodenbakterien und vielseitige Produzenten von 
zahlreichen biologisch aktiven Naturstoffen. Ziel dieser Arbeit war die Charakterisierung von 
neuen Sekundärstoffen dieser gleitenden Bakterien. 
Im Rahmen dieser Arbeit wurde das Sauerstoff- und Licht- empfindlichen Roimatacene (26) 
aus dem Rohextrakt von Cystobacter ferrugineus Stamm Cb G35 auf Grund einer Aktivitäts-
basierten Isolierung identifiziert. Die milde Isolierungsstrategie beinhaltete neben weiteren 
Stabilisierungstechniken die Zugabe des Radikalfängers 4-Ethoxyphenol. Die relative 
Konfiguration von 26 wurde mit Hilfe von Rychonovsky´s Acetonid Methode sowie 1D und 
2D NMR Studien in Kombination mit Molekulardesign hergeleitet. Anschließend wurde die 
absolute Konfiguration mit der Mosher Methode bestimmt. Der Stamm Cb G35 produzierte 
zusätzlich sechs p-Hydroxyacteophenon Amide 34a-f. Die biologischen Vorstufen von 
Roimatacene (26) und p-Hydroxyacetophenon iso-Butanamid (34a) wurden durch 
Fütterungsexperimente mit den D, 13C und 15N-Isotopenmarkierten Vorstufen ermittelt. 
Die Strukturen der myxobakteriellen Sulfangolide 25a-d wurden mit Hilfe ihrer NMR Daten 
verifiziert. Durch detaillierte NMR Analysen und dem Vergleich der modellierten 13R* und 
13S* Diastereomere von Sulfangolid C (25c) wurde die relative Konfiguration als all-trans 
13R*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* hergeleitet. Zusätzlich wurden die 
biosynthetischen Vorstufen von 25c durch Fütterungsexperimente bestimmt. 
     
Abstract 
Myxobacteria are an extraordinary group of soil bacteria and versatile producers of numerous 
biologically active natural products. The aim of the thesis was the characterisation of novel 
secondary metabolites from these gliding bacteria. 
An activity guided isolation procedure for the oxygen- and light-sensitive roimatacene (26) 
from the crude extract of Cytsobacter ferrugineus strain Cb G35 was developed. The mild 
isolation strategy included among other stabilization techniques the addition of the free 
radical scavenger 4-ethoxyphenol. The relative configuration of 26 was establishing by 
applying Rychonovsky´s acetonide method combined with 1D and 2D NMR studies and 
molecular modelling. The absolute configuration of 26 was assigned by Mosher´s method. In 
addition, strain Cb G35 was found to produce a family of six p-hydroxyacetophenone amides 
34a-f. The biosynthetic precursors of roimatacene (26) and p-hydroxyacetophenone iso-
butanamide (34a) were studied by feeding experiments with D-, 13C- and 15N-labelled 
precursors. 
The structures of the myxobacterial sulfangolids 25a-d were verified from their NMR data. 
The relative configuration of sulfangolid C (25c) was derived by detailed NMR analyses and 
comparison of the modelled 13R* and 13S* diastereomeres of 25c to finally establish the 
relative all-trans 13R*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* configuration. The 
biosynthetic precursors of 25c were studied by feeding experiments. 
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1 Introduction 
1.1 The Role of Natural Products in Drug Discovery 
Human medicine has been revolutionized by the application of natural products, which have 
assisted to double the life expectancy from 40 years to more than 77 years in the 20th century.1 
1.1.1 Natural Products as a Source for Drug Development 
The influence of natural products in medicine is enormous. By 2002 over 60% of the 
approved drugs were derived from natural products as a drug themselves, derivative or as lead 
structure.2 The power of Nature is already known for centuries. As one example, Hippocrates 
described the use of willow tree bark extracts against fever and pain in the 5th century B.C..3 
However it is just 200 years ago that morphine was isolated from opium introducing purified 
drugs from plants in drug application.1 It was as late as the 1870s that microorganisms were 
recognized for their therapeutic potential, and it took until 1929, when Alexander Flemming 
published his observation that Penicillium notatum inhibited the growth of Staphylococcus 
aureus. Ten years later the first stable penicillin was described and started the industrial 
production of penicillin during the Second World War. The antibacterial use of penicillin in 
human and animal medicine initiated the golden age of antibiotics, and different classes of the 
“wonder drug” were identified until the 1980s.4 All antibiotics are classified according to their 
structural relations and targets. The commercial antibiotic classes include the most important 
β-lactams, quinolones, tetracyclines, macrolides, aminoglycosides, ansamycins, glycopeptides 
and polypeptides.5 A number of examples of the antibiotic classes are presented in Figure 1. 
The golden age of antibiotics lead to the assumption that infectious diseases were no longer 
life threatening. But today resistances among microbes from hospital and community-
acquired pathogens are continuously rising and infectious diseases have become the third 
major cause of death in developed nations again.6,7 S. aureus isolates resistant to penicillin G 
were already found in the 1940s and today virtually all S. aureus isolates are resistant to β-
lactam antibiotics.8 The number of “superbugs” resistant to nearly all antibiotics has increased 
enormously among hospital and also community-acquired pathogens in the last years. 
Abesides S. aureus isolates resistant to methicillin and glycopeptides, the vancomycin and 
multidrug resistant enterococci sp. and multidrug resistant Gram-negative bacteria as e.g. 
Pseudomonas aeruginosa are the new threats in infectious diseases with high mortality rates.7 
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Figure 1.  Examples of different antibiotic classes (class and targets are given in parentheses): penicillin 
G (1, β-lactame; transpeptidase cell wall); vanosamin (2, glycopeptide, cell 
wall); chlortetracycline (3, tretracycline, 30S-ribosome); erythromycin A (4, macrolide, 50S-
ribosome); sulfamerazin (5 , sulfonamide, nucleic acid synthesis); streptomycin (6, 
aminoglycoside, 30S ribosome); moxifloxacin (7, quinolone, gyrase inhibitor); polymyxin B 
(8, polypeptides, cell membrane). 
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1.1.2 Drug Development 
New drugs and cellular targets are urgently needed to fight multidrug-resistant pathogens like 
MRSA, VRE and Pseudomonas aeruginosa.9 The combination of combinatorial chemistry 
and high-throughput-screening (HTS) has failed to meet these demands over the last 25 
years.10 Due to the high development cost and fast development of resistances, large 
pharmaceutical companies have abandoned their antibiotic research programs leaving this 
field to biotechnology companies and universities.11 
Figure 2.  Chemical processes involved in natural product discovery: Starting from a biologically active 
sample, avoiding replication, purification and characterization of the active natural product, 
carrying out structure-activity relationship (SAR) studies to finally develop a lead compound.12 
The combination of synthetic libraries and HTS enabled a fast screening of numerous 
compounds, which were easily available through chemical synthesis. The low “hit rate” of 
purely synthetic libraries of < 0.001% induced the screening of privileged libraries, which are 
based on biological active drugs.13-15 Although purified natural products can be applied in 
HTS, the purification costs of complex extracts resulting from fermentation of microorganism 
or other natural sources are extremely high. The identification of an active secondary 
metabolite from a complex fermentation mixture and the effort associated with isolation and 
identification are challenging. Known antibiotics, as for example streptomycin, can mask 
other biological activities in crude extracts and it occurs in 1% of soil actinomycetes.1 
Separation techniques like high-performance liquid chromatography (HPLC) can reduce the 
complexity of crude extracts before applying biological assays. The combination of HPLC 
and high-resolution mass spectrometry can avoid replication of known secondary metabolites. 
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The biological test systems differ from whole-cell screenings, for example conducted with 
MRSA strains as well as hypersensitive mutants for the identification of selective protein-
inhibitors,16,17 as well as target specific biochemical assays, like enzyme-linked 
immunosorbent assays (ELISA) for kinases activity.18 Natural products are complex 
structures with a high number of oxygen-containing substituent and stereocentres.19 For these 
reasons, an unambiguous identification is time consuming and larger amounts of material are 
essential (Figure 2). Therefore, the supply has to be secured in order to successfully 
accomplish the verification and development of a drug candidate through medicinal 
chemistry.12 
In order to provide the necessary amount of metabolite, different microbiological techniques 
that include feeding strategies, mutagenesis and up-scale fermentation are necessary. For 
example, optimized producer strains are capable of synthesizing 1.8 g/L of penicillin, which 
reduced the costs from 11.000 $/kg penicillin in 1945 to 4.5 $/kg 50 years later.4 After 40 
years of “brute force” genetics to improve production, combinatorial biology with genome-
based strain reconstruction and heterologous expression are the new tools to increase the 
biotechnological out-put of “biological engineers”.4 
Today a large number of biologically active natural products are known, but only one out of 
10,000-150,000 compounds is of medical use. One out of 3,600 active candidates from 
pharmaceutical screenings is developed further, and only three functional antibiotics were 
found in a screening of 400,000 microorganisms over 10 years. Five out of 5,000 compounds 
approached clinical trials, while only one was approved by the FDA.5 
Figure 3.  Current status of antibiotic R&D activity at each development stage (source IMS Health 
2009).20 
Introduction 
- 5 - 
Figure 3 presents the current status of the development of new antibiotics. In 2009 there were 
152 candidates in preclinical testing, but such a low number as 52 candidates were in clinical 
phase I/II and III. The five candidates in pre-registration are ceftobiprole (new class of 
cephalosporin, Basilea Pharmaceutica), dalbavancin (glycopeptide, Pfizer), iclaprim 
(dihydroholate reductase inhibitor, Arpida) and oritavancin (glycopeptide, the Medicines 
Company). Some of these were especially designed against resistant pathogens and the 
majority is targeting MRSA.20 
1.2 Myxobacteria: a Promising Source for Secondary Metabolites 
“Myxobacteria are a rich source of novel structural ideas.”21 
1.2.1 The Social Life of Myxobacteria 
Myxobacteria belong to the Gram-negative bacteria allocated at the delta branch of the 
Proteobacteria. They have rod-shaped vegetative cells about 4-12 µm long and 0.7–1.2 µm 
wide. Myxobacteria were first recognized by their extraordinary and sophisticated social life: 
they live in swarm colonies, which move by gliding over surfaces (Figure 4a).22 They have a 
remarkable intercellular communication system for swarming in colonies and forming 
myxospores upon starving conditions.23 The formation of fruiting bodies guarantees the start 
of a new life cycle as a swarm rather as an individual cell. The fruiting bodies can have simple 
shapes of soft slime balls like Myxococcus fulvus (Figure 4b) or complex structures as the 
trees of the Chondromyces crocatus (Figure 4c), which consists of a brown slime stalk and 
bright yellow sporangioles. Fruiting bodies come usually in bright colours of yellow, orange, 
red, brown, or black and measure 20-1000 µm. 
 
Figure 4.  (a) Swarming colony of Sorangium cellulosum from cellulose paper on agar, fruiting bodies of 
(b) Myxococcus fulvus and (c) Chondromyces crocatus (pictures by K. Gerth, HZI). 
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Living in large colonies is indispensable for myxobacteria. They are commonly known as soil 
bacteria, even though some halo-tolerant myxobacteria were isolated from the marine 
environment of the Pacific.24,25 The environment, from which the majority of myxobacteria 
were isolated, is rich in organic matter providing sufficient nutrition of soil, rotting plant 
material or dung of various animals as well as other microorganisms.26 Myxobacteria are 
specialized in degrading biomacromolecules, like cellulose or other bacteria and fungi, using 
extracellular enzymes. 
These environmental niches are not only rich regarding nutrition, but also accommodate 
numerous microbial inhabitants. For this reasons myxobacteria are not only interesting 
organisms for studying their remarkable life style, but are also a rich source for structurally 
novel secondary metabolites with new modes-of-action that are excreted from their 
biochemical defence systems in order to protect themselves against other predators such as 
bacteria or fungi.21,27,28 
1.2.2 Secondary Metabolites from Myxobacteria 
During a screening of 1700 Sorangium cellulosum strains about 90% of the extracts were 
found to be biological active. Some secondary metabolite families were frequently found 
during this screening, like icumazole (9) (unpublished data R. Jansen, H. Irschik, HZI), and 
spirangien (10),29 while others are relatively rare, e.g. jerangolid (11)30 was synthesised by 
only 4 producer strains (Figure 5).31 The immense biological activity and high diversity of 
secondary metabolites from myxobacteria is presumably due to their microorganism-rich 
habitat. In the three decades of myxobacterial research approximately 7500 strains have been 
isolated at the Gesellschaft für Biotechnologische Forschung (GBF, today Helmholtz Centre 
for Infection Research, HZI) and about 100 distinct core structures (about 67 have been 
published) and about 500 derivatives have been isolated.28 
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Figure 5.  Frequency of selected secondary metabolite families in the screening of 1700 strains of the 
genus Sorangium cellulosum.31 
At the time of their publication 40% of these secondary metabolites had a completely new 
structural carbon skeleton, while others were still new but contained structural elements 
previously known from other microorganism as Streptomyces or marine microorganism 
(sponges, tunicates and mollusks).21 Myxobacterial secondary metabolites not only possess a 
high structural diversity, as the few examples in Figure 6 show, but exhibit remarkable new 
modes-of-action.28 The soraphen family (12) for example was found to inhibit the growth of 
yeasts and molds (MIC 0.03-4 µg/mL) by selectively targeting fungal acetyl-CoA 
carboxylase.32 Field trials with soraphen against numerous plant pathogenic fungi were 
carried out in cooperation with Ciba-Geigy, although its teratogenic activity prevented a 
commercial application as antifungal agent.31 
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Figure 6.  Examples of the structural diversity of myxobacterial secondary metabolites: 
icumazole A (9), spirangien A (10), jerangolid A (11), soraphen A1α (12), sorangicin A (13), 
myxopyronin A (14), corallopyronin A (15), epothilon B (16), tubulysin (17), agyrin F (18). 
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Other antimicrobial metabolites proved to be active against known targets, but established a 
new mode-of-action: the myxobacterial antibiotic myxopyronin (14)33 and 
corallopyronin(15)34,35 bind to bacterial RNA polymerase (RNAP) as do the rifamycins36 and 
sorangicins (13),37,38 but show a different mode-of-action. Figure 7 shows the mode-of-action 
of myxopyronin (15) at the switch region of RNAP, which inhibits the opening of the clamp 
needed for DNA transcription.39 
 
Figure 7.  Initiation of RNA polymerase (RNAP) transcription: the RNAP can open (B) and close (A) by 
a 30° rotation of the clamp domain (cyan) at the switch region. The clamp is open (B) in order 
for DNA to bind to the catalytic cleft (C), before the clamp is closed (D) and transcription is 
promoted. Myxopyronin binds in the switch region and inhibits opening the clamp (E).40 
Astonishingly, 10% of myxobacterial metabolites specifically interact with the cytoskeleton 
of eukaryotes.21 Epothilon (16) was found to stabilize microtubule formation in eukaryotic 
cells. Consequently a semi-synthetic azaepothilon B was developed by Bristol-Myers Squibb 
(Ixempra®) and is used currently as an antineoplastic agent against Paclitaxel-resistant 
tumours.41-43 In contrast to the microtubule stabilization of epothilon (16), the highly affective 
antimitotic peptide tubulysin (17) dissolved microtubules (IC50 of 0.01-10 nM).44 Further 
investigation of the tubulysin family revealed 23 natural metabolites as well as the initial 
enzyme-free derivative pre-tubulysin.45,46 Various synthetic approaches lead to optimized 
tubulysin–folate conjugates specifically targeting folate-receptor enriched tumours with 
especially good in vivo activity and favourable toxicity profile as drug candidates.47-49 An 
additional myxobacterial compound for therapeutically application against intestinal cancer is 
the proteasome inhibitor (protein p27) argyrin (18) which is currently under investigation.50 
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The last three decades of research have demonstrated that myxobacteria are a rich source of 
potent natural products. The number of myxobacteria-derived secondary metabolites 
established these microorganisms as multiproducers comparable with the Cyanobacteria, 
Actinomycetales (~ 8000 compounds), Bacilli (1400 compounds) and Pseudomonads (400 
compounds). Genome analyses of myxobacteria indicate that the isolated 100 core structures 
just scratch the surface of the true potential of these bacteria.51 With 13.0 Mbp the genome of 
Sorangium cellulosum So ce56 is the largest bacterial genome known.53 The genome of the 
model strain DK1622 from Myxococcus xanthus assigns more than 8.5% to natural product 
synthesis.54 A study comparing the metabolic profiles by liquid chromatography coupled mass 
spectrometry (LC-MS) analysis of 98 M. xanthus strains collected worldwide insinuated the 
numbers of non-ubiquitous compounds per strain ranged from 6 to 24 metabolites.55 
1.3 Structure Elucidation of Natural Products 
“Indeed, structural miss-assignments clearly provide opportunities for synthetic chemists to 
make discoveries through total synthesis, and certainly show that there is still adventure to be 
had in the process of structure assignment.”56 
1.3.1 Structure Elucidation of Natural Products by 1D and 2D NMR Spectroscopy  
Nuclear magnetic resonance (NMR) spectroscopy is the most important method for structure 
elucidation of natural products combined with high resolution mass (HRMS) spectrometry. 
Improvement of hardware and development of multi-pulse sequences for NMR techniques 
(discussed below) in the last years has made NMR spectroscopy a powerful tool in structure 
elucidation of unknown complex natural products. The ultimate tool for molecular structure 
determination will remain X-ray crystallography, but suitable monocrystals of X-ray quality 
are rare in natural products research.57 NMR technology has been dramatically improved over 
the last decade through the use of superconducting cryogenic probeheads, superconducting 
cryogenic high-field magnets (1000 MHz) and smaller sample volumes (30 µL) to enhance 
sensitivity.58 The new NMR hardware enabled liquid chromatography coupled NMR (LC-
NMR) analysis for fast dereplication in high-throughput-screenings (HTS). This approach has 
recently been further improved by Bruker Biospin, who have developed a post column-solid-
phase-extraction unit (LC-SPE-NMR/MS) coupled HPLC/NMR/MS system in order to 
reduce costs and accumulate the metabolite on cartridge systems allowing smaller NMR 
sample volumes (30 µL).59 Figure 8 shows the amount of natural product which was required 
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for complete structure analysis in the year 1995 up to the year 2009 to give an impression of 
the practical advances in analytical technology.60 
 
Figure 8.  Decrease in the required amount of three generations of marine natural products for complete 
structure elucidation due to the continuous improvement in analytical technology.60  
Practical structure elucidation begins with the molecular formula predicted by HRMS. 
Subsequently verification of the proposed molecular formula is based on 1D 1H and 13C NMR 
experiments, as well as on the calculated degree of unsaturation* and on information about 
functional groups obtained from IR- and UV/Vis spectra. The skeleton of an unknown 
compound can be further explored with 2D NMR experiments. The first step is to uniquely 
identify each proton directly bound to carbons by using heteronuclear HMQC (heteronuclear 
multiple quantum coherence) or the phase sensitive HSQC (heteronuclear single quantum 
coherence) experiments. HSQC provides information about carbon multiplicity, which can 
also be gained by 1D NMR experiments like APT or DEPT (see Table 1). The homonuclear 
1H,1H COSY (correlation spectroscopy) experiment identifies structural fragments by 
through-bond coupling of geminal, vicinal and long-range protons. A TOCSY (total 
correlation spectroscopy) experiment is helpful for the analysis of polysaccharides or peptides 
by revealing proton correlations within one spin-system. After the assignment of structural 
fragments, the overall skeletal connectivity is established through a HMBC (heteronuclear 
multiple-bond correlation) experiment, revealing correlations through intervening 
                                                 
*
 Degree of unsaturation = a + 1 – ½(b – d); CaHbOcNd 
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heteroatoms and quaternary carbons linking the structural fragments to an overall connectivity 
of a compound.57,61 All NMR experiments mentioned are tabulated in Table 1 which provides 
basic information about the experiments.62 
Table 1:  Overview of the basic NMR experiments used for structure elucidation.62 
Abbreviation Experiment Purpose Comment Enhanced Experiments 
APT attached proton test 1D inverse technique 
for 13C multiplicity 
includes signals for quaternary 
carbons 
DEPTQ 
DEPT distortionless 
enhancement by 
polarization transfer 
1D inverse technique 
for 13C multiplicity 
standard  diverse  
HMQC heteronuclear 
multiple quantum 
coherence 
2D inverse H,C 
correlation 
decoupled 13C NMR spectrum diverse, better HSQC 
HSQC heteronuclear single 
quantum coherence 
2D inverse H,C 
correlation 
phase-sensitive gradient-
selected version 
gs-HSQC, E-HSQC 
COSY correlation 
spectroscopy 
2D spin coupling 
nucleus 
most important 2D NMR 
experiment: possible nucleus 1H, 
19F, 31P 
Long-Range COSY, 
COSY-45, E.COSY 
TOCSY total correlation 
spectroscopy 
2D correlations of 
protons in one spin-
system 
also called HOHAHA, used for 
peptides and oligosaccharides 
gs-TOCSY, gs-
SELTOCSY,  
HMBC heteronuclear 
multiple bond 
correlation 
2D long-range H,C 
correlation 
2J(C,H) and 3J(C,H) coupling gs-HMBC, ACCORD-
HMBC 
NOESY nuclear Overhauser 
enhancement 
spectroscopy 
2D dipolar cross-
relaxation of nuclei in 
close spatial 
relationship 
assignment of peptide 
conformation and tertiary 
structure of proteins  
gs-NOESY,  
(3D): HN-NOESY-
HSQC, HC-NOESY-
HSQC  
ROESY rotating frame 
Overhauser 
enhancement 
spectroscopy 
2D dipolar cross-
relaxation of nuclei in 
close spatial 
relationship 
also called CAMELSPIN, 
shorter time compared to 
NOESY, also applied for molar 
mass of 1000- 3000 
 
HETLOC heteronuclear long 
range coupling 
2D determination 
long-range C,H spin 
coupling constants 
low sensitivity, overlapping 
signals and coupling constants 
of the same spin system, 
enhanced versions  
PS-HMBC, J-HMBC, 
HSQC-TOCSY, 
HSQMBC 
1.3.2 Assignment of the Relative Configuration of Natural Products 
The biological behaviour of compounds is strongly affected, not only by the connectivity and 
diversity of functional groups, but also by their spatial arrangement. Disclosing the relative 
and absolute configuration is therefore necessary to fully understand their chemical behaviour 
and biological interaction.63 
NMR techniques play an important role providing geometric information of organic 
compounds. The 2D NMR experiments NOESY (nuclear Overhauser enhancement 
spectroscopy) and ROESY (rotating frame Overhauser enhancement spectroscopy) provide 
information about the dipolar cross-relaxation of protons with close spatial relationships. The 
cross peak intensities in these spectra are inversely proportional to the sixth power of the 
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distance separating the interacting protons and are therefore used in the assignment of relative 
configurations.64 Another phenomenon in NMR spectroscopy is the scalar coupling of nuclei. 
The direct correlation of dihedral angles of protons corresponding to their vicinal 3JH,H 
coupling constant was first described by Karplus and became a very essential tool for 
conformation analysis.65 This method has been further developed for heteronuclear coupling 
constants 2,3JC,H and different substituent patterns. Murata´s method is a J-based configuration 
analysis comparing experimental and predicted 3JH,H and 2,3JC,H values of possible rotamers of 
(1,2) or (1,3) acyclic carbon chains.66 The 2,3JC,H values are measured using 2D HETLOC 
(hetero half-filtered TOCSY) or PS-HMBC (phase sensitive HMBC) NMR pulse-sequences. 
Another approach is the comparison of carbon and proton chemical shifts of an unknown 
configuration with model compounds of defined stereochemistry.67 A compound library is 
realized in the universal NMR database (UDB).68,69 Larger molecules with diverse 
stereocentres like natural products can be divided into fragments for comparison with suitable 
known compounds in the database, as shown in the example of oasomycin in Figure 9.68 
Figure 9.  Example of an UDB approach for the natural product oasomycin and suitable fragments for the 
library search.68  
In the last decade computational developments in quantum mechanical (QM) methods have 
progressed into fast empirical methods for calculating NMR parameters useful for the 
configuration assignment of natural products. Here the conformational search and geometry 
optimization of all significant conformers of each stereoisomer are carried out by empirical 
methods such as molecular mechanics (MM) or on the semiempirical level (PM3) followed 
by a QM method for final optimization.70 The 13C and 1H NMR chemical shifts are calculated 
for each stereoisomer and compared with the experimental data. In addition, the resulting 
geometries can be compared with calculated coupling constants analoguously to Murata’s 
method and nOe interactions.71 
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The relative configuration of 1,3-diols can also be established by the synthetic approach of 
Rychonovsky´s acetonide method.72 For this method a six-membered acetonide is synthesized 
from the 1,3-diol. A syn-1,3-diol furnishes a chair conformation of the six-membered 
acetonide, which is indicated by distinct chemical shifts, like δC < 100 ppm for the quaternary 
carbon CMe2, δC of 20.0 ppm for the axial methyl group and δC of 30.0 ppm for the one in the 
equatorial position. An anti-configuration of the 1,3-diol leads to a twisted-boat conformation 
with a characteristic CMe2 δC value > 100 ppm and an average δC value for both methyl 
groups at about 25.0 ppm. The two conformation and the resulting characteristic chemical 
shifts are shown in Figure 10.72 The relative structure of the natural products dermostatins A 
and B were assigned by synthesising multiple acetonides simultaneously and subsequently 
analysing their positions and their chemical shift with 2D NMR spectroscopy.73  
Figure 10.  The chair and the twisted-boat configuration of the six-membered acetonides derived from 
either syn-1,3-diols or anti-1,3-diols, with the resulting characteristic δC shift for 
Rychonovsky`s acetonide method.72 
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1.3.3 Assignment of the Absolute Configuration of Natural Products 
Good quality monocrystals of a compound would be required for an assignment of the 
absolute stereochemistry by X-ray crystallography. Unfortunately they are rarely produced for 
small natural products. Another common approach is the degradation of natural products by 
chemical synthesis using for example ozonolysis, hydrolysis or olefin metathesis. The 
degradation products can be compared to their corresponding enantiomeres by chiral HPLC or 
GC (gas chromatography), as commonly used for amino acid analysis of peptides after 
hydrolyses.74,75 Chiro-optical methods are instrumental approaches that include optical 
rotatory dispersion (ORD) and circular dichroism (CD). The differential absorption of chiral 
molecules of either the specific optical rotation in ORD or the absorption bands in CD are 
used to compare synthetic material to the original natural product for determination of the 
absolute stereochemistry.76,77 The universal NMR database (UDB) uses chiral NMR solvents 
to generate a chiral environment for the enantiomers. This causes small chemical shift 
differences allowing discrimination of the enantiomers, which are subsequently compared 
with the NMR data of the natural product or degradation products.78-80 A larger chemical shift 
difference is produced by covalent binding of a chiral reagent producing diastereomers. 
Lanthanide shift reagents such as chiral complexes of europium (Eu), ytterbium (Yb) and 
praseodymium (Pr) are used to determine enantiomeric purity.81 Mosher´s method is most 
widely used to explore the absolute stereochemistry of alcohol and amine moieties by using 
methoxy(trifluoro-methyl)phenylacetyl (MTPA) acids or derivatives.82,83 For this method the 
compound is derivatized with both enantiomers of the MTPA acids to give diastereomers. The 
ligand of the MTPA ester shields or deshields the proton NMR signal of the neighbouring 
protons next to the MTPA ester as is shown in Figure 11. The shift difference ∆δSR of the 
neighbouring protons in the two distereomers is calculated by subtracting the chemical shift 
δH of the (R)-MTPA ester derivative from the chemical shift δH of the (S)-MTPA ester 
derivative. The resulting ∆δSR values (+/-) of the neighbouring protons are interpreted to give 
the configurational assignment based on the chiral centre of the auxiliary (Figure 11 c and 
d).84 
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Figure 11.  Mosher model of the (R)-MTPA ester (a) and (S)-MTPA ester (b) of an alcohol and the 
interpretation of the observed ∆δSR values of protons for both possible configurations (c and 
d).84 
Research of Reid et al. and Caffrey et al. on stereospecific ketoreductases (KR) enabled a 
complementary genetic approach to assign the absolute configuration of ketoreductase- 
derived hydroxyl-bearing stereogenic centres.85,86 The stereochemical determination of the 
complex myxobacterial polyketide etnangien (35) for example was established by a 
combination of high-field NMR studies, molecular modelling, synthetic derivatization and by 
biosynthetic studies.87  
The improvement of NMR and CD instrumentation permitted the absolute structure 
elucidation of muironolide A (21) (see Chapter 1.3.1, Figure 8) with only 90 µg of material. 
The absolute stereochemistry was assigned by using microcryoprobe NMR spectroscopy, 
high resolution mass spectrometry, circular dichroism (CD), and synthesis.88  
The first results of a structural elucidation of a natural product using atomic-resolution 
scanning probe microscopy for structural determination have been published recently, 
suggesting a novel tool for structure elucidation of organic natural products.89 
1.3.4 Structure Elucidation of Natural Products by Total Synthesis 
The final step in the structure elucidation of natural products is the verification of a proposed 
structure by checking all the data for consistency and by comparison of similar natural 
products with common biosynthetic origins. However, the stereoselective total synthesis 
remains the final proof. A review by Nicolaou and Snyder investigated 300 revised structures 
between January 1990 and April 2004 through all classes of natural products.56 The progress 
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in spectroscopic skills has made structure elucidation of unknown compounds a routine task, 
but does not rule out all pitfalls. 
An exciting discussion of structure elucidation is the case of maitotoxin (23), the largest 
polyether from marine organism and a highly active biotoxin.90,91 The gross structure of 
maitotoxin was described in 1993 by Yasumoto et al.92 and the relative structure by Kishi et 
al.,93 contemporaneously with the absolute stereochemistry by Tachibana et al. in 1996.94,95 
Biosynthetic studies of polyethers by Gallimore and Spencer suggested an opposite 
configuration of two stereocentres connecting the polyether rings J and K (marked red in 
Figure 12).96 Nicolaou et al. applied computational chemistry to support the original 
published structure97 and finally proved the molecular architecture by synthesis of the 
GHIJKLMNO ring system of maitotoxin 2008.98 A total synthesis of the largest natural 
polyether known has not been accomplished as yet. 
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Figure 12.  The structure of the largest polyether isolated so far, maitotoxin (23). The stereocentres 
questioned by Gallimore and Spencer at the connection of the J and K ether ring system are 
highlighted in red. 
This is one of many examples in which the final proof of stereochemistry will be clarified by 
total or partial synthesis. Total synthesis can also provide confirmation if the proposed 
structure correlates with the assigned biological activity.99 
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1.4 Outline of this Work 
Since myxobacteria have proved to be very versatile producers of biologically active 
secondary metabolites, the aim of the present thesis was to identify novel natural products 
from this extraordinary group of gliding bacteria. This thesis comprises the process of the 
isolation of a biologically active metabolite from a complex crude extract, as well as the 
structure elucidation not only the planar structures, but also the determination of the relative 
and absolute configuration of the complex compounds by applying chemical derivatization 
techniques, and detailed 1D and 2D NMR studies combined with molecular modelling.  
Figure 13.  Fruiting bodies of the Cystobacter ferrugineus strain Cb G35 on agar plates (pictures by K. 
Gerth). 
The Cystobacter ferrungineus strain Cb G35 was isolated from a soil sample by Klaus Gerth 
at the Helmholtz Centre for Infection Research (HZI). The crude extract of this strain was 
found to inhibit growth of Staphylococcus aureus, Nocardia flava, Escherichia coli, Mucor 
hiemalis, and Rhodotorula glutinis in an antimicrobial screening of myxobacteria. The strain 
was found to produce myxalamide C (24c), which is responsible for the Nocardia flava, 
Mucor hiemalis, and Rhodotorula glutinis growth inhibition by the crude extract.100 Four 
homologues metabolites of the myxalamide family (Figure 14) were previously described 
from Myxococcus xanthus Mx x12,101,102 and were further reported from the gene cluster 
analysis of Stigmatella aurantiaca Sg a15.103 The aim of this work was to identify the 
unknown secondary metabolites synthesized by this strain and to subsequently elucidate their 
structures. Of special interest was the compound responsible for the Escherichia coli 
inhibition, due to the low number of effective antibiotics against Gram-negative bacteria. 
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Figure 14.  The myxalamide family described from Myxococcus xanthus and Stigmatella aurantiaca. 
This thesis presents the developed isolation procedure of the light- and oxygen-sensitive 
polyunsaturated carboxylic acid roimatacene (26). The absolute stereochemistry of 
roimatacene (26) was derived by 1D and 2D NMR spectroscopy, derivatization to acetonides 
and Mosher´s esters as well as by molecular modelling. In addition, six novel p-
hydroxyacetophenone amides (34a-f) were isolated from the crude extract of strain Cb G35 
and their structures were elucidated. The biosynthetic precursors of 26 and 34a were studied 
by feeding experiments and are presented in the course of this thesis.  
Another project involved the family of sulfangolids (25a-d). Sulfangolid A (25a) and B (25b) 
were first reported in the annual report of the GBF 1996.104 Further the sulfangolids were 
mentioned in numerous review articles as frequently found metabolites from the genus 
Sorangium cellulosum.21,31,51,105 In the past the four myxobacterial sulfangolids 25a-d were 
isolated from different strains of Sorangium cellulosum and the planar structures presented in 
Figure 15 were postulated in the research groups of Prof. Dr. H. Reichenbach and Prof. Dr. G. 
Höfle, but unfortunately not described exhibiting the required data (unpublished data H. 
Augustiniak, M. Herrmann, R. Jansen, H. Steinmetz, K. Gerth, H. Irschik, H. Reichenbach, 
W. Kessler, G. Höfle at HZI, former GBF). During my diploma thesis I concentrated on the 
isolation and further structure elucidation of sulfangolids A (25a) and C (25c). Subsequently 
to the isolation, complete sets of NMR data of 25a and 25c were measured and analysed. In 
my diploma thesis I presented a first proposal of the relative configuration of sulfangolid C 
(25c), subsequently I continued to verify the proposed relative configuration of 25c by 
molecular modelling studies and extensive comparison of the NMR data. In addition, the 
biosynthetic precursors of sulfangolid C (25c) were studied by feeding experiments as a basis 
for further genetic studies. Further I verified all proposed structures of sulfangolids 25a-d 
from their NMR data and summarized the combined detailed data (Manuscript is to be 
submitted). 
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Figure 15.  The proposed planar structures of the sulfangolid family (25a-d) isolated from different strains 
of the genus Sorangium cellulosum in the research groups of Prof. Dr. Reichenbach and Prof. 
Dr. Höfle at the HZI (former GBF). 
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2 Results 
2.1 Roimatacene, a Polyunsaturated Carboxylic Acid from Cystobacter 
ferrugineus Cb G35 
2.1.1 Development of an Isolation Procedure for Roimatacene (26) 
The antibiotic activity of Cystobacter ferrugineus, strain Cb G35, against E. coli was detected 
in a broad antimicrobial screening. The crude extract was fractionated by HPLC and each 
fraction was tested against E. coli. Thus, the growth inhibition of E. coli was correlated to an 
unknown compound with a HRESIMS molecular ion cluster [M-H]- at m/z 515.3021 and a 
corresponding molecular formula of C30H44O7 (calc. 515.3014). Accordingly, the unknown 
compound was isolated from the Amberlite XAD-16 adsorber resin of fermentation (70 L) in 
a bioactivity-guided procedure. Because the compound repeatedly decomposed during the 
isolation process, several fermentations were necessary for the development of a protective 
protocol for the oxygen- and light-sensitive polyene roimatacene (26). General aspects 
stabilizing the compound during the isolation were considered to finally result in the isolation 
strategy presented in Figure 16. Especially, all extracts had to be kept dissolved in methanol 
containing 4-ethoxyphenol as free radical scavenger. Prior to use, all solvents were saturated 
with nitrogen gas and all operations were carried out under nitrogen atmosphere. Ethyl acetate 
was filtered over aluminum oxide to remove peroxides, and extracts and fractions were 
handled in amber glassware. 
Figure 16.  Isolation procedure for roimatacene (26), starting from Amberlite XAD-16 resin. 
XAD-16 resin Elution MeOH Ethyl acetate 
extraction
HPLC 
chromatography
Acid-base partitionn-Heptane/MeOH partition
Ethyl acetate 
extraction
Water layer
Water layer
Strata X cartridge
pH 9
pH 4.5
Ethyl acetate 
extraction
n-Heptane 
extraction
Water layer
- All solvents were saturated with N2-gas
- All ethyl acetate was filtered over aluminum oxide
- All extracts were kept in solution
- All evaporations and extractions were carried out under N2-protection gas 
- 4-Ethoxyphenol was present as antioxidant
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The Amberlite XAD-16 resin was harvested from the fermentation by sieving and was then 
eluted with methanol. Subsequently to evaporation of the organic solvent, the water layer was 
extracted with filtered ethyl acetate, and after evaporation of the ethyl acetate an n-
heptane/methanol partition was carried out, in order to remove lipophilic by-products from the 
crude extract. The antibiotic 26 was further enriched by an advanced acid-base partition. The 
partition started with an ethyl acetate extraction of the alkaline water layer, which was 
subsequently acidified to pH 4.5. An additional extraction of the acidic water layer with n-
heptane removed large amounts of fatty acid, which otherwise interfered with the further 
purification process by RP-chromatography. The enriched roimatacene (26) was extracted 
from the acidic water layer with ethyl acetate. The final purification was carried out by RP-
chromatography using N2-saturated solvents and providing 4-ethoxyphenol to each HPLC 
fraction. The methanol of the combined roimatacene (26) fractions was evaporated in vacuo 
and the residual water was applied on a strata-X cartridge (phenomenex) under nitrogen 
atmosphere. The newly established isolation procedure permitted the isolation of sufficient 
material for a complete structure elucidation as well as for all biological assays. 
2.1.2 Structure Elucidation of the Core Structure of Roimatacene (26) 
The biological active roimatacene (26), isolated according to the isolation protocol described 
in chapter 2.1.1, was analysed by HRESIMS, as well as 1D and 2D NMR spectroscopy for 
structure elucidation. Due to the instability of roimatacene (26) meaningful IR data were not 
obtained. HRESIMS of the molecular ion cluster [M-H]- at m/z 515.3021 established the 
molecular formula C30H44O7 (calc. 515.3014) for 26 with 9 degrees of unsaturation. The 
molecular formula was supported by the NMR data, presented in Table 2.  
Figure 17.  Structural elements A to D of roimatacene (26) assigned from the 1H,1H COSY spectrum and 
selected 1H,13C HMBC correlations. 
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All protons were assigned to their directly bound carbons from the 1H,13C HMQC spectrum. 
The interpretation of the 1H,1H COSY spectrum furnished four structural elements A to D 
presented in Figure 17. The connection of the structural elements was accomplished by the 
interpretation of the 1H,13C HMBC spectrum, allocating the carboxylic acid carbon C1 to 
subunit A by its HMBC correlations with 2H and 3H. The quaternary carbon C8 (δC 134.4 
ppm) was verified by 13C ATP NMR spectroscopy under the overlapping 13C signal of C13 
(δC 134.4 ppm). C8 was correlated to methyl group C28 and subsequently identified as 
connection between the structural fragments A and B from HMBC correlations with 7H and 
9H, and correlations of methyl group C28 with the same protons (7H and 9H). Further, 
methines C7 and methine C9 showed mutual HMBC correlations securing the connection of 
subunits A and B. Similarly, the quaternary carbon C16 and the directly bound methyl group 
C29 showed HMBC correlations with 15H of subunit B, as well as with 17H and 18Hβ of 
subunit C. The final connection of structural unit D was indicated by HMBC correlations of 
C20 with 18H and 22H, as well as by mutual correlations of the methyl group C30 at C20 
with methines 19H and 21H. In addition, methines 19H and 21H showed the expected mutual 
HMBC correlation between subunit C and D.  
The interpretation of the 1H NMR spectrum of roimatacene (26) clearly indicated the trans-
configurations of the double bonds by vicinal coupling constants of 15 Hz. The trans-
configurations were additionally supported by the corresponding nOes (Table 2). 
The resulting planar structure of the polyunsaturated carboxylic acid roimatacene (26) is 
presented in Figure 18. The structure revealed an unusual accumulation of reactive functional 
groups, like a tertiary alcohol at C16, as well as three α-polyunsaturated alcohol groups at C5, 
C15 and C19, an acrylic acid residue and polyenes, altogether providing a well-founded 
justification for the observed sensitivity of 26. 
Figure 18.  The planar structure of roimatacene (26). 
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Table 2:  NMR data of roimatacene (26) (1H 600 MHz, 13C 150 MHz, [D6]DMSO). 
Atom δH H m J [Hz] COSY δC HMBC ROESY[d] 
1 - - - - - 167.1 3, 2 - 
2 5.79 1 d 16.0 3, 4 123.6 4 > 3 (3) 
3 6.80 1 ddd 16.0, 7.0, 7.0 2, 4 145.6 4 (2) >(4),5 
4 2.35 2 m[b] - 3, 5[d] 40.0 3, 2, 6, 5OH >(5), 2, (3) 
5 4.18 1 ddd 11.0, 6.7, 5.5 4 > 6, 5OH 69.9 7, 6, 4 >3 7, (4,6), 3 
5OH 5.01 (1) s(br) - 5 - - - 
6 5.67 1 dd(br) 15.8, 5.9 7, 5 132.0 7, 4 28, (7, 5), 4 
7 6.25 1 d 15.8 6 133.6 28, 6, 9, 10 9, 5, (6) 
8 - - - - - 134.4[c] 28, 10, 7, 9[d] - 
28 1.80 3 s - 9 12.6 7, 9 6, 10 
9 6.10 1 m[a] - 10, 12 131.0 7, 11, 28 7, 11 
10 6.47 1 dd 14.6, 11.6 7, 9 126.9 12 28, 12 
11 6.27 1 dd 14.6, 10.6 10, 12 133.9 13, 9 13, 9 
12 6.16 1 m[a] - 11, 13 131.7 10, 11 > 14α/β 10 
13 5.82 1 ddd 15.1, 7.3, 7.3 12, 14β 134.4 14α/β, 11 11, 15, (14α/β) 
14α 2.35 1 m[b] - 13, 15, 14β 34.6 12, 13 > 15OH (14β, 15, 13), 12, 17 
14β 2.02 1 dddd 15.4,7.7,7.7, 1.5 14 α, 15, 13 - - (14α, 13) 
15 3.51 1 dd[d] 9.7, 1.7[d] 15OH, 14β 73.4 29, 18β 13, 17, (14α), 29, 18α/β 
15OH 4.52 (1) s(br) - 15 - - - 
16 - - - - - 74.3 29, 18β - 
16OH 4.43 (1) s(br) - 17 > 15OH - - - 
29 0.93 3 s - - 18.2 17OH 17, 15 > 12, 18α 
17 3.29 1 dd[d] 10.5, 1.5[d] 18 β[d] 73.5 29[d], 18β 19, 15, (18α), 29, 30, 21 
17OH 4.08 (1) s(br) - 17 - - - 
18α 1.70 1 ddd 13.8, 10.2, 1.3 19, 18 β 36.1 > 18β (18β, 17), 15, 29 
18β 1.49 1 ddd 13.8, 10.2, 6.4 19, 18 α >17 - - 30, 15, (19) 
19 4.14 1 dd 7.0, 6.4 18 α/β > 19OH 74.9 29, 30, 21, 18α/β 21, 17, (18α/β) 
19OH 4.85 (1) s(br) - 19 - - - 
20 - - - - - 140.2 30, 18α/β > 22 - 
30 1.67 3 s - 21 11.6 21, 19 19, 22 
21 6.00 1 d(br) 11.2 22, 30 125.2 30, 23, 19 23, 19 > (22), 17 
22 6.37 1 dd 14.5, 11.2 23, 21 126.9 21, 23 30, 24, (23, 21) 
23 6.14 1 m[a] - 22, 24 132.2 21, 25 21, (22) > 25, 30 
24 6.14 1 m[a] - 25, 23 129.9 22, 26 26, (23, 25) 
25 5.74 1 ddd 14.3,7.1, 7.1 24, 26 135.6 27, 26, 23 (24, 26), 27 
26 2.08 2 dt 7.1, 7.5 27, 25 25.2 27, 25, 24 (27, 25), 24 
27 0.97 3 t 7.5 26 13.5 26, 25 (26), 25 
The compound was stabilized with 4-ethoxyphenol (1H NMR (600 MHz, [D6]DMSO) δ ppm 1.26 (t, J = 6.97 Hz, 3 H) 3.89 
(q, J = 6.97 Hz, 2 H) 6.65 (d, J = 8.80 Hz, 2 H) 6.72 (d, J = 8.80 Hz, 2 H); 13C NMR (150 MHz, [D6]DMSO) δ ppm 14.8, 
63.3, 115.3, 115.7, 151.0, 151.3. [a] multiplet of 4 protons at 6.15 ppm, one AA'-system consisting of 23/24H and an overlap 
with 9H and 12H. All proton shifts were taken from the HMQC spectrum. [b] overlap of 4H and 14Hα. Proton shifts from the 
HMQC spectrum. [c] 13C shift from APT spectrum after H/D exchange. [d] data after H/D exchange.  
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2.1.3 The Relative Configuration of Roimatacene (26) 
In order to establish the relative configuration of the polyol fragment C15 to C19, three 
acetonides (28-30) were prepared from roimatacene methyl ester (27) by the reaction with 
2,2-dimethoxypropane presented in Scheme 1. 
Scheme 1.  Preparation of acetonides 28 to 30 from roimatacene methyl ester (27); a) 2,2-
dimethoxypropane, PPTS, 4°C, 18h. 
Subsequent to the isolation of all three acetonides, their complete NMR data were intensely 
studied. The analysis of the 17,19-acetonide 28 revealed a typical shift of δC 98.9 ppm for the 
quaternary carbon CMe2 (C32) and δC 20.0 and 30.1 ppm (Table 3) for the methyl groups 
C33/34, characteristic for a chair conformation of acetonides as analyzed by Rychnovsky´s 
method.72 The chair conformation was further supported by nOe correlations of 33H, 17H and 
19H in coaxial positions. Supplementary, 18Hβ in the equatorial position was distinguished 
from the axial 18Hα by nOes with 17H and 19H. A chair conformation is only possible for 
syn-1,3-diols, and therefore 17OH and 19OH take the syn-configuration. 
Conversely, the second product assigned as 15,17-acetonide 29, showed chemical shifts of δC 
100.2 ppm for the quaternary carbon CMe2 (C32) and very similar carbon shifts of δC 25.2 
and 23.7 ppm for the methyl groups C33/34, unambiguously indicating a twisted-boat 
conformation and thus the anti-configuration of 15OH and 17OH (see Table 4).72 An 
unambiguous assignment of the relative configuration of stereocentre C16 considering the 
nOe correlations from the 1H,1H ROESY spectrum is impossible from this twisted-boat 
conformation. 
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Table 3:  NMR data of 17,19-acetonide 28 (1H, 600 MHz, 13C 150 MHz, CDCl3) 
Atom δH  H m J [Hz] COSY δC HMBC ROESY 
31 3.74 3 s - - 51.5 - - 
1 - - - - - 166.7 31, 3 > 2 - 
2 5.94 1 d 15.8 3 > 4 123.7 4 (3) 
3 6.98 1 ddd 15.7, 7.2, 2.2 4, 2 144.7 4 (2, 4) 
4 2.51 2 m - 5, 3 >2 40.3 > 2, 6, 3 (3), 2, (5), 6 
5 4.37 1 ddd 12.0, 7.0, 1.8 4, 6 71.8 4, 7, 6 7, (4) > 3, (6) 
5OH 1.43 1 m - 5  - - 
6 5.7 1 dd 15.4, 7.0 7, 5 129.7 4 > 7 (7, 5), 28, 4 
7 6.32 1 d 15.4 6 136.1 28, 9 5, (6), 9, 4 
8 - - - - - 139.7 - - 
28 1.87 3 s - 9 12.8 9 10, 6 
9 6.09 1 m - 10, 28 132.2 28, 7, 11 7, 9 
10 6.50 1 dd 13.6, 11.4 9, 11 127.7 9 (11, 9), 28 
11 6.28 1 dd 15.0, 11.2 12, 10 133.7 28, 9 (10), 13 
12 6.26 1 dd 15.0, 11.0 11, 13 133.2 10 > 14α/β 10, (13) 
13 5.86 1 ddd 14.4, 7.3, 7.3 12, 14α/β 132.1 14α, 11, 10 11, 15, (14α/β) 
14α 2.51 1 m - 14β, 15, 13 35.9 11 29, (14β), 16OH, (15) 17, 12 
14β 2.21 1 ddd 14.5, 10.1, 7.7 14α, 13, 15   (14α), 17, 29, 13, 12 
15 3.58 1 ddd 10.3, 8.1, 2.2 14α/β 77.3 29, 14α/β 29, 16OH, (14α), 13, 17 
15OH 2.58 1 m - 15  - - 
16 - - - - - 73.7 15OH, 14α - 
16OH 2.84 1 s - 29  - - 
29 1.06 3 s - - 18.8 16OH 17, 15, 16OH, 15OH, 18β 
17 4.11 1 dd 11.6, 2.4 18α/β 72.9 29, 18α 19, 33, 18β, 29, 15OH, 16OH, 15, 18α 
18α 1.84 1 m - 19, 17, 18β 28.6 - (18β), 29, 16OH 
18β 1.45 1 m - 18α, 19, 17   (18α), 29, 19, 17 
19 4.31 1 dd 11.7, 1.8 18α/β 74.0 29, 30, 21 33, 21, 17, 30, 18β 
32 - - - - - 98.9 33, 34 - 
33 1.52 3 s - >34 20.0 34 17, 19 
34 1.45 3 s - >33 30.1 33 - 
20 - - - - - 136.4 30, 22, 21, 19 - 
30 1.80 3 s - 21 12.9 21 22, 19 
21 6.09 1 m - 22, 30 126.0 30, 22, 19 19 
22 6.34 1 dd 14.5, 11.0 21, 23 126.2 23, 30 30, (21), 24 
23 6.21 1 dd 15.0, 11.0 22, 24 133.6 25 25, (22, 24) 
24 6.09 1 m - 23 > 25 129.6 26 26 
25 5.76 1 dt 15.0, 6.8 24, 26 136.8 26, 27, 23 23, (24, 26) > 27 
26 2.13 2 quintet 7.3 27, 25 25.8 27, 25, 24 (27, 25), 24 
27 1.03 3 t 7.3 26 13.5 -  
The compound was stabilized with 4-ethoxyphenol: 1H NMR (600 MHz, CDCl3): δ 1.39 (t, J = 7.2 Hz, 3 H) 3.99 (q, J = 7.0 
Hz, 2 H) 6.78 ppm (q, J = 9.2 Hz, 4 H); 13C NMR (150 MHz, CDCl3): δ 14.9, 64.1, 115.6, 116.0, 149.4, 153.2 ppm. 
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Table 4:  NMR data of 15,17-acetonide 29 (1H 600 MHz, 13C 150 MHz, CDCl3). 
Atom δH  H m J [Hz] COSY δC HMBC ROESY 
31 3.74 3 s - - 51.5 - - 
1 - - - - - 166.7 31, 3 - 
2 5.94 1 d 15.8 3 123.6 4 (3) > 4 
3 6.98 1 dt 15.4, 6.6 4, 2 144.8 4 (2), (4) 
4 2.50 2 t 7.3 5, 3 40.3 2 (3), (5), 2 > 6 
5 4.36 1 q(br) 6.4 4, 6, 5OH 71.8 7 > 4, 6  
5OH 1.76 1 s (br)  5   5 
6 5.68 1 dd 15.8, 7.0 7, 5 129.3 4, 7 28, (7, 5)> 4 
7 6.32 1 m[a] - 6 136.2 9, 28 5, 9 
8 - - - - - 135.4 28 > 9 - 
28 1.88 3 s - >>9 12.8 7, 9 6, 10 
9 6.11 1 m[a] - 10> 28 132.4 7, 10 (10), 7, 11 
10 6.44 1 dd 13.2, 11.7 9, 11 127.1 - (9, 11), 28 
11 6.26 1 m[a] - 10, 12 134.3 9, 13 (10), 13, 9 
12 6.26 1 m[a] - 13, 11 132.5 10 (13), 10 
13 5.79 1 ddd 15.0,7.5,1.5 14α, 12, 14β 132.2 14α/β (12), 11> 15 
14α 2.41 1 ddd 14.9, 7.4, 1.8 14β, 13, 15 32.1 - (14β,15)> 29, 12, (13)  
14β 2.15 1 ddd 14.9, 10.0, 7.4 15, 14α >13 - - (14α), 29 > (15) 
15 3.65 1 s - 14β > 14α 72.3 29 33/34 , 19, 17 > 13, (14α) 
16 - - - - - 85.2 29, 18 - 
29 1.18 3 s - - 19.3 - 17>> 30, 14β, 18 
17 4.00 1 dd 6.0, 3.5 18 78.5 29, 18 (18), 33/34, 29, 15 
32 - - - - - 100.2 33/34 - 
33 1.35 3 m - - 25.2 34 15, 17 
34 1.35 3 m - - 23.7 33 15, 17 
18  1.93 2 m - 19, 17 37.1 - (17, 19), 30 >29 
19 4.67 1 dd (br) 8.6, 6.8 18 84.0 30 > 21 21, 15, 18 > 30 
20 - - - - - 133.6 > 30 - 
30 1.75 3 s - > 21 12.1 19, 21 >22, 19 
21 6.15 1 m[a] - 22 126.5 30, 23, 19 19 
22 6.33 1 m[a] - 21, 23 126.3 30, 23 (23),30 
23 6.19 1 m[a] - 24, 22 > 30 133.4 25 > 22 19, 21 
24 6.12 1 m[a] - 25, 23 129.7 26, 22 >26 
25 5.75 1 dt 7.2, 14.7 24, 26 136.7 27, 26> 23 (24), 23, (26) 
26 2.13 2 quint 7.2 27 > 25 25.8 27 > 25> 24 (27) > (25), 24 
27 1.02 3 t 7.3 26 13.5 26 > 25 (26) 
The compound was stabilized with 4-ethoxyphenol: 1H NMR (600 MHz, CDCl3): δ 1.39 (t, J = 7.2 Hz, 3 H) 3.99 (q, J = 7.0 
Hz, 2 H) 6.78 ppm (q, J = 9.2 Hz, 4 H); 13C NMR (150 MHz, CDCl3): δ 14.9, 64.1, 115.6, 116.0, 149.4, 153.2 ppm. [a] 
multiplet of 8 protons in between 6.35 – 6.10, proton shifts from 1H,13C HSQC spectrum 
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In order to establish the relative configuration of stereocentre C16 in roimatacene (26), the 
NMR data of bis-acetonide 30 were studied in detail (Table 5). The syn-configuration of the 
17,19-acetonide was secured by the observation of the same chemical shifts and nOe 
correlations in bis-acetonide 30 as for 28. Further, the relative configuration of the anti-15,17-
acetonide 29 was considered, before the two possible diastereomers of C16 were modelled 
applying the “Conformational Search” module of HyperChem (Version 8.5) using MM+ 
calculations. Both optimized alternative conformers were then carefully compared with the 
NMR data of 30 (Table 5, Figure 19). 
 
Figure 19.  Partial view of 30 resulting from modelling studies with HyperChem and selected nOe of 30, a) 
the relative 15S*,16R*,17S*,19R* isomer and b) the relative 15S*,16S*,17S*,19R* isomer of the 
bis-acetonide 30. 
The nOes of the chair conformation of the 17,19-syn-acetonide unit in 30, differentiating the 
equatorial 18Hβ (δH 1.41 ppm) and axial 18Hα (δH 1.77 ppm) protons as in 28, are presented 
in Figure 19b. The methyl group C29 at C16 in the 15,16-acetonide unit of 30 showed 
ROESY correlations with 18Hβ and 17H of the 17,19-syn-acetonide. These nOe correlations 
are feasible for both isomers of 30 presented in Figure 19a and b. However, the strongest nOe 
of methyl group C29 was indicated with 15H, thus enabling a discrimination between both 
isomers, because this observation is only compatible with the distance of 2.5 Å in the relative 
15S*,16S*,17S*,19R* configuration in Figure 19b. The distance of 3.8 Å in the 
15S*,16R*,17S*,19R* configuration (Figure 19a), besides the trans-orientation of methyl group 
C29 and 15H, would not allow a strong nOe. Instead, a strong nOe between 15H and 18Hα 
would be expected from a distance of 2.6 Å in the model, which is missing in the 1H,1H 
ROESY spectrum of 30 (Figure 19a). Further, a nOe between 17H and 14Hβ of the side chain 
was observed, which is impossible for the S*,R*,S*,R* isomer (Figure 19a), even after rotation 
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of the side chain. However, the observation is fully compatible with the distance of 2.5 Å 
between 17H and 14Hβ in the S*,S*,S*,R* configuration (Figure 19b). A strong nOe between 
19H and 21H strongly supports the orientation of the triene side chain as it is presented in the 
S*,S*,S*,R* model, although the expected nOe between methyl group 30H (δH 1.79 ppm) and 
18Hα (δH 1.71 ppm) could not be observed, due to their overlapping 1H NMR signals.  
The extensive NMR analyses and the comparison with the result of the molecular modelling 
of both possible 16R* and 16S*-diastereomeres strongly support the 15S*,16S*,17S*,19R* 
configuration of roimatacene (26) as presented in Figure 20. 
Figure 20.  The relative 15S*,16S*,17S*,19R* configuration of roimatacene (26). 
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Table 5:  NMR data of 15,16,17,19-bis-acetonide 30 (1H 600 MHz, 13C 100 MHz, CDCl3). 
Atom δH  H m J [Hz] COSY δC HMBC ROESY 
31 3.74 3 s - - 51.5 (31) - 
1 - - - - - 166.7 31, 3 >2 - 
2 5.94 1 dd 15.8, 1.1 3 123.6 4 (3) 
3 6.98 1 dt 15, 7 2, 4 144.7 4, 5 (2) > (4) 
4 2.51 2 ddd 7.4, 6.2, 1.3 5, 3 40.3 2, 3, 5, 6 (5,3), 2, 6 
5 4.38 1 m - 4, 6 71.7 7,4,6>3 (4), 7 
6 5.70 1 dd 15, 7 7, 5 126.6 4,7,5 28, (7),4, (5) 
7 6.33 1 d 15.4 6 136.1 28, 9, 5 5, (6), (9 overlap with 22) 
8 - - - - - 134.1 28, 6, 7,9 - 
28 1.88 3 s - - 12.8 7 6, 10 
9 6.12[a] 1 m[a] - 10 132.2 28, 7 (10), 11, 7 
10 6.48 1 dd 15, 11 9, 11 127.7 28 28 > (9,11) 
11 6.28[a] 1 m[a] - 10, 12 133.8 9, 13 (12), 9, 13 
12 6.27[a] 1 m[a] - 13,11 132.7 14α/β, 10 10, (13,11) 
13 5.81 1 ddd 14.6,7.9,6 12 >14α 131.6 15, 14α/β (12), 11 
14α 2.74 1 ddd 15,9,6 14β,15 32.4 >12 (14β) 
14β 2.55 1 m - 14α, 15   (14α) 
15 3.91 1 dd 8.1, 5.5 14α/β 84.2 29> 14α/β 33, 29 
16 - - - - - 82.1 29,18α,14α - 
29 1.18 3 s - - 23.0 15 15 >17, 18β 
32 - - - - - 108.0 33,34 - 
33 1.38 3 s - - 26.8 34 34, 15 
34 1.53 3 s - 33 26.8 33 - 
17 3.76 1 m - 18α/β 71.6 29,18α, 15 36,19>29,14β,18β 
18α  1.77 1 m - 18β,19, 17 29.4 - 18β 
18β 1.41 1 m - 18α   18α>17,19, 29 
19 4.26 1 dd 11.9, 1.7 >18α/β 74.2 30>18α,21 36,21,17,30,18β 
20 - - - - - 136.9 30>22, 19 - 
35 - - - - - 98.5 36,37 - 
36 1.50 3 s - - 19.6 37 19,17,33 
37 1.47 3 s - - 30.1 36 - 
30 1.79 3 s - - 12.9 21,22>>19 >22, 19 
21 6.10[a] 1 m[a] - 22 >30 125.8 30>23,22,19 19, (22) 
22 6.34[a] 1 dd 15,11 21,23 126.4 >23,21/24 24, (23) 
23 6.20 1 dd 15,11 22,24 133.4 25, 24,22 25, (22,24) 
24 6.12[a] 1 m[a] - 25, 23 129.7 26, 22 22, (25) 
25 5.75 1 dt 13.6, 6.6 26, 24 136.6 27, 26, 23 (24) >23, (26) 
26 2.13 2 quin 7.2 27 >25 25.8 27, 25, 24 (27)>(25),24 
27 1.02 3 t 7.3 26 13.5 26,25 (26) 
The compound was stabilized with 4-ethoxyphenol: 1H NMR (600 MHz, CDCl3): δ 1.39 (t, J = 7.2 Hz, 3 H) 3.99 (q, J = 7.0 
Hz, 2 H) 6.78 ppm (q, J = 9.2 Hz, 4 H); 13C NMR (150 MHz, CDCl3): δ 14.9, 64.1, 115.6, 116.0, 149.4, 153.2 ppm. [a] 
multiplet of 8 protons between 6.35 – 6.10 ppm, proton shifts from 1H,13C HSQC spectrum 
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2.1.4 The Absolute Stereochemistry of Roimatacene (26) 
The absolute stereochemistry of roimatacene (26) was established applying Mosher´s 
method.82 Exasperatingly, the methoxy(trifluoro-methyl)phenylacetyl (MTPA) esters 
prepared directly from 26 or from the acetonides 28, 29 decomposed during isolation. In order 
to stabilize the MTPA esters, roimatacene (26) was completely hydrogenated under mild 
conditions, although two additional isomeric stereocentres at C8 and C20 were created. A 
separation of the four resulting diastereomeres was not accomplished. Neither a more 
selective hydrogenation procedure was successfully applied. The octahydroroimatacene (31) 
was then further esterified with p-bromophenacyl bromide to give the UV-active p-
bromophenacyl octahydroroimatacene ester (32). Finally, the tris-(R)- and the tris-(S)-MTPA 
esters 33a/b were derived by Yamaguchi esterification of p-bromoacetophenone-
octahydroroimatacene ester 32.106 Without further optimization 36.6 mg of roimatacene (26) 
finally yielded 2.8 mg of the tris-(S)-MTPA ester and 2.1 mg of tris-(R)-MTPA ester of the p-
bromoacteophenone-octahydroroimatacene ester 33a/b. The synthesis route is presented in 
Scheme 2. 
Scheme 2.  Preparation of the tris-(R)- and the tris-(S)-MTPA esters of p-bromoacetophenone-
octahydroroimatacene ester 33a/b. a) Pd/C (10%), H2, RT, 4.5 h; b) p-bromophenacyl bromide, 
3Å mol sieve, Et3N, acetone, 19 h; c) MTPA, 2,4,6-trichlorobenzoyl chloride, DMAP, Et3N, 
0°C to RT, 4 h. 
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The structure elucidations of the tris-(R)- and tris-(S)-MTPA esters of p-bromoacetophenone-
octahydroroimatacene ester 33a/b were accomplished by using complete NMR data sets of 
each ester. Due to the epimeric centres at C8 and C20 two of the four possible diastereomers 
were visible in the NMR data in the vicinity of each epimeric centre. In Table 6 and Table 7 
the consequential assignments of the protons and carbons based on 1H,13C HMQC, 1H,1H 
COSY, 1H,13C HMBC, and 1H,1H ROESY spectra are presented. The integrals of the proton 
signals were defined for each visible isomer at both epimeric centres. 
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Table 6:  Tris (S)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33a) 
Atom δH  H m J [Hz] COSY δC HMBC ROESY calc. δC 
36 - - - - - 128.9[b] 34,34’ - 129.1 
35,35’ 7.65 4 d br. 8.4 34,34’ 132,3 (35,35’),35,35’ 34,34’ 132.3 
34,34’ 7.77 4 d br. 8.4 35,35’ 129.2 (35,35’) 31 129.4 
33 - - - - - 132.9 35,35’ - 133.0 
32 - - - - - 191.1[b] 34,34’,31 - 190.7 
31 5.27 4 d 0.7 - 65.7 - 2 65.5 
1 - - - - - 189.2 31,2 - 173.0 
2 2.44 4 t br 7.0 3 33.3 >3,4 31 33.9 
3α 1.67[a] c m - 2,4 20.3 2>4 5,4 20.8 
β 1.59[a] c m -      
4 1.71[a] c m - 5,3 32.8 2 - 33.1 
5 5.12[e] 2 m - 4,6 77.3[a] >6,3 4,3,6 74.8 
6α 1.67[a] c m - - 31.3 - (5) 32.7 
β 1.60[a] c m - 5,7   (5),8  
7 [f]         
8 1.35[a] d m - 28,9 32.7 28 (28,9)>6 32.6 
28 0.84 6 t br 7.0 8 19.4 - (8),9 20.2 
9α 1.24[a] d m - CH2 36.8[a] 28 (9) 37.2 
β 1.07[a] d m - 8,CH2  28 (9)  
10-13 CH2         
14α 1.82 c m - 15 28.7[a] - - 30.9 
β 1.57 c m - 15     
15 5.10[e] 2 m - 14 78.9[a] 29 29,CH2 77.6 
16 - - - - - 74.7[b] 29 - 76.8 
29 1.04 6 d 5.9 - 17.2 - 18,17,15 16.7 
17 3.38[a] 1 m - 18 70.2[b] 29 29,18,15,19 72.8 
18α 1.91 d m - 17,19,18β 31.2 30 20,19 31.5 
β 1.75[a] c m - 18α - - -  
19 5.25 1 m - 20,18 78.1[b] 30 (18,20),CH2 76.6 
20 1.75[a] c m - 19,CH2 36.1 30 18,30 37.4 
30 0.78 3 d 7.0 20 15.0 - 20 14.7 
17’ 3.40[a] 1 m - 18’ 71.0[b] 29 29,15 72.8 
18’ 1.86[a]  c m - 17’,19’ 30.7[a] - (18’) 31.5 
19’ 5.12[e] 1 m - 30’,18’α 79.8[a] - 30’ 76.6 
20’ 1.62[a] c m - 19` 35.3 30’ 30’ 37.4 
30’ 0.80 3 d 6.6 20` 13.4 - 20’ 14.7 
21-24 CH2         
25α 1.24[b] d m - 25,CH2 31.8 27,26 - 32.0 
β 1.29b d m - CH2   -  
26 1.30[a] d m - 27,25 22.6 27,25 (27) 22.7 
27 0.89 6 td 7.1, 1.3 26 14.1 - (26) 14.1 
37 [f]        168.9 
38 - - - - - 84.4[b] 44>40,40’ - 84.0 
39 - - - - - 128.3 41,41’ - 132.5 
40,40’ 7.56 12 m - 41,41’,42 127.4 - 41,41’,42 127.4 
41,41’ 7.40 12 m - 42,40,40’ 129.5, 128.4 - - 128.4 
42 7.43 6 m - 41,41’,40,40’ 129.9, 128.6 41,41’,40,40’ - 128.7 
43 [f]        127.5 
44 3.56, 3.50 18 m -  55.5, 55.4  40,40’ 55.5 
33a contains two isomeric centres at C8 and C20 and the integrals are normalized for each visible isomer at each epimeric 
centre; some signals are doubled or broad, the signals from C15 to C20 could be assigned to each isomer. [a] proton shift from 
1H,13C HSQC; [b] 13C shift from the 1H,13C HMBC; [c] integral of overlapping protons between 1.90 – 1.55 ppm of 26 protons; 
[d]
 integral of overlapping protons between 1.35 – 1.15 ppm of 53 protons; [e] 1H shift from the J-resolved spectrum; [f] not 
assigned, due to the low amount of compound. 
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Table 7:  Tris (R)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33b)  
Atom δH  H m J [Hz] COSY δC HMBC ROESY calc. δC 
36 - - - - - 129.3[b] 34,34’,35,35’ - 129.1 
35,35’ 7.65 4 d 8.4 34,34’ 132.3 35,35’ 35,35’ 132.3 
34,34’ 7.77 4 d 8.4 35,35’ 129.2 34,34’,35,35’ 34,34’,31 129.4 
33 - - - - - 133.1[b] 35,35’ - 133.0 
32 - - - - - 191.0[b] 31,34,34’ - 190.7 
31 5.29 4 s - - 65.6[a] - 34,34’ 65.5 
1 - - - - - 172.3[b] 31,2,3  - 173.0 
2 2.51 4 t br 6.6 3 33.4 4 4 33.9 
3α 1.79[b] [c] m - 2,4 20.4[a] 2,4,5 5,2 20.8 
β 1.74[b]         
4 1.76[b] [c] m - 5 32.9[b] 2,3,6 4,5 33.1 
5 5.11[d] [e] m - 4,6 77.2[a] 3,7 3,8 74.8 
6α  1.60[d] [c] m - 5,7 30.9 - 5,4 32.7 
β 1.56[d]         
7α 1.22[a] [c] m - 6,7β,8 31.6[b] 28,5 - 33.1 
β 1.01[a] [c] m - 7α   -  
8 1.26[f] [g] m - 7 32.5[b] 28,28’,6 >28,28’,9 32.6 
28 0.80 3 d 6.6 - 19.5 9 8 20.2 
28’ 0.78 3 d 6.6 - 19.3 9 8  
9α 1.20[a] [g] m - 8 36.7[a] 28,28’ - 37.2 
β 1.02 [g] m - - - - -  
10-13 CH2         
14α 1.85[a] [c] m - 15 28.8 CH2 - 30.9 
β 1.58[a] [c] m - 15     
15 5.10[a] [c] m - 14 78.7[a] 29,CH2 CH2 77.6 
16 - - - - - 75.0[b] 29,15,17 - 76.8 
29 0.97 6 d 6.6 - 16.9+16.8 >15 CH2 16.7 
17 3.31[a] 1 m - 18 70.2[a] 29>18 15 72.8 
18α 1.85[a] [c] m - 17,18β,19 28.8 - 18β 31.5 
β 1.58[a] [c] m - 18α,19   18α,19  
19 5.20 1 m - 18 78.4 30,18α 17,18β 76.6 
20 1.67 [c] m - 30,19 35.3[a] 30 30,18 37.4 
30 0.84 3 d 6.6 20 13.1 - 20 14.7 
17’ 3.28 1 m - 18’ 71.0 29,18’ 19’,20’>30’ 72.8 
18’   1.68[a] [c] m - 17’,19’ 30.7 17’ 19’,17’,30’ 31.5 
19’ 5.07[d] [e] m - 18’ 79.9 30’ 17’,30’ 76.6 
20’ 1.76 [c] m - 30’ 36.0 30’,18’ 19` 37.4 
30’ 0.90[b] [h] m - 20` 13.5 - 20` 14.7 
21-24 CH2         
26 1.29 [g] m - 27,CH2 22.6 27,CH2 (27),CH2 22.7 
27 0.90 [h] m - 26 15.3+14.1 CH2 (26) 14.1 
37 - - - - - 167.2+166.8+166.1[b] 5,15,19 - 168.9 
38 - - - - - 84.7[b] 44, Aromatic - 84.0 
39 - - - - - 128.7+132.3+131.7[b] Aromatic - 132.5 
40,40’ 7.57 12 m - Aromatic 127.6+127.5+127.4 Aromatic Aromatic 127.4 
 41,41’,42 7.41 18 m - Aromatic 129.5-128.4 Aromatic Aromatic 128.4 
43 - - - - - [i] - - 127.5 
44 3.57 6 s br - - 55.4 - - 55.5 
 3.53 12 m - - 55.3 - -  
33b contains two isomeric centres at C8 and C2; integrals were normalized for each visible isomer at the epimeric centre; 
some signals are doubled or broad; the signals from C15 to C20 could be assigned to each isomer. [a] proton shift from 1H,13C 
HSQC; [b] carbon shift from 1H,13C HMBC; [c] integral of overlapping protons 1.88- 1.57 ppm = 26 protons; [d] proton shift 
from 1H,1H COSY correlation; [e] integral of overlapping protons 5.13 – 5.06 ppm = 5 protons; [f] no assignment, due to low 
amount of compound, proton shift from 1H,1H ROESY; [g] integral of overlapping protons from 1.32- 0.99 ppm = 70 protons; 
[h]
 integral of 9 protons at 0.90 ppm; [i] could not be assigned. 
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The presence of the p-bromophenacyl residue was indicated by the expected signals in the 1H 
and 13C NMR spectra as well as several HMBC correlations presented in Figure 21. Between 
31H and 16H only very small shift differences were visible and for both MTPA esters 33a/b 
the common values of this structural element were noted in the NMR tables (Table 6 and 
Table 7). The partial structure between C17 and C20 including methyl group C30, the two 
isomeric structures were separately identified in both esters 33a/b. 
Figure 21 shows the structural elements assigned from the 1H,1H COSY spectra and selected 
HMBC correlations of the tris-(S)-MTPA esters of p-bromoacetophenone-
octahydroroimatacene ester 33a. The position of the MTPA ester residues were indicated by 
their characteristic acyl shifts of 5H (δH 5.12 ppm), 15H (δH 5.10 ppm) and 19H (δH 5.25 and 
5.12 ppm). A COSY sequence between 2H and 6H was assigned and supported by HMBC 
correlations (Table 6). The COSY sequence between methyl group C28 and 9H was allocated 
from unambiguous correlations between 28H and 8H, as well as 8H with 9Hβ. All protons 
between 31H of the p-bromophenacyl residue and 9H showed a doubling of their 1H signals 
with small shift differences due to isomerisation at C8.  
The doublet signals of methyl groups 30H (δH 0.78 ppm) and 30’H (δH 0.80 ppm) were used 
as starting points to establish the COSY sequence between C17 and C20 of both isomers, 
which were confirmed by mutual HMBC correlations. The further connection was revealed by 
the HMBC cross correlations of C17 with 29H and 29’H. The methyl groups C29/29’ 
identified the quaternary carbon C16 by a broad HMBC cross peak. The signal of C15 was 
identified from its HMBC correlation with methyl group C29. Additionally, 15H showed a 
COSY correlation with 14H (δH/C 1.82 and 1.57/28.7 ppm). 
Figure 21. COSY sequences of the tris-(S)-MTPA esters of p-bromoacetophenone-octahydroroimatacene 
ester 33a and selected HMBC correlations. The two separately assigned isomers from 
C15/C15’ to C20/C20’ are presented with their COSY sequence and selected HMBC 
correlations. 
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The (R)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester 33b was assigned 
analogously to 33a (Figure 22). The methylene group C7 was identified from HMBC 
correlations with methyl group 28C and 5H, as well as 7H revealed a COSY correlation with 
6H and 8H. The methyl groups C30 (δH 0.84 ppm) and C30’ (δH 0.90 ppm) were separately 
assigned and used as starting point for the COSY sequences of each isomer up to 17/17’H. 
The quaternary carbon C16 was assigned from HMBC correlations with 15H, 17H and 
29/29’H. The 1H chemical shift of the narrow singlets of methyl group 29H and 29’H was 
averaged to δH 0.97 ppm. Oxymethine C15 was assigned from HMBC correlations with C16 
and mutual HMBC correlations with the methyl groups C29/29’. In addition 15H showed 
COSY cross peaks with 14H at δH 1.85 and 1.58 ppm. 
Figure 22.  COSY sequences of the tris-(R)-MTPA esters of p-bromoacetophenone-octahydroroimatacene 
ester 33b and selected HMBC correlations. The two separately assigned isomers from 
C15/C15’ to C20/C20’ are presented with their COSY sequence and selected HMBC 
correlations. 
After detailed NMR assignment of the diastereomeric MTPA-esters 33a and 33b, the 1H 
chemical shifts of the two Mosher esters 33a/b were compared to calculate the ∆δSR values in 
the vicinity of the MTPA esters (Table 8). 
Table 8:  ∆δSR values of the tris-(S)- and tris-(R)-MTPA esters of p-bromoacetophenone-
octahydroroimatacene ester (33a/b) 
H Ø δH(S-MTPA) Ø δH (R-MTPA)  ∆δSR H Ø δH(S-MTPA) Ø δH (R-MTPA)  ∆δSR 
31 5.27 5.29 -0.02 14α 1.82 1.85 -0.03 
2 2.44 2.51 -0.07 14β 1.57 1.58 -0.01 
3α 1.67 1.79 -0.12 15 5.10 5.10 0.00 
3β 1.59 1,74 -0.15 29 1.04 0.97 0.07 
4 1.71 1.76 -0.05 17 3.39 3.30 0.07 
5 5.12 5.11 0.01 18α 1.91 1.83 0.08 
6α 1.67 1.60 0.07 18β 1.75 1.66 0.09 
6β 1.60 1.56 0.04 18` 1.80 1.68 0.12 
8 1.35 1.26 0.09 19 5.19 5.14 0.05 
28 0.84 0.79 0.05 20 1.69 1.72 -0.03 
9α 1.24 1.20 0.04 30 0.79 0.87 -0.08 
9β 1.07 1.02 0.05     
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Consequently, the absolute configuration of the stereocentres C5, C15 and C19 were 
assigned. The (S)-configuration of C5 was indicated by negative ∆δSR values for 31H to 4H 
and positive values for 6H, 8H, 9H and methyl group 28H (Figure 23). Similarly, the 15S- and 
19R-configurations were identified from completely positive ∆δSR values between both 
stereocentres C15 and C19, and from negative ∆δSR values of 14H, 20H and 30H
 
on both 
sides (Figure 23,Table 8). 
Figure 23.  ∆δSR values after comparison of the 1H NMR data of the tris-MTPA esters 8a/b and the 
evaluation of the stereocentres C5, C15, C19. 
The Mosher-derived 15S,19R-configuration agrees with the relative configuration of 26 
assigned from the acetonide derivatives 28-30 of roimatacene methyl ester (27) described in 
chapter 2.1.3. Thus, the absolute configuration of roimatacene (26) was unambiguously 
derived as all-trans-5S,15S,16S,17S,19R configuration presented in Figure 24. 
Figure 24.  The absolute configuration of all-trans-5S,15S,16S,17S,19R roimatacene (26). 
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2.1.5 The Biosynthetic Precursors of Roimatacene (26) 
In order to determine the biosynthetic precursors of roimatacene (26), Cystobacter 
ferrugineus strain Cb G35 was fed with different amounts of acetate, methionine and 
propionate in pre-experiments to evaluate the optimal feeding concentration for the labelled 
precursors. For this reason 100 mL cultures of Cb G35 were fed with 25, 50, and 100 mg of 
the precursors. The roimatacene (26) production of these cultures are presented in Figure 25. 
Feeding acetate increased the roimatacene (26) production from 1.08 mg/L to 1.20 mg/mL in 
100 mL cultures. This observation was transferred to the up-scale fermentation feeding 1.15-
1.75 g/h sodium acetate (100g/kg). The feeding experiments were conducted with 100 mg of 
[1-13C]- and [2-13C]-labelled acetate and 50 mg of labelled [13CH3]-methionine and [1-13C]-
propionate. 
 
Figure 25. Different concentrations of acetate, methionine and propionate were fed to a Cb G35 culture, 
controlling the roimatacene (26) production under feeding conditions to evaluate the limiting 
concentration of the labelled precursors.  
After feeding [1-13C]- and [2-13C]-labelled acetate, as well as [13CH3]-methionine and [1-13C]-
propionate to 100 mL cultures of strain Cb G35, the labelled roimatacene (26) was isolated 
and 13C NMR spectra were measured. According to 13C NMR analysis, the C3 starter unit 
derives from S-adenosyl-L-methionine (SAM) and acetate as in the case of the biosynthesis of 
apicularen.107 The remaining carbon chain of roimatacene (26) was exclusively assembled 
from acetyl-CoA. The labelling of all methyl groups originated from [13CH3]-methionine. For 
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this reason, roimatacene (26) derived from the [1-13C]-propionate feeding showed no enriched 
13C signals. The results of the feeding experiments are summarized in Figure 26. 
 
Figure 26.  Incorporation of 13C-labelled precursors in roimatacene (26). 
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2.1.6 Biological Activity of Roimatacene (26) 
Roimatacene (26) was screened against various Gram-positive and Gram-negative bacteria, 
yeasts and the fungus Mucor hiemalis (Table 9).108 26 exclusively showed antimicrobial 
activity against Gram-negative bacteria. Due to the instability of roimatacene (26), 26 was 
introduced in methanolic as well as in DMSO solution into the serial dilution test assays. In 
addition, the supernatant of an E. coli tolC assay was analysed by HPLC-HRESIMS to prove 
the stability of roimatacene (26) during incubation of the assays (Appendix, Spectrum 16). 
Accessorily, the test solutions were stabilized by the radical scavenger 4-ethoxyphenol. The 
radical scavenger showed no growth inhibition up to a concentration of 3.4 µg/mL. Thus, the 
maximum concentration of 4-ethoxyphenol used in the roimatacene-test solutions was limited 
to 3.0 µg/mL. The MICs of roimatacene (26) in the µg/mL range are rather moderate. 
In the proliferation assay of the mouse fibroblast cell line L-929 the IC50 of roimatacene is ≥ 
18 µg/mL. At this dilution the IC50 (8.8 µg/mL) of the radical scavenger 4-ethoxyphenol in 
the roimatacene (26)-test solution limited the experiment and therefore no explicit results are 
available. 
Table 9:  MIC of roimatacene (26) in DMSO (1.28 mg/mL + 0.46 mg/mL 4-ethoxyphenol) and in methanol 
(1.34 mg/mL + 0.44 mg/mL 4-ethoxyphenol) 
organism 
MIC  
(µg/mL, 
DMSO) 
MIC  
(µg/mL, 
MeOH) 
organism 
MIC  
(µg/mL, MeOH and 
DMSO) 
Escherichia coli 2 DC 14 PS 2.2 2.3 Micrococcus luteus >9.0 
Pseudomonas stutzeri 4.2 4.4 Schizosaccharomyces pombe >9.0 
Escherichia coli tolC 0.1 0.1 Pichia anomala >9.0 
Escherichia coli CG 8.6 9.0 Rhodotorula glutinis >9.0 
Chromobacterium violaceum 0.3 0.3 Candida albicans >9.0 
Klebsiella pneumonia >8.6 >9.0 Mucor hiemalis >9.0 
Bacillus subtilis >8.6 >9.0 Nocardia flava >9.0 
Staphylococcus aureus >8.6 >9.0 Pseudomonas aeruginosa >9.0 
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2.2 Six p-Hydroxyacetophenone Amides Isolated from Cystobacter 
ferrugineus Cb G35 
2.2.1 Isolation of the p-Hydroxyacetophenone Amides 34a-f 
In addition to roimatacene (26), Cystobacter ferrugineus strain Cb G35 was found to produce 
myxalamide C (24c) and a family of six novel p-hydroxyacetophenone amides 34a-f. These 
were isolated from one fermentation (70 L), which showed a significantly decreased 
production of roimatacene (26). A chromatogram of the crude extract, showing the UV 
spectra of p-hydroxyacetophenone iso-butanamide 34a at 8.2 min, a tremendously decreased 
roimatacene (26) signal at 13.5 min and the myxalamide C (24c), peak at 21.5 min, presented 
in Figure 27. 
 
 
Figure 27.  Standard analytical HPLC of the crude extract of fermentation KVT 268, showing signals of 
roimatacene (26) (peak at 13.5 min), p-hydroxyacetophenone iso-butanamide (34a) (8.2 min) 
and myxalamide C (25c) (21.5 min), detected at 200-500 nm. 
The Amberlite XAD-16 absorber resin was recovered from the culture broth by sieving and 
was eluted with methanol. After evaporation of the organic solvent the remaining aqueous 
mixture was extracted with ethyl acetate. Lipophilic by-products were removed from the raw 
extract by a methanol/n-heptane partition yielding 17.5 g of polar raw material. 1.0 g of the 
methanol extract was fractionated by silica gel flash chromatography and further purified by 
RP-HPLC to yield 59.6 mg of 34a, 7.1 mg of 34b, 3.3 mg of 34c and 6.9 mg of 34d, 
respectively. In order to isolate the minor metabolites, 4.4 g of the polar crude extract was 
processed similarly to yield 0.8 mg of 34e and 1.1 mg of 34f after RP-chromatography. The 
isolation process is displayed in Figure 28. 
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Figure 28.  Isolation of the six p-hydroxyacetophenone amides 34a-f from XAD-16 resin of the Cb G35 
fermentation KVT 268 
2.2.2 Structure Elucidation of the p-Hydroxyacetophenone Amides 34a-f 
The structures of the p-hydroxyacetophenone amides 34a-f were unambiguously elucidated 
using a combination of HRESIMS, as well as 1D and 2D NMR spectroscopic data. 
Table 10:  NMR data of p-hydroxyacetophenone iso-butanamide (34a) 
    34a    
No. δH  H m J [Hz] COSY δC HMBC 
1      164.2 3/5 > 2/6 
2/6 6.90 2 d 8.7 3/ 5 116.4  
3/5 7.94 2 d 8.7 2/ 6 > 8 131.6  
4      128.2 2/6 
7      194.6 8 > 3/5 
8 4.66 2 s  > 3/ 5 46.6  
9      176.0 8, 10 >11 
10 2.21 2 d 7.1 11 > 8 46.2 12/13 > 11 
11 2.14 1 m  12/13 > 10 27.4 12/13, 11 
12/13 1.03 6 d 6.6 11 22.8 12/13, 11 
The main component 34a was crystallized from methanol as white needles and had a 
molecular formula of C13H17NO3 for the [M+H]+ ion at m/z 236.1287 (calcd. 236.1281) 
according to HRESIMS analysis. Subsequent to the assignment of the directly bound protons 
to the corresponding carbons from 1H,13C HSQC, the 1H,1H COSY and 1H,13C HMBC NMR 
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data revealed two substructures, a p-hydroxybenzoyl and a 3-methylbutanoyl unit (Table 10, 
Figure 29). One characteristic key fragment in the HRESIMS was found at m/z 152.0710 with 
an elemental composition C8H10NO2 indicating the presence of an amidic nitrogen linking the 
two subunits. This observation was confirmed by characteristic chemical shifts of the attached 
carbon atoms C8 (δH/C 4.66/46.6 ppm) and the amide C9 (δC 176.0 ppm), as well as congruent 
long-range HMBC correlations shown in Figure 29. Of particular importance, the position of 
the carbonyl group C7 in the aromatic subunit was unambiguously evident from the HMBC 
correlations with 3/5H and 8H as well as from the characteristic chemical shift at δC = 194.6 
ppm. Compatible observations were reported for hibispeptin A (39), a cyclic peptide 
containing an analogous aromatic ketone unit.109 
Figure 29.  The structure of p-hydroxyacetophenone iso-butanamide 34a with COSY derived structural 
elements, selected HMBC correlations and the key fragment in the ESI mass spectrum. 
In addition to 34a, five secondary metabolites of this family were isolated from the crude 
extract of strain Cb G35 presented in Figure 30. The structures of p-hydroxyacetophenone 
amides 34b-f derived from NMR studies analogously to 34a and the NMR data are presented 
in Table 11-12. 
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Figure 30.  p-Hydroxyacetophenone amides 34a-f isolated from Cystobacter ferrugineus, strain Cb G35. 
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Metabolite 34b had a HRESIMS molecular ion at m/z 222.1125 and a corresponding 
molecular formula of C13H17NO3 for the [M+H]+ ion (calc. m/z 222.1125). In 34b an n-propyl 
residue replaced the iso-butyl side chain of 34a. The smallest metabolite 34c with an 
HRESIMS molecular ion at m/z 194.0809 for the molecular formula C10H11NO3 (calc. 
194.0812) showed an acetyl residue with the characteristic methyl singlet at δH = 2.05 ppm as 
amide side chain. The main UV absorption of compound 34d, which had a HRESIMS 
molecular ion at m/z 220.1331 and a corresponding molecular formula of C13H17NO2 (calc. 
220.1332), shifted from 278 nm to 285 nm due to the replacement of the C7 carbonyl group 
by a trans-double bond (3J = 14.5 Hz) conjugated to the aromatic system (Appendix, 
Spectrum 17 and 18). Analogously to 34a, the amide moiety of 34d was an iso-butyl residue. 
The minor compounds 34e and 34f were lipophilic isomers with a common molecular 
formula of C14H19NO3 corresponding to their [M+H]+ ions at m/z 250.1447 (calc. 250.1438). 
Their NMR structure elucidation revealed the difference of their side chains, i.e. an iso-pentyl 
group in 34e and an n-pentyl group in 34f. 
Table 11:  NMR data of p-hydroxyacetophenone n-butanamide (34b) and p-hydroxyacetophenone acetamide 
(34c) (1H 300 MHz, 13C 75 MHz, CD3OD) 
   34b        34c     
No. δH H m J [Hz] COSY δC HMBC No. δH H m J [Hz] COSY δC HMBC 
1      164.2 3/5, 2/6 1      164.4 3/5, 2/6 
2/6 6.90 2 d 8.7 3/5 116.4 2/6 >3/5 2/6  6.86 2 d 8.8 3/5 116.6 2/6 >3/5 
3/5 7.93 2 d 8.7 2/6 > 8 131.6 3/5 3/5 7.90 2 d 8.8 2/6 131.7 3/5 
4      128.1 2/6 > 8 4      128.2 2/6 > 8 
7      194.6 3/5, 8  7      194.7 3/5, 8 
8 4.66 2 s  > 10, 3/5 46.6  8 4.62 2 s  > 10 46.9  
9      176.5 10, 8, 11 9      173.8 8, 10 
10 2.33 2 t 7.4 11, 8 > 12 38.8 11, 12 10 2.05 3 s  > 8 22.5  
11 1.72 2 tq 7.4, 7.4 12, 10 20.3 10, 12         
12 1.03 3 t 7.4 11  14.0 10, 11         
Table 12:  NMR data of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 13C 100 MHz, CD3OD) 
   34d     
No. δH H m J [Hz] COSY δC HMBC 
1      157.6 3/5, 2/6 
2/6 6,75 2 d 8.7 3/5 116.5 2/6 
3/5 7.19 2 d 8.7 2/6 127.7 7, 3/5 
4      129.2 2/6, 8 
7 6.18 1 d 14.5 8 114.8 3/5 > 8 
8 7.31 1 d 14.5 7 121.5 7 
9      172.9 11, 8 
10 2.18 2 m  11 46.2 12/13 > 11 
11 2.16 1 m  12/13, 10 27.5 10, 12/13 
   12/13 1.02 6 d 6.6 11 22.7 12/13 > 10, 11 
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Table 13.  NMR data of p-hydroxyacetophenone iso-pentanamide (34e) and p-hydroxyacetophenone n-
pentanamide (34f) (1H 600 MHz, 13C 150 MHz, CD3OD) 
   34e        34f     
No. δH H m J [Hz] COSY δC HMBC No. δH H m J [Hz] COSY δC HMBC 
1      164.5 2/6,3/5 1 - - - - - 164.4 3/5,2/6 
2/6 6.91 2 d 8.8 3/5 116.6 3/5 2/6 6.86 2 d 8.8 3/5 116.6 3/5 
3/5 7.95 2 d 8.8 2/6 131.7 2/6 3/5 7.90 2 d 8.8 2/6 131.7 2/6 
4      128.2 2/6 4 - - - - - 128.3 2/6 
7      194.8 8,3/5  7 - - - - - 194.4 3/5,8 
8 4.66 2 s   46.8  8 4.62 2 s - - 46.8 - 
9      177.0 10,8,11 9 - - - - - 176.9 8,7>11 
10 2.38 2 m  11>12 35.2 11>12 10 2.31 2 t 7.5 11 37.1 11 
11 1.60 2 m  10,13/14,12 36.1 10,13/14,12 11 1.66 2 quintet 7.5 12,10 26.8 10 
12 1.66 1 m  13/14, 11 29.1 13/14,11,10 12 1.39 2 m - 11,13,14 32.7 14,12,11 
   13/14 0.99 6 d 6.6 12,11, 13/14 22.9 13/14,11,12 13 1.38 2 m - 14,12 23.6 14,12,11 
        14 0.93 3 t 6.6 13,12 14.4 - 
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2.2.3 Biosynthetic Precursors of p-Hydroxyacetophenone iso-Butanamide (34a) 
The biosynthetic precursors of the main metabolite 34a were determined by feeding 
experiments with D-, 13C- and 15N-labelled amino acids in 100 mL cultures. These were 
supplemented with traces of unlabelled methionine to increase the production of 34a in strain 
Cb G35 under feeding conditions. 
Feeding [D10]-leucine resulted in HRESIMS molecular ion clusters at m/z 236.1268 for 
[M+H]+ of the unlabelled compound 34a and at m/z 245.1834 for [C13H7D9NO3+H]+ of the 
[D9]-labelled metabolite 34a showing an incorporation of 65% of the precursor (Appendix, 
Spectrum 59). Consistent with the high incorporation of deuterium, the 1H NMR spectrum of 
the raw sample showed decreased intensities of the 1H signals for the N-acyl residue of 34a 
(Appendix, Spectrum 58). 
Table 14:  13C Incorporation in labelled 34a from feeding experiments with [13C9,15N]-tyrosine.  
Position 13C incorporation [%] from 13C NMR 13C incorporation [%] from 1H NMR 
1 53 - 
2/6 53 51[c] 
3/5 53 53[c] 
4 53 - 
7 53[a] - 
8 53 n.a. 
9 8[b] n.a. 
10 7-8 n.a. 
11 7-8 n.a. 
12/13 7[b] n.a. 
n.a. = signals were not analyzed; [a] calculation with reference C9; [b] calculated from labelled to natural 13C signal ratio;110 
[c]
 calculated 13C incorporation from the 1H NMR spectrum. 
After feeding [13C9,15N]-tyrosine the complete molecule 34a was found to be 13C-enriched in 
the 13C NMR analysis, which is presumably due to partial scrambling of the precursor by 
primary metabolism via fumarylacetoacetate to doubly 13C-labelled acetate. The NMR 
analysis of the [13C9,15N]-tyrosine labelled p-hydroxyacetophenone iso-butanamide (34a) are 
presented in Table 14. Due to the scrambling, the acyl residue showed a low 13C incorporation 
of 7-8%, which was calculated from the doublet signals of the 13C-labelled C9 and the methyl 
groups C12 and C13 compared to their corresponding natural singlet signals (Appendix, 
Spectrum 57).110 In contrast, the 13C signals of the p-hydroxyacetophenone unit in 34a 
showed complex signal patterns due to the intact incorporation of the completely 13C-labelled 
tyrosine (Appendix, Spectrum 57). Representative for this structural unit, a 53% 13C 
incorporation of carbonyl C7 was calculated, compared to the natural singlet signal of C9, the 
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second carbonyl group in 34a. Reference 13C signals for the other carbon types were not 
available. In addition, the 1H NMR spectrum showed broad doublets for the aromatic protons 
of the 13C-labelled part of the sample with a direct CH coupling of 1JC,H ~ 150 Hz.111 
Compared to the unlabelled aromatic proton signals, the doublets indicated 52% 13C 
incorporation, fully supporting the 13C NMR result (Appendix, Spectrum 56). In order to 
assess the incorporation of 15N, the 1H doublet signal of the 15N-labelled NH proton with a 
direct coupling of 1JN,H ~ 95 Hz was compared to the unlabelled singlet NH signal in the 1H 
NMR spectrum to give a 15N incorporation of 30% (Appendix, Spectrum 56). This result was 
supported by HRESIMS of the sample, which showed the natural key fragment 
[C8H9NO2+H]+ at m/z 152.0701 and two labelled monoisotopic ions (Appendix, Spectrum 
60). One peak at m/z 161.0938 for [13C8H915NO2+H]+ with 29% incorporation of the complete 
labelled fragment and a second ion with 30% at m/z 160.0966 for [13C8H9NO2+H]+ missing 
the labelled nitrogen. The total 13C incorporation of 59% for the fragment ion of 34a is in 
good agreement with the results from the NMR analyses. 
2.2.4 Biological Activity of p-Hydroxyacetophenone Amides 34a-f 
The p-hydroxyacetophenone amides 34a-f were tested up to a concentration of 100 µg/mL but 
did not show any significant antibiotic activity against Mucor hiemalis, Gram-positive 
bacteria (Staphylococcus aureus, Nocardia flava, Micrococcus luteus), Gram-negative 
bacteria (Escherichia coli, Chromobacterium violaceum) or yeasts (Candida albicans, 
Rhodotorula glutinis, Pichia anomala, Schizosaccharomyces pombe). In addition 34a-f were 
screened against various micro algae (Scenedesmus bajacalifornicus, Chlamydomonas sp., 
Bracteacoccus sp., Pseudococcomyxa simplex and Botryococcus brauni), and only 34d 
induced growth inhibition of Pseudococcomyxa simplex at the highest concentration tested 
(100 µg/mL). Similarly, 34a-f showed no cytotoxic effect or growth inhibition in cell culture 
assays with human leukemic U-937 cells up to a concentration of 100 µg/mL. 
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2.3 Sulfangolids, Macrolide Sulfate Esters from Sorangium cellulosum  
2.3.1 Verification of the Proposed Structures of Sulfangolids 25a-d 
Sulfangolid A (25a) was isolated from Sorangium cellulosum strain So ce666 during my 
diploma thesis. In the HRESIMS 25a showed a molecular ion cluster [M-H]- at m/z 663.3208 
for the molecular formula C35H51O10S (calc. 663.3206). In the direct chemical ionisation mass 
spectrum 25a provided a highly abundant negative charged fragment ion at m/z 566 (100%). 
The characteristic loss of 97 u suggested the elimination of a HSO4- residue. The sulfate 
residue was also present in the IR spectrum with strong bands at 1252 (s) and 1011 (s) cm-1. 
The absorption at 342 nm in the UV spectrum indicated a tetraene chromophore conjugated 
with a carbonyl group and a second absorption at 283 nm suggested a dienone chromophore.  
The detailed structure was elucidated by 1D and 2D NMR spectroscopy (Table 15). A 1H,13C 
HMQC spectrum correlated the protons to their directly bound carbons and the analysis of the 
1H,1H COSY spectrum furnished four structural elements A–D (Figure 31). The exchangeable 
protons of the alcohols were assigned to oxygenated methines C14 and C17 from their 1H,1H 
COSY correlations, thus locating the sulfate moiety to the oxygenated methine C13 (δH/C 
4.36/77.4 ppm). The lactone carbon C1 (δC 165.1 ppm) showed HMBC correlations with 2H 
and 3H of subunit A. Due to the high order spin system of the olefinic protons, the coupling 
constants in Table 15 were deduced from a simulated 1H spectrum using ACD/C+H Predictor 
(Version 11) to match the observed 1H NMR signal pattern of 25a (Appendix, Spectrum 69). 
All double bonds of the tetraene in subunit A were trans-configured according to their vicinal 
coupling constants 3J of 15 Hz. 
The structural elements A and B were connected via carbonyl C15 (δC 217.5 ppm) by HMBC 
correlations with 14H, 14OH of subunit A and 16H and methyl group C32 of subunit B. 
Carbonyl C21 (δC 202.2 ppm) displayed cross peaks in the HMBC spectrum with methyl 
group C33 of subunit B and with the unsaturated methines 22H and 23H of subunit C. 
Subunit C was further connected to the quaternary carbon C24 (δC 134.2 ppm) and subunit D 
following several HMBC correlations: the mutual HMBC correlations between methyl group 
C34 and methines 23H and 25H, as well as between methines 23H and 25H, and the 
quaternary C24 with 22H and 34H. The trans-configuration of the double bonds was 
unravelled from the vicinal coupling constant 3J22,23 of 15.4 Hz and the 1H,1H ROESY 
correlation of methyl group C34 with 22H and 25H, as well as correlations between 23H and 
25H. The last double bond equivalent was used to close the macrolide ring of sulfangolid A 
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(25a) at position C27, which was indicated by a characteristic acyl shift of 27H (δH/C 
4.91/74.2 ppm). 
Figure 31.  The structures of sulfangolid A (25a) and sulfangolid B (25b) with the COSY sequences and 
selected HMBC correlation. 
Sulfangolid B (25b) was isolated from Sorangium cellulosum strain So ce192 (H. Irschik, R. 
Jansen) and showed a molecular ion cluster [M-H]- at m/z 693.3314 in the HRESIMS 
establishing the molecular formula of C36H53O11S (calc. 693.3308). Similar to sulfangolid A 
(25a), variant B (25b) showed analogue COSY sequences and HMBC correlations presented 
in Figure 31. Sulfangolid B (25b) differed from 25a by an additional methoxy group in the 
unusual position at C2 (Table 16). The position of the methoxy group was indicated by the 
chemical shift of quaternary carbon C2 at δC 145.5 ppm showing HMBC correlations with the 
methoxy group (δH/C 3.75/60.8 ppm) and with methines 3H and 4H (Figure 31). 
Sulfangolid C (25c) was isolated from Sorangium cellulosum strain So ce12 during my 
diploma thesis. The compound 25c showed a molecular ion [M-H]- at m/z 681.3314 in the 
HRESIMS establishing the molecular formula C35H53O11S (calc. 681.3317). The UV 
maximum at 311 nm indicated the loss of one conjugated double bond from the unsaturated 
lactone chromophore compared to 25a. Subsequently to 1H,13C HSQC analysis, the 1H,1H 
COSY data revealed five structural fragments A-E (Figure 32). The lactone C1 was connected 
with fragments A and D from HMBC correlations with 2H and the acyl proton 27H (δH/C 
4.94/74.4 ppm). The quaternary carbon C15 was correlated with 13H and 14H of fragment A 
and 16H and methyl group C31 of fragment B. In addition, C15 showed a characteristic 
carbon shift of a hemiketal at δC 100.4 ppm. A six-membered ketal ring was formed with the 
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oxymethine C19 (δH/C 3.84/68.3 ppm) of fragment B, which was supported by nOe 
correlations between 15OH, 17H and 19H. Further carbonyl C21 showed HMBC correlations 
with methyl group C32 and 23H of subunit C. The quaternary carbon C24 connected 
fragment C and D, evident from various HMBC correlations of C24 with 22H and 23H, as 
well as with 25H. In addition the directly bound methyl group C34 showed HMBC 
correlations with 23H, and the mutual HMBC cross peaks between C23 of subunit C and C25 
of subunit D (Figure 32). The final connection of the iso-butyl side chain was accomplished 
by HMBC correlations of C27 and C29, as well as mutual HMBC cross peaks between the 
methyl groups C30, C31 and C28. 
Figure 32.  The structures of sulfangolid C (25c) and sulfangolid D (25d) with the COSY sequences and 
selected HMBC correlations important for the structure elucidation. 
Sulfangolid D (25d) was isolated from Sorangium cellulosum strain So ce1375 (K. Gerth, M. 
Herrmann). The HRESIMS analysis showed a molecular ion cluster [M-H]- at m/z 677.3343 
for the elemental composition C36H53O10S (calc. 677.3365). After 1H,13C HSQC analysis, four 
structural subunits were assigned from the 1H,1H COSY spectrum of 25d. Subunit A was 
correlated by HMBC correlations of C1 with 2H and 3H, and on the other side to carbonyl 
C15 by HMBC cross peaks of C15 with 14H. On the other hand, C15 showed HMBC 
correlations with 16H and 32H of fragment B. The quaternary carbon C21 was HMBC 
correlated with a methoxy group (δH/C 3.15/49.8 ppm) while its characteristic carbon shift at 
δC 103.2 ppm indicated a ketal carbon. This ketal was formed within subunit B as six-
membered ring with the ether at C17, due to the characteristic chemical shifts of δH 3.63 ppm 
and δC 72.5 ppm. Further C21 was connected to fragment C by HMBC correlations of 22H 
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and 23H. The quaternary carbon C24 and the methyl group C33 interconnected fragment C 
and fragment D according to various HMBC correlations of C24 with 22H and 23H, as well 
as mutual HMBC correlations of methyl group C34 with 23H and 25H presented in Figure 32. 
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Table 15:  NMR data of sulfangolid A (25a) (1H 600 MHz; 13C 150 MHz, [D6]DMSO) 
Atom δH m J [Hz] COSY[a] ROESY[a,b] δC HMBC[c] 
1 - - -   165.1 2>>3 
2 5.76 d 14.8[d] 3 4 o. 5>>34 119.8  
3 6.88 m 14.8, 11.0[d] 4 o. 5, 2 4 o. 5>>34 145.2  
4 6.35 m 11.0, 15.0[d] 3, 6 o. 7 2 o. 3>>33, 34 128.4 2 
5 6.36 m 15.0, 11.0[d] 3, 6 o. 7 2 o. 3>>33, 34 142.1 6 o. 7 
6 6.23 m 15.0, 11.0[d] 4 o. 5, 8 4 o. 5, 9>33 128.9 4 o. 5 
7 6.22 m 15.0, 11.0[d] 4 o. 5, 8 4 o. 5, 9>33 138.6  
8 6.14 m 14.8, 11.0[d] 7 o. 6, 9 (9), 10β 130.6  
9 5.67 ddd 14.8,  10.1, 4.8 8, 10α/β (10α),10β,  6 o. 7 139.0  
10α 2.30 m  10β, 9, 11α/β (10β) 32.1  
10β 1.92 m  10α, 9 (10α, 9), 8   
11α 1.69 m  11β, 12β>10α/β (10α), 9, 8 24.9  
11β 1.26 m  11α, 12β>10 α /β, 12α 13>9   
12α 1.00 m  12β, 11β>13 (13)>9 28.4 14 
12β 1.47 m  12α, 11α/β, 13 (13)   
13 4.36 dd 10.0, 2.1 14, 12α/β 14OH, 12β, 11β>12α>11α>10α 77.4 14OH 
14 4.46 dd 6.6, 2.1 13, 14OH 32, (14OH), 16 77.2  
14OH 5.76 d 6.6 14    
15 - - -   217.5 32, 16, 14, 14OH 
16 3.01 dq 9.3, 7.2 17, 32 (32), 14OH, 18β>18α, 14, 17OH 47.9 32 
 32 1.00 d 7.2 16 (16), 17>17OH, 14 14.6  
17 3.34 dddd(br) 9.3, 7.3, 1.3, 9.5 16, 18α>18β 32, 19β, 18α, 19α 71.3 32 
17OH 4.39 d 7.3 17 32, 16>19α   
18α 1.33 m  18β, 19α, 17 33 33.8 17OH 
18β 0.83 m Σ32.2[f] 18α, 19α/β, 17 (19α), 16>20   
19α 1.92 m  19β, 18α>11α/β, 18β  (20, 19β), 22, 14OH 28.9 33 
19β 0.89 m Σ31.4[f] 19α, 18α/β >17   
20 2.34 ddq 9.5, 7.0, 2.5 33, 19α/β 22, 19α>18β 45.6 33 
 33 0.95 d 7.0[e] 20 (20), 22>4 o. 5 15.4  
21 - - -   202.2 33>22, 23 
22 6.20 d 15.4 23 34, 20>19α 122.8  
23 7.20 d 15.4 22 25  145.9 34>25  
24 - - -   134.2 34>22 
 34 1.52 s  25 26, 22>3>2>4 o. 5 12.6 23, 25 
25 5.98 d 11.2 26, 34 23, 28α, 35 142.3 35, 34>23 
26 2.93 ddq 11.2, 11.5, 7.0 25, 35>27 34, (27>35) 35.4 30, 31, 35 
 35 0.95 d 7.0[e] 26 25>27, 28β, (26) 15.9 26, 25 
27 4.91 ddd 11.5, 4.5, 2.0 26, 28α/β 35, 31, 26, 29, (28β) 74.2 35 
28α 1.58 m  28β, 27 25 35.3 35 
28β 1.33 m  28α, 27, 29 35, (27)   
29 1.47 m  28β, 30, 31 27 24.2 30, 31 
30 0.85 d 6.4 29 (29) 23.4 31 
31 0.81 d 6.4 29 (29), 27  21.0 30 
NH4+ 7.03 s(br)      
[a]
 signals are sorted by intensity. [b] vicinal nOe are indicated by brackets. [c] sorted by intensity of the cross peaks. 
[d]
 overlapping signals of higher order, coupling constants were calculated by ACD/C+H NMR Predictor (Version 11). 
[e]
 overlapping signals. [f] data from J-resolved spectrum. 
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Table 16:  NMR data of sulfangolid B (25b) (1H 600 MHz; 13C 150 MHz, CD3OD) 
Atom δH m J [Hz] COSY δC HMBC 
1 - - - - 164.6 3, 27 
2 - - - - 145.5 3, OMe 
OMe 3.75 s - - 60.8 - 
3 6.55 ma - 4 128.2 5,4 
4 6.55 ma - 3,5 125.2 6 
5 6.36 m - 4,6 140.6 3,7 
6 6.29 mb - 5,7 131.1 4,8 
7 6.29 mb - 6,8 138.6 5,9 
8 6.19 m - 7,9 132.5 6, 10 
9 5.78 ddd 14.8, 10.1, 4.7 8,10 139.1 10β, 11β 
10α 2.46 m - 9, 11 33.7 - 
10β 2.08 md -    
11α 1.80 m - 10,12 26.1 9 
11β 1.50 m -    
12α 1.63 m - 11, 13 29.6 14, 10 
12β 1.28 m -    
13 4.75 dt 10.1, 2.2 12, 14 81.6 - 
14 4.79 d 2.2 13 78.8 - 
15 - - - - 217.5 14,16,32 
16 3.18 mc - 32,17 48.7 - 
 32 1.20 d 7.1 16 14.4 17,16 
17 3.66 ddd 10.5,9.3,1.9 16, 18 73.7 32,19 
18α 1.57 m - 17,19 35.0 16 
18β 1.12 m -    
19α 2.08 md - 18, 20 30.7 17, 33 
19β 1.23 m -    
20 2.58 qt 7.0, 6.7 19,33 47.3 - 
 33 1.14 d 6.7 20 16.5 19 
21 - - - - 205.9 22,23,20,33,19 
22 6.34 d 15.5 23 124.1 - 
23 7.37 d 15.5 22 148.4 25, 34 
24 - - - - 136.3 22,26,34 
 34 1.70 d 3.9 - 13.1 26,25,23 
25 6.03 d 10.9 26 143.7 27,35, 34, 23 
26 3.18 mc - 27,25,35 37.0 - 
 35 1.09 d 6.9 26 16.3 25,26 
27 5.12 ddd 11.4, 4.8, 2.0 26,28 77.3 25 
28α 1.68 m - 27,29 37.1 30,31,26 
28β 1.50 m -    
29 1.63 m - 30,31,28 25.9 27 
30 0.99 d 6.6 29 24.0 28,31 
31 0.96 d 6.6 29 21.6 29,30 
[a]
 multiplet of 3H and 4H at 6.55 ppm; [b] multiplet of 6H and 7H at 6.29 ppm; [c] multiplet of 16H and 26H at 3.18 ppm; 
[d]
 multiplet of 10Hβ and 19Hα in between 2.12 and 2.03 ppm. 
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Table 17:  NMR data of sulfangolid C (25c) (1H 600 MHz, 13C 150 MHz, [D6]DMSO) 
Atom δH  m J [Hz] COSY[a] ROESY[a,b] δC HMBC[c] 
1 - - -   165.1 2, 3>27 
2 5.81 d 15.2 3 (3), 4, 33 120.3 4 
3 6.91 dd 15.2, 11.2 2,4 (2, 4), 5, 33 144.4 5 
4 6.31 dd 14.7, 11.2 3,5 (3, 5), 2>6 127.5 2>3,6 
5 6.44 dd 14.7, 10.6 4, 6 (4, 6), 3, 7>>8α, 32  141.3 3, 4, 7 
6 6.19 dd 15.1, 10.6 5, 7 (5), 4>8α 130.3 4>8α 
7 5.87 ddd 15.1, 9.3, 5.3 6, 8α/β (6, 8α/β), 5 >>32 140.8 5>8α 
8α 2.08 m  7, 8β, 9α/β (7, 9α/β), 6 31.0 6 
8β 2.19 m  7, 8α, 9α/β (8α, 9α/β), 6>5   
9α 1.45 m  8α/β, 10  28.9 >>8α/β 
9β 1.32 m  8α/β, 11α, 10    
10 1.26 m  11, 9α/β 13 27.7 8α/β 
11α 1.41 m  12, 10  13 26.3  
11β 1.26 m  12    
12 1.51 m  13  30.7 13, 6 
13 4.39 t (br) 6.4 12, 14 (14), 15OH, (12β), 11, 33 78.1 11 
14 3.87 d (br) 7.55, (1.1[d] ) 14OH > 13 > 15OH (13, 14OH), 15OH, 32, 16 75.1 14OH, 15OH 
14OH 4.73 d (br)  14 (14>15OH), 16   
15 - - -   100.4 32, 16, 14OH, 15OH > 14, 13 
15OH 5.49 s   13, 14, 19 (17, 32)   
16 1.65 dq (br) 10.4, 6.6 17, 31, 14OH (32, 17), 17OH, 14OH, 14 41.6 15OH, 14OH, 14 
32 0.86 d 6.6 16 14, 17OH>15OH>14OH 11.2 16>>17 
17 3.39 ddd (br) 10.4, 10.8,  5.3 18α, 16, 18β (18α, 17OH), 19, 32>15OH 67.6 32, 17OH, 16 
17OH 4.33 d 5.3 17 (>17, 18α), 16   
18α 1.77 ddd(br) 11.7, 4.5, 1.8 18β, 19, 17 (17OH, 19, 17) 39.0  
18β 0.88 ddd[e] 11.7, 11.8, 10.8[e] 18α, 19, 17 (19, 17), 20   
19 3.84 ddd(br) 11.8, 10.0, 1.8 20, 18α/β (20, 18α), 17, 33 68.3 33 
20 2.68 dq 10.0, 7.2 19, 33 (33, 19), 22, 18β, 23 51.4 33 
33 1.05 d 7.2 20 (20), 19, 22, 5, 13>7 15.2 20>>19 
21 - - -   201.5 33>23, 22>20  
22 6.34 d 15.5 23 (23), 34, 20>32 124.2  
23 7.18 d 15.5 22 (22), 25, 34>>20 146.2 34>25 
24      134.2 34, 22>23, 26 
34 1.61 d(br) 0.8 25 22, 26>3 12.6 23>25 
25 6.0 d 11.0 26, 33 23>(26), 34, 28α 142.7 34, 23>27 
26 3.01 ddd 11.0, 7.2, 4.6 27, 25, 35 (35, 25, 27), 34, 30, 28β  35.2 35 
35 1.00 d 7.2 26 27, 25, (26), 28β 15.8 26, 25 
27 4.94 ddd 11.5, 4.6, 2.8 26, 28α/β 34, 35, 30, 29, (28β, 26) 74.4 35, 26>28α 
28α 1.58 ddd(br) 14.2, 11.5, 4.2 27, 28β (28β), 25, 27 35.6 30, 31, 26 
28β 1.36 m  27, 28α (27), 35>>25, 26   
29 1.49 m  30, 34, 28β 27 24.2 30, 35, 27 
30 0.88 d 6.8 29  23.4 31, 28α/β 
31 0.84 d 6.8 29 27, 26 21.1 30>28α/β 
NH4+ 7.06 s(br)   15OH, 14OH, 17OH   
[a]
 signals are sorted by intensity. [b] vicinal nOe are indicated by brackets. [c] signals are sorted by intensity of the cross peaks. 
[d]
 after H/D-exchange. [e] data from J-resolved spectrum. 
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Table 18:  NMR data of sulfangolid D (25d) (1H 300 MHz, 13C 75 MHz, CD3OD) 
Atom δH  m J [Hz] COSY[a] δC HMBC[b] 
1 - - - - 168.3 2 >3 
2 5.80 d 15.5 3 121.5 - 
3 7.11 m - 2, 4 o. 5 147.0 - 
4 6.46[c] m - [d] 130.5 3,2 
5 6.45[c] m - [d] 143.3 3 >6 o. 7 
6 6.33[c] m - [d] 131.1 4 o. 5 
7 6.34[c] m - [d] 139.2 - 
8 6.26[c] m - [d], 9 132.9 - 
9 5.69 ddd 14.2, 10.6, 3.7 10α/β, 8 140.2 - 
10α 2.52 m - 9, 10β, 11α 34.2 - 
10β 2.02 m - 9,10β, 11α/β   
11α 1.98 m - 12α/β, 11β, 10α/β 26.3 - 
11β 1.36 m - 12α/β,11α   
12α 1.60 m - 11α/β, 13,12β 30.5 14 
12β 1.30 m - 11α/β, 13,12α   
13 4.40 dt 10.7, 1.5 14, 12α >β 83.1 14 
14 4.76 d 1.5 13 80.6 - 
15 - - - - 218.3 14,32>16 
16 3.12 dq 9.6,6.9 17, 32 49.3[e] 32, 17 
32 1.20 d 6.9 16 15.4 >16 
17 3.63 m - 16,18α/β 72.5 32>16 
18α 1.60 m - 17, 19, 18β 32.1 - 
18β 1.09 m - 19,18α   
19 1.64 m - 18α, 20 28.7 33 
20 1.57 m - 19, 33 40.3 33 
33 1.04 d 6.8 20 16.4 >20 
21 - - - - 103.2 23,22,33 >>OMe 
OMe 3.15 s - - 49.8[e] >20 
22 5.15 d 16.4 23 128.0 >23 
23 6.22 d 16.4 22 138.2 35, 22 
24 - - - - 136.2 35, 23, 22 
34 1.60 d 0.9 - 13.7 23 
25 5.44 d 10.5 26>35, 23 133.5 35,36,23 
26 3.06 m - 25,36> 27 36.2 36 
35 1.07 d 6.8 26 16.7 >26,25 
27 5.04 ddd 10.5,4.7,2.4 26,28 α/β 77.1 36 
28α 1.63 m - 27,29 37.4 30,31 
28β 1.46 m - 27   
29 1.65 m - 30,31,28α 26.1 30,31 
30 0.98 d 6.4 29 24.1 31 >29 
31 0.94 d 6.4 29 21.9 30 >29 
[a]
 signals are sorted by intensity. [b] signals are sorted by intensity of the cross peaks. [c] multiplet from 6.46 to 6.26 ppm 
containing 5 protons. [d] Overlapping COSY cross correlations in the multiplet from 6.46 to 6.26 ppm. [e] 13C shift from the 
HMBC correlation. 
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2.3.2 The Relative Configuration of Sulfangolid C (25c) 
The relative configuration of sulfangolid C (25c) was determined utilizing 1D and 2D NMR 
studies (Table 17) assisted by molecular modelling with HyperChem (Version 8.5). The 28-
membered macrolide ring of sulfangolid C (25c) contains three large inflexible structural 
elements, the triene lactone, the six-membered hemiketal ring and the dienone, which 
alleviated the modelling. Analogously to sulfangolid A (25a), the double bonds of the lactone 
and the unsaturated ketone of 25c maintain the all-trans-configuration. The six-membered 
hemiketal formed the basis for the elucidation of the relative configuration. Initially, the seat 
conformation of the hemiketal was assigned from nOe correlations of 15OH, 17H, 19H 
indicating their coaxial positions (Figure 33). Further nOes of 15OH, 17H and 19H with 
18Hα and methyl group C32 defined the equatorial positions of 18Hα and C32 in the 
hemiketal. The axial position of 18Hβ (δH 0.88 ppm, ddd) was supported by three trans 
coupling constants between 11.8 and 10.8 Hz for 3J17,18β, 3J19,18β, and the geminial 2J18α,18β 
coupling constants observed in the J-resolved NMR spectrum (Appendix, Spectrum 91). 
Further, the vicinal coupling constant 3J16,17 of 10.4 Hz between 16H and 17H was only 
feasible for a coaxial relation of both protons. Another large vicinal coupling constant 3J19,20 
of 10.0 Hz positioned 20H anti to 19H, which is realized in the model (Figure 33) by a 
dihedral angle φ19H,20H of 165.9°. This anti-position was supported by the nOe of 20H with the 
axial 18Hβ (2.4 Å) while the methyl group C33 at C20 points into the macrolide ring as 
indicated by nOe correlations with 19H, 13H, 5H and 7H. The nOe observations are fully 
compatible with the modelled configuration (Figure 33) by the calculated distances of 2.4 Å 
between 33H and 13H, as well as 1.7 Å between 33H and 5H and 2.4 Å between 33H and 7H 
across the macrolide ring. The methyl group C34 substituting the trans-diene inclines towards 
the lactone ring according to the nOe correlation with 3H. The vicinal coupling 3J25,26 of 11.0 
Hz indicates a transoid-relation between both methines 25H/26H which is compatible with 
the dihedral angle φ25H,26H of 167.3° in the model. This position is additionally indicated by 
the nOe between 26H and methyl group C34. Consequently, the exocyclic orientation of 
methyl group C35 was supported by the nOe with 25H. The position of the macrolide at C27 
was assigned on the basis of the small coupling constant 3J26,27 of 4.6 Hz compatible with a 
calculated torsion angle φ26H,27H of 57.2° and the nOe correlation between 27H and 35H.  
On the opposite side of the ketal ring, the position of 14H was indicated by nOe correlations 
with the axial 16H and the equatorial methyl group C32 feasible for an anti-orientation of 
14H and 15OH. The small coupling constant 3J13,14 of 1.1 Hz observed after H/D-exchange 
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reflects the calculated torsion angle φ13H,14H of 75.5° in the model. In addition, the nOe 
between 13H and 33H crossing the lactone ring was observed in the 1H,1H ROESY spectrum 
of sulfangolid C (25c). Both relative configurations, the 13R* and the 13S* of 25c, were 
modelled with HyperChem (Figure 33 and Figure 34). In each case the configuration with the 
lowest global minimum showed very similar torsion angles for φ13H,14H (13R* = 75.5°, 13S* = 
82.9°) and a similar distance between 13H and 33H with 2.6 and 2.4 Å (Table 19 and Table 
20), well matching the observed nOes. However, in the 13R*-model the smaller distances 
across the macrolide ring between methyl group C33 with 5H (1.7 Å) and 7H (2.4 Å) agree 
with the observed nOes of 33H far better than the corresponding distances of 3.7 and 4.2 Å in 
the 13S*-model (Table 20). Additionally, the 13R*-configuration included two hydrogen 
bonds stabilizing the position of the sulfate ester residue. For these reasons the 13R* 
configuration of sulfangolid C (25c) is favoured. The resulting all-trans 
13R*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* configuration of sulfangolid C (25c) is 
presented in Figure 35. 
Figure 33.  The model of all-trans 13R*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* sulfangolid C (25c) 
with selected nOe correlations. Two hydrogen bonds are formed between the sulfate group at 
C13 and 15OH and between 15OH and 14OH. 
 
 
 
 
Results 
- 58 - 
Table 19.  The proton/proton distances and dihedral angles φ of all-trans 13R*,14S*,15R*,16R*,17S*,19S*, 
20R*,26R*,27R* model of sulfangolid C (25c) presented in Figure 33. 
 
 
Figure 34.  Model with the lowest global minimum of sulfangolid C (25c) with 13S*,14S*,15R*,16R*,17S*, 
19S*,20R*,26R*,27R* configuration and selected nOe enhancements. 
Table 20:  The measured proton/proton distances and dihedral angles φ of the modelled 
13S*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* configuration of sulfangolid C (25c) presented in 
Figure 34. 
Position 
 
dihedral angle φ  
[degree] 
atom distance 
[Å] 
Position 
 
dihedral angle φ  
[degree] 
atom distance 
[Å] 
13H,14H 82.9  33H,5H  3.7 
13H,33H  2.6 33H,7H  4.2 
14H,32H  3.0 22H,34H  1.8 
14H,16H  2.2 23H,25H  2.4 
16H,17H 171.5  34H,3H  3.7 
17H,18Hβ 173.8  34H,26H  1.8 
17H,18Hα 56.9  25H,35H  2.6 
18Hβ,19H 176.6  25H,26H 174.5  
18Hβ,20H  2.6 25H,28Hα  2.2 
19H,33H  2.6 26H,27H 46.7  
19H,20H 173.5  35H,27H  2.6 
33H,22H  1.8 27H,29H  2.6 
 
Position dihedral angle φ 
[degree] 
atom distance [Å] Position dihedral angle 
φ [degree] 
atom distance 
[Å] 
13H,14H 75.5  33H,5H  1.7 
13H,33H
 
 2.4 33H,7H  2.4 
14H,32H
 
 3.3 22H,34H
 
 1.8 
14H,16H  2.4 23H,25H  2.4 
16H,17H 169.2  34H,3H  3.8 
17H,18Hβ 174.1  34H,26H  1.8 
17H,18Hα  2.5 25H,35H
 
 2.8 
18Hβ,19H 176.7  25H,26H 167.3  
18Hβ,20H  2.4 25H,28Hα  2.5 
19H,33H
 
 2.7 26H,27H 57.2  
19H,20H 165.9  35H,27H  2.6 
33H,22H  2.8 27H,29H  2.3 
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Figure 35.  The relative configuration of all-trans 13R*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* 
sulfangolid C (25c). 
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2.3.3 Studies towards the Biosynthetic Precursors of Sulfangolid C (25c) 
Two sulfangolid C (25c) producer strains So ce757 and So ce804 were analysed for their 
sulfangolid C (25c) production and found to synthesise 19 mg/L and 8.5 mg/L, respectively. 
Subsequently, strain So ce757 was used to inoculate a 70 L fermentation to observe the 
production kinetics of 25c presented in Figure 36. Sulfangolid C (25c) is produced during 
days 2-8 in the exponential growth phase of the strain. In addition, the increasing glucose 
concentration in the supernatant was correlated to the 25c production (Figure 36). As the 
strain grew in lumps this observation was used to determine the beginning of feeding the 
labelled precursor. In order to have a high incorporation, the precursors were fed in equal 
portions during sulfangolid C (25c) production starting at a glucose content of 0.25% in the 
medium.  
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Figure 36.  Sulfangolid C (25c) production in a 70 L fermentation of strain So ce757, measuring the 
glucose concentration in the media. 
[1-13C]-, [2-13C]- and [1,2-13C]-acetate, as well as [1-13C]-propionate, and [D10]-leucine were 
fed as biosynthetic precursors to Sorangium cellulosum strain So ce757. Subsequent to 
purification from the crude extract, 13C NMR spectra of each isolated compound were 
measured. The resulting 13C enriched NMR signals of sulfangolid C (25c) are listed in Table 
21.  
The starter unit of the sulfangolid C (25c) biosynthesis was identified as isovaleryl-CoA 
derived from leucine followed by two extensions with methylmalonyl-CoA precursors.112,113 
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The following ketone at C21 originates from C1 of malonyl-CoA. The metabolite 25c is then 
elongated by units derived from propionate, acetate and the last propionate unit within the 
hemiketal, synthesising all methyl groups from propionate. The remaining part of 25c is 
assembled from acetate exclusively. The sulfate residue at C13 presumable originates from 
sulfate in the medium, since the production of 25c decreased dramatically from 19 to 2 mg/L 
after two passages in the same but sulfate-free medium. The final product 25c is presumably 
released from the polyketide synthase assembly line (PKS) by lactonization.51  
Table 21:  Results of the feeding experiments: 13C enriched NMR signals of labelled acetate (table) and 
propionate (table footnote) as well as HRESIMS and 1H NMR analysis of [D10]-leucine feeding 
experiments (table footnote). 
n.e. = not enriched carbon signal, [a] high enrichment ratio signal/noise (= 1), [b] enrichment calculated with unlabelled 
reference signal; [c] enrichment calculated by the ratio of labelled doublet signal to unlabelled singulett signal of the 
respective carbon; [d] signal was not observed, [e] in. = incorporation, no reference carbon available for the calculation of the 
enrichment, [f] 13C signal is overlapping with DMSO signal and no analysis was possible. [1-13C] propionate labelled carbons 
(enrichment) [a]: C15 (43.8), C19 (35.8), C23 (33.8) and C25 (29.5); [D10]-leucine incorporation as [M-H+9D]- in HRESIMS 
obsd. 690.3867 (calc. 690.3879 for [C35H44D9O11S]-) and decreased 1H NMR signals for 30H (δH 0.88 ppm) and 31H (δH 
0.84 ppm). 
Pos.[1-13C] acetate 
enrichment[a] 
[2-13C] acetate 
enrichment 
[%][b] 
[1,2-13C] acetate 
enrichment [%, m, 
1Jc,c Hz][c] 
Pos. [1-13C] acetate 
enrichment[a] 
[2-13C] acetate 
enrichment 
[%][b] 
[1,2-13C] acetate 
enrichment [%, m, 
1Jc,c Hz][c] 
1 30 n.e. 2, d, 75.7 18 n.e.[d] n.e. n.e. 
2 n.e.[d] 6 2, d, 75.7 19 n.e.[d] n.e. n.e. 
3 27.5 n.e. 1, d, 55.8 20 n.e.[d] n.e. n.e. 
4 n.e.[d] 5 1, d, 55.8 33 n.e.[d] n.e. n.e. 
5 33.5 n.e. 1, d, 54.6 21 29.5 n.e. 3, d, 52.8 
6 n.e.[d] 7 1, d, 54.6 22 n.e.[d] 4 2, d, 52.8 
7 27 n.e. 1, d, 42.2 23 n.e.[d] n.e. n.e. 
8 n.e.[d] in.[e] 1, d, 42.2 24 n.e.[d] n.e. n.e. 
9 27 n.e. 2, d, 36.0 34 n.e.[d] n.e. n.e. 
10 n.e.[d] in.[e] 1, d, 36.0 25 n.e.[d] n.e. n.e. 
11 25 n.e. 2, d, 35.7 26 n.e.[d] n.e. n.e. 
12 n.e.[d] in.[e] 1, d, 35.7 35 n.e.[d] n.e. n.e. 
13 26 n.e. 1, d, 42.8 27 n.e.[d] n.e. n.e. 
14 n.e.[d] in.[e] 2, d, 42.8 28 n.e.[d] n.e. n.e. 
15 n.e.[d] n.e. n.e. 29 n.e.[d] n.e. n.e. 
16 n.e.[d] n.e. n.e. 30 n.e.[d] n.e. n.e. 
32 n.e.[d] n.e. n.e. 31 n.e.[d] n.e. n.e. 
17 27 n.e. 1, d, 34.7     
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Figure 37.  Biosynthetic precursors of sulfangolid C (25c) according to feeding experiments with labelled 
precursors. 
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3 Conclusion 
3.1 General Scope of this Work 
The present thesis deals with the isolation and identification of secondary metabolites from 
myxobacteria. At first, a protective isolation strategy for the light- and oxygen- sensitive 
polyunsaturated carboxylic acid roimatacene (26) has been developed. Furthermore the 
absolute configuration of 26 was established by chemical derivatization techniques, detailed 
NMR analyses and molecular modelling. Besides roimatacene (26) and traces of the known 
myxalamid C (24c) Cystobacter ferrugineus strain Cb G35 was found to produce six novel p-
hydroxyacetophenone amides 34a-f, which were isolated and characterised. 
A further project included the verification of the proposed structures of the four natural 
sulfangolid variants 25a-d by elucidation of their NMR data. These compounds were 
previously isolated from different Sorangium cellulosum strains. The relative configuration of 
sulfangolid C (25c) was finally established by comparison of detailed NMR data and the 
calculated diastereomeres from molecular modelling. 
The biosynthetic precursors of roimatacene (26), p-hydroxyacetophenone iso-butanamide 
(34a) and sulfangolid C (25c) were studied by feeding experiments with D-,13C- and 15N- 
labelled precursors.  
3.2 Novel Secondary Metabolites from Cystobacter ferrugineus Cb G35 
3.2.1 Roimatacene (26), a Novel Polyunsaturated Carboxylic Acid 
The activity guided isolation of the oxygen- and light- sensitive polyunsaturated carboxylic 
acid 26 often terminated prematurely due to the decomposition of roimatacene (26). The 
compound decomposed during silica flash chromatography, exposure to oxygen of dried 
extracts, and due to traces of peroxides in solvents. The compound rearranged under acidic 
conditions (below pH 3). MPLC or size exclusion chromatography (Sephadex LH-20) were 
also unfavourable for the isolation of roimatacene (26). The first enriched sample of 26 
contained about 50% fatty acids, which stabilized the compound and allowed measurement of 
a complete set of NMR data for structure elucidation. The structure elucidation revealed 
numerous sensitive structural elements in close proximity, e.g. an unsaturated carboxylic acid, 
a high degree of unsaturation, three α-polyunsaturated alcohol moieties and one tertiary 
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alcohol group (Figure 39). These structural elements are all combined in one carbon chain 
consisting of only 27 carbons, thus explaining the instability of roimatacene (26). The acryl 
acid residue in 26 led to use an antioxidant for stabilization. Different stabilization agents 
were tested and 4-ethoxyphenol proved to be slightly more effective compared to 4-
brenzcatechol, which was previously used for the stabilization of etnangien (35).114 The 
stabilizer did not exhibit growth inhibition of the antimicrobial screening. In addition, it could 
be removed by chromatography and was commercial available. Advantageously, the NMR 
signals of 4-ethoxyphenol did not overlap with the signals of roimatacene (26), thus 
permitting a straightforward structure elucidation. 
Subsequent to the first structural analysis of roimatacene (26), the protective isolation strategy 
described in chapter 2.1.1 was successfully developed. Amber glass ware was used in order to 
protect roimatacene (26) against light, and the extracts were kept dissolved in methanol 
supplemented with the free radical scavenger 4-ethoxyphenol. During chromatography the 
mobile phases were buffered with ammonium acetate and saturated with nitrogen gas. The 
free radical scavenger 4-ethoxyphenol was added to each fraction during chromatography, 
since the separation could not be carried out under nitrogen gas. An advanced acid-base 
partition plays an important role in this isolation. Herewith the majority of by-products are 
selectively removed from the crude extract and roimatacene (26) is strongly enriched using 
the acidic character of the carboxylic acid. Previously, acid-base partition proved to be a very 
powerful tool in the isolation of sorangicins (13), as well as of etnangien (35).114,115 In the 
case of the roimatacene (26) isolation fatty acids were co-purified and also showed a similar 
retention time in the RP-chromatography. In the advanced partition process an additional n-
heptane extraction was carried out, in order to remove the large amount of fatty acids and to 
facilitate the following chromatography, before the acidic water layer was extracted with ethyl 
acetate. The newly developed isolation strategy and several 70 L fermentations finally 
provided sufficient material for a complete structure elucidation and for a biological screening 
of roimatacene (26). 
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Figure 38. The secondary metabolite etnangien (35) isolated from myxobacteria and the atropisomeres 
elansolid A1 and A2 (36a and 36b) isolated from Chitinophaga sancti.87,116 
Chemical derivatization of a sensitive compound like roimatacene (26) usually involves 
difficulties. In order to synthesize the roimatacene methyl ester (27) the diazomethane 
solution had to be purified from the initial reaction mixture by distillation, in order to prevent 
decomposition of 26 by alkaline impurities. This observation also proved useful for the 
repeated esterification of etnangien (35) (R. Jansen; personal communication).87 
Subsequently, the derivatization to the corresponding acetonides 28-30 from 27 was 
straightforward. 
The relative configuration of C15, C17, and C19 of the polyol fragment in roimatacene (26) 
was unambiguously established as 15OH, 17OH anti-, and 17OH, 19OH syn-configuration 
from the corresponding acetonides 28 and 29 analyzed by Rychonovsky´s method (chapter 
2.1.3). The assignment of the relative configuration of the stereocentre C16 from either 28 or 
29 comprising coupling constants and nOe correlations alone remained unconvincing. Finally, 
the relative configuration of roimatacene (26) was established from the resulting relative 
configuration of C15, C17 and C19 from 28 and 29, as well as from a detailed study of the 
NMR data of the bis-acetonide 30 combined with molecular modelling. The comparison of 
the NMR data with the two possible diastereomeres at C16 of roimatacene bis-acetonide 30 
revealed a very good agreement of observed nOes and calculated distances in the 
15S*,16S*,17S*,19R*-isomere (Figure 19b, chapter 2.1.3). Detailed NMR analysis supported 
by molecular modelling studies was also used for the assignment of the absolute 
stereochemistry of etnangien (35), and for the elucidation of the two atropisomeres of 
elansolid (36) presented in Figure 38.87,116 
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The definition of the relative configuration of roimatacene (26) was essential for the 
assignment of the absolute stereochemistry of the natural product. The synthesis and isolation 
of MTPA esters from the acetonides 28 and 29 or directly from roimatacene (26) was 
impossible. For this reason, 26 was gently hydrogenated to the octrahydroroimatacene (31) by 
Pd/C catalysis under H2 atmosphere. The formation of two additional stereocentres at C8 and 
C20 could not be avoided, e.g. by using Raney-nickel, or Ru(PPh3)3Cl catalyst. After 
esterification of the carboxylic acid with p-bromophenacyl bromide, the tris-(R)- and the tris-
(S)-MTPA ester 33a/b were derived by Yamaguchi esterification.106 The elucidation of the 
structures of the tris-MTPA esters 33a/b from complete NMR data sets was rather complex as 
presented in chapter 2.1.4. The observed ∆δSR values of the 1H chemical shifts of the tris-(S)-
MTPA ester of octahydroroimatacene (33a) and the tris-(R)-MTPA ester of 
octahydroroimatacene (33b), revealed the absolute configuration of the stereocentres C5, C15 
and C19 as 5S, 15S and 19R, which was followed by the assignment of the relative 
configuration of the polyol fragment of C15 to C19 found in chapter 2.1.3. The absolute 
configuration of roimatacene (26) was determined as all-trans-5S,15S,16S,17S,19R, shown in 
Figure 39. 
Figure 39.  The absolute configuration of all-trans-5S,15S,16S,17S,19R roimatacene (26). 
Subsequent to the isolation, roimatacene (26) was screened against various microorganisms 
and a mouse fibroblast cell line as described in chapter 2.1.6. Roimatacene (26) showed 
biological activity against Gram-negative bacteria summarized in Table 22. 
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Table 22:  Minimum inhibitory concentration (MIC) of roimatacene (26) against selected Gram-negative 
bacteria. 
test organism MIC [µg/mL] 
Escherichia coli tolC 0.1 
Escherichia coli CG 8.6 
Escherichia coli 2 DC 14 PS 2.2 
Chromobacterium violaceum 0.3 
Pseudomonas stutzeri 4.2 
Pseudomonas aeruginosa >9.0 
Klebsiella pneumoniae >9.1 
The MICs in the µg/mL range are rather moderate. The lowest MIC (0.1 µg/mL) was found 
against E. coli tolC, which can be expected due to the inactivation of the major RND 
(resistance-nodulation-cell division) efflux pumps in this strain. One mechanism known for 
multi-drug resistance of Gram-negative bacteria is the ability to drain off drugs by the efflux 
pump systems of the outer membrane.117 Since 26 was also active against the E. coli 2 
DC14PS mutant (MIC = 2.2 µg/mL), which shows an overexpression of one RND efflux 
pump,118 the target of roimatacene (26) is most likely not related to the resistance against the 
tripartite efflux pump systems of the RND family. Chromobacterium violaceum is prevalently 
used as model strain for simple analysis of quorum sensing activity. The biosynthesis of the 
quorum sensing indicator violacein was inhibited by 26 with a MIC of 0.3 µg/mL. The mode-
of-action against Pseudomonas stutzeri, (MIC = 4.2 µg/mL) was further investigated against 
the Pseudomonas aeruginosa, because of the rapidly increasing clinical multi-drug resistance, 
but 26 showed no significant growth inhibition.7,119-121  
The sensitivity of roimatacene (26) and the origin of the soil sample motivated the name for 
the carboxylic acid 26. The conserved soil sample, from which the strain was isolated, was 
collected in New Zealand at the Franz Josef glacier. The Franz Josef glacier is called Kā 
Roimata o Hine Hukatere in Māori, with “Roimata” meaning tear. Therefore the name 
roimatacene (26) translates to tear of the Cystobacter ferrugineus polyene. 
The work on roimatacene (26) can be seen as a representative example of the development of 
an activity-guided isolation, starting with a biologically active crude extract of a 
myxobacterium to finally establish the absolute configuration of the active secondary 
metabolite.  
Conclusion 
- 68 - 
3.2.2 A Family of Six Novel p-Hydroxyacetophenone Amides 34a-f  
In addition to the polyunsaturated carboxylic acid roimatacene (26), a family of six p-
hydroxyacetophenone amides 34a-f was isolated and described from Cystobacter ferrugineus 
Cb G35 in the course of this thesis. The p-hydroxyacetophenone acetamide 34c has 
previously been described as synthetic product in the partial synthesis of chloramphenicol 
derivatives and in the total synthesis of tyrosine kinase inhibitors.122,123 Further the two 
closely related natural product families, the arylethylamides 37a-n and the acylated tyramides 
38a-j, are presented in Figure 40. The first arylethylamines 37a-f were isolated from three 
limnic strains of a new subspecies of bacillus,124 while the arylethylamines 37g-n were 
obtained in a screening of numerous Cytophaga, Frigoribacter, and marine Streptomyces 
extracts.125 In this screening of 500 bacterial isolates ten acylated tyramides 38a-j were found, 
produced by different Vibrio sp. 
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Figure 40:  The p-hydroxyacetophenone amides 34a-f and the closely related families of acylated 
arylethylamides (37a-n) and tyramides (38a-j). 
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Of particular importance in the family p-hydroxyacetophenone amides is the carbonyl group 
at C7, which was unambiguously identified by the chemical shifts of C7 and C8, as well as 
the corresponding HMBC correlations described in chapter 2.2.2. These data correspond well 
with the observed chemical shifts and correlations of the cyclic peptide hibispeptin A (39) 
isolated from Hibiscus syriacus, which contained an analogous aromatic ketone moiety 
(Figure 41).109 
Figure 41: The structure of hibispeptin A (39), a cyclic peptide isolated from Hibiscus syriacus.109 
The biosynthetic precursors of 34a were studied by feeding experiments with D, 13C and 15N- 
labelled leucine and tyrosine, presented in chapter 2.2.3. The combined 13C and 1H NMR as 
well as HRESIMS data indicate tyrosine as precursor of the complete p-hydroxyacetophenone 
amine moiety, including the amide nitrogen, and leucine as precursor of the aliphatic iso-butyl 
residue of 34a. Thus, Cystobacter ferrugineus strain Cb G35 is able to oxidize tyrosine to the 
atypical carbonyl at C7, revealed from the high significant incorporation of 13C-labelled 
tyrosine. A degradation pathway discussed in biosynthesis studies of ubiquinone (41, 
coenzyme Q) involves the formation of 4-hydroxycinnamate (40d) and 4-hydroxybenzoate 
(40g), which could be conceivable precursors for 34d and the carbonyl group of C7 in the 
other p-hydroxyacetophenone amides (Figure 42).126 However, the amine of tyrosine is lost in 
the first step of this pathway, which is not correlating with the observed significant 
incorporation of the 15N originating from the [15N,13C9]-labelled tyrosine in the feeding 
experiments, as well as the high incorporation of C8. For this reason the biosynthetic pathway 
of tyrosine to form the p-hydroxyacetophenone amides should be further investigated. The 
side chains of 34a originated from leucine, while the modified side chains of 34b-f can be 
suggested to derive from different amino acid or fatty acid precursors. 
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Figure 42.  Proposed pathway of tyrosine for the biosynthesis of ubiquinone (41, coenzyme Q) and the 
structures of p-hydroxyacetophenone amides 34a and d. Tyrosine (40a); 4-
hydroxyphenylpyruvate (40b); 4-hydroxy-phenyllacetate (40c); 4-hydroxycinnamate (40d), p-
coumaroyl-CoA (40e); 4-hydroxybenzoyl-CoA (40f); 4-hydroxybenzoate (40g).126 
An antimicrobial screening of the p-hydroxyacetophenone amides 34a-f showed no 
significant growth inhibition of the tested microorganisms. Due to the described biological 
activity of arylethylamide 37e against the microalgae Chlorella sorokiniana, Chlorella 
vulgaris and Scenedesmus subspicatus,124 the p-hydroxyacetophenone amides 34a-f were 
further tested against various microalgae presented in chapter 2.2.4. In this screening of 
microalgae only 34d inhibited growth of Pseudococcomyxa simplex at a concentration of 
100 µg/mL. 
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3.3 Sulfangolids 25a-d from Sorangium cellulosum 
The four sulfangolid derivatives 25a-d were isolated from different strains of the species 
Sorangium cellulosum. In a screening of 1700 Sorangium cellulosum strains remarkably 90% 
of the isolates were found to produce biologically active secondary metabolites. Especially 
members of the genus Sorangium are versatile multiproducers, for example strain So ce1525 
produces chivosazoles,127,128 disorazols,129,130 sorangicins,37,38 soraphens,32,131 sorangolide,132 
chlorotonil133 and sulfangolid simultaneously.31 The sulfangolids 25a-d were isolated as side-
products during the investigation of biologically active metabolites from Sorangium 
cellulosum. Sulfangolid A (25a) and D (25d) were isolated from strain So ce1375, at that time 
investigated for fungicidal soraphen derivatives (unpublished data K. Gerth, H. Reichenbach 
M. Herrmann, G. Höfle). So ce666 and So ce192 produced the cytotoxic chivosazols and 
disorazols as biologically active metabolites, as well as traces of sulfangolid A (25a) and B 
(25b). Whereas strain So ce12 mainly synthesised sorangicin, diszorasol, chivosazol and 
sorangolid derivatives in addition to traces of sulfangolid C (25c) (unpublished data K. Gerth, 
H. Reichenbach, R. Jansen, G. Höfle). All the NMR data for the structure elucidation, as well 
as from the previous isolations of the four sulfangolids 25a-d have been assembled. The NMR 
data were analyzed to verify the proposed structures for sulfangolid A to D (25a-d) as 
presented in chapter 2.3.1. The final NMR data are combined in this thesis and the manuscript 
“Sulfangolids, Macrolide Sulfate Esters from Sorangium cellulosum” (W. Zander, H. Irschik, 
H. Augustiniak, M. Herrmann, R. Jansen, H. Steinmetz, K. Gerth, W. Kessler, M. Kalesse, G. 
Höfle, R. Müller, to be submitted). 
The structure of sulfangolid C (25c) containing three inflexible structural elements in the 28-
membered macrolide ring, i.e. the polyunsaturated ester, the α,β-unsaturated ketone at C21, 
and the six-membered hemiketal, altogether stabilize the conformation of the macrolide ring, 
thus allowing elucidation of the relative stereochemistry. The relative all-trans 
13S*,14S*,15R*,16R*,17S*,19S*,20R*,26R*,27R* configuration of sulfangolid C (25c) proposed 
in my diploma thesis was revised to the all-trans 13R*,14S*,15R*,16R*,17S*,19S*,20R*, 
26R*,27R* configuration, due to the better agreement of interatomic distances of the modelled 
diastereomere in comparison with the NMR data presented in chapter 2.3.2. In addition the 
biosynthetic precursors of sulfangolid C (25c) were studied as a basis for further genetic 
research of the frequently observed sulfangolids. 
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The four sulfangolid derivatives 25a-d present an extraordinary group of polyketides, because 
they are the first group of myxobacterial secondary metabolites containing a sulfate ester 
residue. A sulfate-free analogue of the sulfangolids is the myxobacterial kulkenon (42) 
isolated from Sorangium cellulosum So ce1426 (unpublished data R. Jansen, H. Irschik, G. 
Höfle, H. Reichenbach). Comparing kulkenon (42) to the family of sulfangolids 25a-d, 42 has 
one additional methyl group at position C2, while the southern fragment shows high similarity 
to sulfangolid C (25c). The 26-membered macrolide of 42 is reduced by two carbons 
compared to the 28-membered macrolide rings of the sulfangolid family, and the sulfate ester 
moiety is absent. Further the northern fragment of kulkenon (42) is identical to sulfangolid A 
(25a). Due to the high similarity of kulkenon (42) to the sulfangolids, 42 can be considered as 
a sulfate-free analogue. 
Commonly, sulfate ester residues are known from Streptomyces sp. or marine 
microorganisms, like the earlier described marine polyether maitotoxin (23). Structural 
similarities are found in the Streptomyces natural products clethramycins (43c) and the 
analogue family of mediomycins, here represented by mediomycin A (43a) and B (43b) in 
Figure 43.134,135 These secondary metabolites are highly functionalized polyketides containing 
a sulfate ester residue at C29, multiple hydroxyl groups and a ketone at C31 in addition to 
several double bonds. Of special interest are the differences between the secondary 
metabolites from Streptomyces and the sulfangolid family. A sulfate-free derivative with 
identical carbon skeleton of these metabolites was described with mediomycin B (43b). In 
addition, a derivative of mediomycin A (43a) with hydrogenated double bonds was 
characterised, while such derivatives have not been found for the sulfangolids. The ketal 
found in sulfangolid C (25c) and D (25d) would also be feasible between 35OH and the 
carbonyl group at C31 in 43a-c, but such a derivative has not been described to data. 
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Figure 43  The secondary metabolites mediomycin A (43a) and B (43b) and the analogue clethramycin 
(43c) isolated from Streptomyces, the myxobacterial sulfangolids 25a-d and the analog 
kulkenon (42).135 
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3.4 Summary and Future Aspects 
The thesis presents results of extensive studies in the field of structure elucidation of labile 
secondary metabolites. On the one hand, the assignment of the relative configuration of 
sulfangolid C (25c) based mainly on detailed NMR studies and molecular modelling, while on 
the other hand the absolute configuration of roimatacene (26) is supported by derivatization 
techniques coupled to NMR analysis and sustained by molecular modelling. The structure 
analysis of roimatacene (26) lead to the development of a protective isolation strategy creating 
the basis for solving the relative and later the absolute configuration of a compound that 
already proved problematic during isolation. The assignment of the absolute stereochemistry 
of the novel secondary metabolite roimatacene (26) is the basis for a total synthesis, and 
required for the synthesis of stable derivatives of 26, for example by selective hydrogenation 
of double bonds. In addition to SAR-studies, the evaluation of the biological target would be 
indicated as next step.  
The p-hydroxyacetophenone amides 34a-f with the atypical oxidation of the tyrosine moiety 
and the family of sulfangolids 25a-d with the sulfate ester residue present two novel motives 
of myxobacterial biosynthesis worthy of further investigations.136 The high biodiversity of 
myxobacteria is also unambiguously revealed in the genome sequencing projects of 
Sorangium cellulosum (strain So ce56, 13.0 Mbp),53 Myxococcus xanthus (strain DK1622, 9.1 
Mbp),54 Stigmatella aurantiaca (10.2 Mbp)137 and Anaeromyxobacter dehalogenans (strain 
2CP-C, 5.1 Mbp).138 The Sorangium cellulosum genome with 13.0 Mbp is the largest genome 
sequenced from any bacterium so far. In Myxococcus xanthus DK1622 over 8.5% of the 
genome are dedicated to secondary metabolism, which is more than it has been observed in 
other microorganisms.139 This observation leads to the conclusion, that still a high number of 
natural products can be discovered from myxobacteria in the future and will reveal more of 
the true potential of these gliding bacteria.27 
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4 Experimental 
4.1 Material 
4.1.1 Instruments 
The standard analytical reversed phase liquid chromatography (RP-HPLC) system was a 
Agilent 1100 series HPLC system [column 125×2 mm, Nucleosil 120 EC, 5 µm, C18, 
(Macherey-Nagel); temperature 40°C; solvent A: H2O/ACN (95/5) + 5 mM/L of NH4Ac + 40 
µL/L of acetic acid; solvent B: H2O/ACN (5/95) + 5 mM/L of NH4Ac + 40 µL/L of acetic 
acid, gradient: 10% B increasing to 100% B in 30 min, maintained 100% B for 10 min; flow 
rate (FR) = 0.3 mL/min; UV detection 210-500 nm]. 
The HPLC- high resolution mass spectrometry (HPLC-HRESIMS) was done on a Agilent 
1200 series RRLC system, ESI-TOF-MS Maxis (Bruker) [column 50×2.1 mm, Acquity 
UPLC BEH C-18, 1.7 µm (Waters), solvent A: 0.1% formic acid in water; solvent B: 0.1% 
formic acid in ACN, gradient 5% B for 0.5 min, increasing to 100% B in 19.5 min and 
continued at 100% B for 5 min, FR = 0.6 mL/min; NH4Ac-buffer gradient: column 100×2.1 
mm, XBridgeTM C18 3.5 µm, (Waters), solvent A: H2O/ACN (95/5) + 5 mM/L of NH4Ac + 
40 µL/L of acetic acid; solvent B: H2O/ACN (5/95) + 5 mM/L of NH4Ac + 40 µL/L of acetic 
acid, gradient from 10% B increasing to 100% B in 30 min and continued at 100% B for 10 
min, FR = 0.3 mL/min, UV detection 210-500 nm]. 
The preparative reversed phase high pressure liquid chromatography (RP-HPLC) 
system was a preparative Agilent 1100 series HPLC system or the HPLC system consisting of 
a manual injection system (Rheodyne), the preparative K-1800 pump system with mixing 
chamber (Knauer) connected to an UV-detector (Techlab). 
The preparative reversed phase- medium pressure liquid chromatography (RP-MPLC) 
system consisted of two pumps C-605, control unit C-620, fraction collector C-660 and 
photometer C-635 (Büchi). 
Silica-gel-flash chromatography was carried out with the silica-gel-flash system from 
Biotage and the cartridge Si 40 S 2976-1 (Biotage), or with open-glass columns packed with 
silica gel 60, particle size 0.063-0.200 mm (Merck). 
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Thin-layer chromatography (TLC) in analytical scale was carried out with TL-Silica-Gel 
60 F254-Aluminium (Merck), staining was done with aqueous cer-dye (10 g cer(IV)-sulfate, 
25 g phosphor-molybdäne acid, 80 mL sulphuric acid in 1 L) and heating 120°C. For semi-
preparative scale PSC-plates (20×20×0.1 cm, silica gel 60 F254, Merck) with concentration 
zone were used. The RP-cartridge system of strata-X cartridges (0.5 g and 1.0 g, 
Phenomenex) were used for concentration from water layers. 
Optical rotation was determined with a Perkin-Elmer 241 instrument, UV spectra were 
recorded with a Shimadzu UV-Vis spectrophotometer UV-2450, and IR spectra were 
measured with a Nicolet 20DXB FT-IR spectrometer.  
Centrifugation was carried out with a Varifuge 20RS (Heraeus Sepatech). 
NMR spectra were recorded with Bruker NMR spectrometer DPX-300 (1H 300 MHz, 13C 75 
MHz), ARX-400 (1H 400 MHz, 13C 100 MHz); AVANCE DMX-600 (1H 600 MHz, 13C 150 
MHz) with the assistance of C. Kakoschke, B. Jaschok-Kenter and M. Rettstadt (University 
Hannover). 
The up-scale fermentation was carried out in a 100 L fermentor (Giovanola Frères SA, 
Monthey, Switzerland) with an inoculation volume of 70 L in the presence of Amberlite 
XAD-16 (Rohm & Haas) with the assistance of K. I. Mohr, H. Irschik, K. Gerth, D. 
Telkemeyer, W. Kessler, B. Ebert, A. Perreth, A. Schulz and R. Sterlinski. 
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4.1.2 General Chemicals 
Table 23. Chemicals used (in alphabetical order) and the supplying company  
Chemicals Supplying Company 
acetic acid Roth 
acetone Merck 
acetone, dry Merck 
acetonitrile, p.a. J.T. Baker 
ammonia Riedel-de Haen 
ammonium acetate Roth 
buffer, pH 7 Roth 
celite Merck 
diazald® Aldrich 
dichloromethane J.T. Baker 
diethyl ether J.T. Baker 
dimethoxypropanne Sigma-Aldrich 
DMAP Fluka 
ethanol J.T. Baker 
4-ethoxyphenol Aldrich 
ethyl acetate J.T. Baker 
formic acid Roth 
H2SO4  Roth 
KOH Merck 
methanol Merck 
methanol p.a. J.T. Baker 
methanol (Uvasol) Merck 
Milli-Q-Wasser Millipore 
mol sieve (3Å) Merck 
(R)/(S)-MTPA Fluka 
NaCl Roth 
NaHCO3 Fluka 
n-heptane Roth 
p-dibromoacetophenone Aldrich 
Pd/C Merck 
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continuing Table 23: 
 
Chemicals Supplying Company 
pyridin-p-toluenesulfonic acid Fluka 
sodium acetate Roth 
TEA Fluka 
toluene Merck 
2,4,6-trichlorobenzoyl chloride Aldrich 
water, p.a. J.T. Baker 
Media  
Amberlide XAD-16 Rohm and Haas 
CaCl2 × 2H2O Merck 
casitone BD 
1-docosanol Merck 
fructose Fluka 
glucose Cerestar 
glycerine (87%) Merck 
HEPES Roth 
H2SO4 AppliChem 
leucine Merck 
methionine Merck 
MgSO4 × 7H2O Merck 
Na-Fe-EDTA Fluka 
NaNO3 Merck 
skim milk AppliChem 
sodium acetate Merck 
sodium propionate Merck 
soyabean flour Cargill 
starch 12018 Cargill 
tegosipon antifoam Evonik 
tyrosine Merck 
yeast extract Ohly 
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continuing Table 23:  
Chemicals Supplying Company 
Feeding Experiments  
[1-13C]-acetate (99%) Cambridge Isotope Laboratories 
[1,2-13C]-acetate (99%) Cambridge Isotope Laboratories 
[2-13C]-acetate (99%) Cambridge Isotope Laboratories 
[D10]-leucine (98%) Campro Scientific 
[13CH3]-methionine (98%) Cambridge Isotope Laboratories 
[1-13C]-propionate (97%) Cambridge Isotope Laboratories 
[13C9,15N]-tyrosine(98% 13C, 98% 15N) Campro Scientific 
NMR-solvents  
CDCl3 Deutero GmbH 
CD3OD Deutero GmbH 
[D6]DMSO Deutero GmbH 
[D3]trifluoroethanol Deutero GmbH 
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4.2 Fermentation of Cb G35 and Isolation of Roimatacene (26) 
4.2.1 Fermentation of Cb G35 for the Isolation of Roimatacene (26) 
Cystobacter ferrugineus strain Cb G35 (deposited at Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH; DSM 24415) was transferred to a liquid medium 
consisting of soybean flour 4 g/L, glucose 2 g/L, starch 8 g/L, CaCl2 × 2 H2O 1 g/L, MgSO4 × 
7 H2O 1 g/L, HEPES 11.9 g/L and Na-Fe-EDTA 8 mg/L at pH 7.4. 5 L of a 4 day old pre-
culture was used to inoculate a volume of 70 L of the same medium in a 100 L fermentor in 
the presence of 1.4 kg adsorber resin Amberlite XAD-16. The culture was supplemented with 
1.15-1.75 g/h of NaAc solution (100 g/kg) during seven days of cultivation (blade impeller 
150 rpm, aeration 7 L/min, 30°C, pO2 20%, pH regulated between pH 7.15 and 7.25 with 10% 
KOH and 5% H2SO4). For harvesting the culture broth was passed through a process filter 
collecting the absorber resin. Residual cells were floated from the recovered XAD-16 resin 
with water. 
4.2.2 Isolation Procedure of Roimatacene (26) 
General remark: Handling of roimatacene (26) extracts and ethyl acetate: Extracts 
containing roimatacene (26) were kept in solution (methanol) supplemented with 4-
ethoxyphenol. As far as possible N2-gas was used at all times. Ethyl acetate was filtrated over 
aluminium oxide before use. Amber glassware was used for handling and for storage at 4°C. 
The XAD-16 absorber resin was eluted with methanol/water (3/7), methanol and acetone (4 L 
each) saturated with N2-gas. After addition of saturated NaCl solution (250 mL), the water 
layer (300 mL) remaining after evaporation of the methanol was adjusted to pH 4.2 with 
formic acid and extracted with ethyl acetate (5 portions of 100 mL). The ethyl acetate was 
supplemented with 0.1 M 4-ethoxyphenol (100 µL) and methanol (100 mL). The ethyl acetate 
layer was evaporated and dissolved to a 140 mL methanol layer, without drying the samples. 
The extract was analysed by HPLC to contain 504 mg of roimatacene (26) in 13.4 g of crude 
extract. The extract was partitioned between methanol and n-heptane to provide 12.9 g of 
polar raw material, containing 440 mg roimatacene (26) according to HPLC analyses 
(supplemented with 200 µL of 0.1 M 4-ethoxyphenol). The methanol extract was stored in 
142 mL of methanol (c = 3.1 mg/mL) at 4°C. After 6 weeks HPLC analysis showed 
degradation to 256 mg of 26 (58%, c = 1.8 mg/mL) in the crude extract. Half of the extract 
was dissolved in 2 N ammonia (75 mL) and methanol was evaporated. The pH of the water 
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layer was adjusted to pH 9.5 with 2N ammonia and extracted with ethyl acetate (3 portions of 
95 mL). The water layer was acidified to pH 4.2 with formic acid and then extracted twice 
with n-heptane (55 mL) to remove fatty acids from the crude extract. The acidic water layer 
was then extracted with ethyl acetate (4 portions of 75 mL) supplemented with 4-
ethoxyphenol (200 µL, 0.1 M), methanol and toluene before evaporation of the ethyl acetate. 
The methanol/toluene solution yielded 99.4 mg enriched roimatacene (26) according to HPLC 
analyses. 26 was further purified by preparative RP-HPLC in 7 batches [column VP250/21 
Nucleodur 100-10 C-18 ec (Macherey-Nagel), solvent methanol/water (6:4) containing 
50 mM/L of NH4Ac and 400 µL/L of acetic acid; the solvents were saturated with N2-gas and 
10 µL of 0.1 M 4-ethoxyphenol were provided in each test tube of the fraction collector]. 26 
eluted at Rt = 34 min. The fraction was evaporated and the water layer was passed through a 
strata-X cartridge (1.0 g) under N2-protection gas, washed with water, and eluted with 
methanol. 4-Ethoxyphenol (200 µL, 0.1 M) was added to the methanol layer before the 
concentration was adjusted to 50 mL containing 38.5 mg of roimatacene (26).  
Roimatacene (26): Pale yellow solution in methanol; [α]DRT = + 58.4 (c = 0.65, methanol); 
NMR data (1H NMR 600 MHz, 13C NMR 150 MHz, [D6]DMSO): Table 2; UV (methanol) 
λmax (lg ε) = 276 (4.323), 286 (4.332), 308 (4.369), 323 nm (4.309); HRESIMS: m/z: calcd. 
for C30H43O7: 515.3014, found 515.3021. 
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4.2.3 Derivatization of Roimatacene (26) 
Roimatacene methyl ester (27): Diazald(R) (5.3 g) was dissolved in ether (20 mL) and 
ethanol (3 mL), and was stirred with aqueous KOH (2.0 g in 3.2 mL H2O). After heating to 
35°C the ether/diazomethane solution was distilled and then added drop-wise to a stirred 
solution of roimatacene (26) and 4-ethoxyphenol in methanol at room temperature. After 20 
min ether and diazomethane were evaporated under nitrogen gas to the crude product in 
methanol. The product was purified by preparative RP-HPLC [column VP250/21 Nucleodur 
100-10 C-18 ec (Macherey-Nagel); solvent A: methanol water (6/4) supplemented with 
50 mM/L NH4Ac and 400 µL/L formic acid, solvent B: methanol same buffer concentration; 
gradient: 100% A increasing to 100% B in 50 min, continued for 15 min, FR = 20 mL/min, 
UV detection 278 nm, Rt = 60 min]. After evaporation of the methanol, the water layer was 
diluted and passed through a strata-X cartridge (1.0 g) under nitrogen atmosphere. The 
cartridge was rinsed with water and roimatacene ester (27) was eluted with methanol 
(supplemented with 40 µL of 0.1 M 4-ethoxyphenol).  
Roimatacene methyl ester (27): Pale yellow solution in methanol; 1H NMR (600 MHz, 
[D6]DMSO): δ = 0.92 (s, 4 H) 0.93 - 0.95 (m, 1 H) 0.95 (t, J = 7.52 Hz, 4 H) 1.45 - 1.52 (m, 2 
H) 1.66 (s, 4 H) 1.67 - 1.72 (m, 2 H) 1.79 (s, 4 H) 1.90 (s, 2 H) 1.98 - 2.04 (m, 1 H) 2.07 (t, J 
= 7.34 Hz, 3 H) 2.32 - 2.43 (m, 5 H) 2.50 (dt, J = 3.67, 1.83 Hz, 2 H) 3.32 (d, J = 10.27 Hz, 2 
H) 3.48 - 3.55 (m, 7 H) 3.63 (s, 4 H) 4.12 - 4.22 (m, 3 H) 5.66 (dd, J=15.59, 6.05 Hz, 1 H) 
5.70 - 5.76 (m, 1 H) 5.81 (dt, J = 14.95, 7.38 Hz, 1 H) 5.89 (d, J = 15.41 Hz, 1 H) 5.97 (d, J = 
11.00 Hz, 1 H) 6.08 - 6.19 (m, 5 H) 6.24 (dd, J = 15.22, 8.25 Hz, 2 H) 6.36 (dd, J=13.94, 
11.37 Hz, 1 H) 6.46 (dd, J = 14.67, 11.74 Hz, 1 H) 6.87 ppm (d, J = 15.77 Hz, 1 H); 13C NMR 
(150 MHz, [D6]DMSO): δ = 172.4, 166.3, 146.8, 140.2, 135.9, 134.5, 134.1, 133.8, 132.4, 
132.4, 132.0, 131.9, 131.2, 130.0, 127.0, 125.5, 122.4, 75.0, 74.5, 73.6, 70.0, 63.5, 51.4, 48.8, 
40.0, 36.2, 34.7, 25.4, 21.2, 18.3, 13.6, 12.8, 11.7 ppm; 4-ethoxyphenol: 1H NMR (600 MHz, 
[D6]DMSO): δ = 1.25 (t, J = 6.97 Hz, 4 H) 3.88 (q, J = 6.97 Hz, 3 H) 6.63 - 6.66 (m, 2 H) 
6.69 - 6.73 ppm (m, 2 H); 13C NMR (150 MHz, [D6]DMSO): δ = 151.5, 151.1, 115.9, 115.5, 
15.0 ppm; HRESIMS: m/z: calcd. for C31H46O7Na  553.3136, found 553.3128. 
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Acetonides of roimatacene methyl ester (28-30): 31.7 mg of 27 were dried and dissolved in 
2,2-dimethoxypropane (4 mL). Pyridium-p-tolouenesulfonic acid (12.5 mg) was added and 
the reaction was stirred over night at 4°C. After quenching with 5% NaHCO3 solution the 
reaction was extracted with DCM (3 portions of 50 mL). After evaporation of DCM the crude 
extract was further purified by RP-HPLC [column VP250/21 Nucleodur 100-10 C-18 ec 
(Macherey-Nagel), solvent A: methanol/water 1/1; solvent B: methanol; gradient: 70% B 
increasing to 100% B in 50 minutes and maintained at 100% B for 10 minutes, FR = 20 
mL/min, UV detection 210-500 nm] yielding 17,19-acetonide 28 (5.5 mg, Rt = 9.1 min), 
15,17-acetonide 29 (2.4 mg, Rt = 22.9 min) and the bis-acetonide 30 (4.2 mg, Rt = 20.9 min).  
17,19 acetonide of roimatacene methyl ester (28): yellow oil, NMR data (1H NMR 600 MHz, 
13C NMR 150 MHz, CDCl3): Table 3; HRESIMS m/z: calcd. for C34H50O7Na 593.3449, 
found 593.3448.  
15,17 acetonide of roimatacene methyl ester (29): yellow oil, NMR data (1H NMR 600 MHz, 
13C NMR 150 MHz, CDCl3): Table 4; HRESIMS m/z: calcd. for C34H54O7N 570.3789, found 
570.3801.  
15,16,17,19-bis-acetonide of roimatacene methyl ester (30): yellow oil, NMR data (1H NMR 
600 MHz, 13C NMR 150 MHz, CDCl3): Table 5; HRESIMS m/z: calcd. for C37H54O7Na 
633.3762, found 633.3768. 
Tris-(S)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33a): For 
the (S)-Mosher ester about 25 mg of roimatacene (26) were hydrogenated in methanol in 
presence of Pd/C (10%, 31.4 mg) under H2-atmosphere at RT for 4.5 h. The reaction mixture 
was filtered over celite and dried in vacuo to yield 35.2 mg extract of octahydroroimatacene 
(31). The extract was dissolved in dry acetone (2 mL) and stirred for 19 h at RT with TEA 
(15 µL) and p-dibromoacetophenone (24.1 mg) in the presence of 3Å mol sieve. The mixture 
was filtered over celite and dried to give 66.9 mg. p-Bromoacetophenone-
octahydroroimatacene ester (32) was separated by silica gel plate chromatography [two PSC-
plates 20×20×0.1 cm, silica gel 60 F254 with concentration zone (Merck), solvent ethyl 
acetate/n-heptane 8/2]. The UV active zone (Rf = 0.42) was eluted with ethyl acetate to give 
5.3 mg of p-bromoacetophenone-octahydroroimatacene ester (32). 2,4,6-trichlorobenzoyl 
chloride (12.5 µL) and 5.3 mg of 32 were dissolved in dry toluene (0.7 mL) and added to a 
solution of (S)-MTPA (16.2 mg), DMAP (14.4 mg) and TEA (12.5 µL) in dry toluene (0.4 
mL) at 0°C. The reaction mixture was stirred for 15 min at 0°C and 4 h at RT. The reaction 
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was quenched with buffer (pH 7) and extracted with ethyl acetate (3 portions of 50 mL) to 
yield 14.6 mg crude product. The tris-(S)-MTPA derivative 33a was further purified by RP-
HPLC [column VP 250/10 Nucleodur 100-7 C-18 ec (Macherey-Nagel); solvent A: 
methanol/water 1/1, solvent B: methanol, gradient: 85% B in 20 min to 86% B, in 3 min to 
90% B, maintained at 90% B; FR = 6 mL/min, UV detection at 259 nm, Rt = 49 min] to yield 
2.8 mg of 33a. 
Tris-(R)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33b): Tris-(R)-
MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33b) was prepared 
analogously starting with 11.6 mg of roimatacene (26) and obtaining 2.1 mg of tris-(R)-
MTPA ester 33b for NMR spectroscopy. 
Octahydroroimatacene (31): yellowish oil; 1H NMR (300 MHz, CD3OD): δ = 0.88 - 0.93 (m, 
10 H) 1.06 - 1.17 (m, 5 H) 1.31 – 1.35 (m, 24 H) 1.56 -1.84 (m, 10 H) 2.44 (m, 4 H) 3.35 (br. 
s, 1 H) 3.54 (m, 2 H) 3.65 ppm (br. s, 1 H); 13C NMR ( 75 MHz, CD3OD): δ = 177.8, 76.6, 
76.6, 76.5, 76.4, 76.2, 76.1, 76.1, 76.0, 72.6, 72.6, 38.4, 38.2, 37.9, 37.8, 36.0, 36.0, 34.4, 
34.3, 34.2, 34.1, 33.8, 33.2, 32.2, 31.3, 31.2, 31.0, 30.9, 30.7, 30.6, 28.7, 28.7, 28.3, 28.1, 
23.9, 20.4, 20.2, 15.68, 15.5, 14.5 ppm; doubling of signals due to isomers at C8 and C20; 
4-ethoxyphenol 1H NMR (300 MHz, CD3OD): δ = 3.94 (q, J = 6.97), 6.71 (m, Hz, 4 H), CH3 
in 1.31 – 1.35 ppm (m, 24 H); 13C NMR ( 75 MHz, CD3OD): δ = 153.8, 152.4, 116.9, 116.8, 
65.3, 14.6 ppm; HRESIMS m/z: calcd. for C30H60O7Na 555.4231, found 555.4233. 
p-bromoacetophenone-octahydroroimatacene ester (32): yellowish oil, 1H NMR (300 MHz, 
CDCl3) δ = 0.85 - 0.96 (m, 11 H) 1.05 (s, 3 H) 1.08 - 1.18 (m, 4 H) 1.27 – 1.33 (m, 17 H) 1.39 
- 1.51 (m, 8 H) 1.63 - 1.81 (m, 4 H) 2.55 (t, J = 7.25 Hz, 2 H) 3.45 (m, 1 H) 3.62 (m, 1 H) 
3.83 (m, 1 H) 3.98 (m, 1 H) 5.31 (s, 2 H) 7.65 (d, J = 8.7 Hz, 2 H) 7.79 ppm (d, J = 8.7 Hz, 2 
H), 13C NMR (75 MHz, CDCl3) δ = 191.5, 173.2, 133.0, 132.3, 129.3, 129.2, 80.3, 77.3, 74.0, 
74.0, 71.9, 71.8, 65.7, 39.8, 39.6, 36.9, 36.8, 36.7, 36.6, 35.1, 34.9, 33.8, 33.4, 32.9, 32.7, 
32.1, 32.0, 31.9, 29.9, 29.8, 29.6, 29.3, 27.4, 27.3, 26.9, 22.7, 21.2, 21.0, 19.8, 19.7, 14.9, 14.1 
ppm; doubling of signals due to the isomers at C8 and C20; HRESIMS m/z: calcd. for 
C38H66BrO8 729.3936, found 729.3972. 
Tris-(S)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33a): oil; NMR 
data (1H NMR 600 MHz, 13C NMR 150 MHz, CDCl3): Table 6; HRESIMS m/z: calcd. for 
C68H90BrF9O14N 1394.5395, found 1394.5404. 
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Tris-(R)-MTPA ester of p-bromoacetophenone-octahydroroimatacene ester (33b): oil; NMR 
data (1H NMR 600 MHz, 13C NMR 150 MHz, CDCl3): Table 7; HRESIMS m/z: calcd. for 
C68H86BrF9O14Na 1399.4949, found 1399.4957. 
4.2.4 Biosynthetic Studies of Roimatacene (26) by Feeding Experiments 
100 mL cultures of strain Cb G35 of the described medium were supplemented with 25 mg, 
50 mg and 100 mg of methionine, acetate and propionate additionally to 1% XAD-16 
absorber resin. After 7 days of incubation at 30°C the XAD-16 resin of each culture was 
harvested, eluted with methanol and acetone supplemented with 4-ethoxyphenol (100 µL, 
0.1 M) and analysed by HPLC. 
50 mg of [13CH3] sodium methionine (98%), 50 mg of [2-13C] sodium propionate (97%), 100 
mg of [1-13C]- and [2-13C] sodium acetate (99%, all Cambridge Isotope Laboratories) were 
fed in two portions after 16 and 40 hours of incubation to shaken cultures (100 mL) of strain 
Cb G35. The cultures were incubated at 30°C for 7 days. After washing with water each 
XAD-16 resin was eluted twice with 3 bed volumes of methanol and twice with acetone. The 
organic layers of each experiment were evaporated to a small volume before adjusting their 
concentration to 100:1 under the addition of 4-ethoxyphenol (50 µL, 0.1 M). All extracts were 
partitioned between methanol and n-heptane. The methanol layers were subjected to acid-base 
partition. They were dissolved in 2 N ammonia (10 mL) and the methanol was evaporated. 
The aqueous layer was extracted with ethyl acetate (3 portions of 10 mL). The water layers 
were acidified to pH 3.3 with formic acid and extracted with n-heptane (10 mL) and then with 
ethyl acetate (3 portions of 10 mL). 4-ethoxyphenol (20 µL, 0.1 M) was added to the ethyl 
acetate layers of each experiment. Ethyl acetate was evaporated after addition of toluene and 
methanol. The solvents were evaporated after addition of [D6]DMSO and 13C-NMR spectra of 
all samples of the feeding experiments were measured.  
[13CH3]-methionine labelled roimatacene (26): 13C NMR (100 MHz, [D6]DMSO): δ 
(signal/noise) = 18.3 (16.5/1), 13.6 (19.2/1), 12.7 (13.2/1), 11.7 ppm (14.4/1). 
[1-13C]-acetate labelled roimatacene (26): 13C NMR (100 MHz, [D6]DMSO): δ (signal/noise) 
= 167.3 (4.3/1), 145.8 (5.1/1), 135.8 (3.5/1), 134.5 (2.1/1), 134.0 (2.7/1), 133.8 (2.9/1), 132.4 
(3.5/1), 131.2 (3.1/1), 125.4 (2.2/1), 75.1 (2.3/1), 73.6 (2.3/1), 70.1 ppm (3.1/1). 
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[2-13C]-acetate labelled roimatacene (26): 13C NMR (100 MHz, [D6]DMSO): δ (signal/noise) 
= 140.3 (5.0/1), 133.7 (5.5/1), 132.1 (5.5/1), 131.8 (6.0/1), 130.0 (9/1), 127.0 (9.5/1), 123.7 
(11/1), 74.4 (9/1), 36.1 (5.5/1), 34.7 (5.0/1), 25.3 ppm (10/1). 
[2-13C]-acetate labelled roimatacene (26): APT 13C NMR (100 MHz, [D6]DMSO): δ ppm 
(signal/noise) = 134.4 (1.4/1).  
[1-13C]-propionate labelled roimatacene (26): no enriched signals. 
4.3 Fermentation of Cb G35 and Isolation of p-Hydroxyacetophenone 
Amides 34a-f 
4.3.1 Fermentation of Cb G35 for the Isolation of p-Hydroxyacetophenone Amides 
34a-f  
Cystobacter ferrugineus, strain Cb G35 was transferred to a liquid medium consisting of 
soybean flour 4 g/L, glucose 2 g/L, starch 8 g/L, CaCl2 x 2 H2O 1 g/L, MgSO4 x 7 H2O 1 g/L, 
HEPES 11.9 g/L and Fe-EDTA 8 mg/L at pH 7.4. 70 L of the same medium in a 100 L 
fermentor (blade impeller 150 rpm, aeration 9 L/min, 30°C, pO2 20%, pH regulated between 
pH 7.15 and 7.25) were inoculated in the presence of 1.4 kg of XAD-16 resin. After 7 days 
the culture broth was passed through a process filter to collect the absorber resin. Residual 
cells were floated from recovered XAD-16 resin with water. 
4.3.2 Isolation of p-Hydoxyacetophenone Amides 34a-f  
Isolation of p-hydroxyacetophenone amides 34a-c: The XAD resin was eluted with 4 L of 
methanol/H2O (30/70), methanol (4 L) and acetone (4 L) in a column. The organic solvent 
was evaporated from the methanol fraction to give 550 mL of an aqueous mixture, which was 
extracted with ethyl acetate (5 portions of 250 mL). The combined ethyl acetate layer was 
dried in vacuo to give 18.6 g crude extract. The extract was dissolved in methanol and 
partitioned between methanol and n-heptane, to provide 17.5 g of more polar raw material. 
1.0 g of this extract was separated by silica gel flash chromatography [Flash40 (Biotage), 
cartridge Si 40 S 2976-1 (Biotage); solvent DCM/methanol/n-heptane (18/1/1)]. 4 main 
fractions were collected according to the analysis of all fractions by thin layer 
chromatography (TLC). Fraction 3 yielded 124.4 mg which were further purified in 3 batches 
by preparative RP-HPLC [column 250×21 mm, Nuleodur 100 EC (10 µm, C18) (Macherey-
Nagel); solvent A: methanol/H2O (10/90 + 0.01% acetic acid), solvent B: methanol/H2O 
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(90/10 + 0.01% acetic acid); gradient 25% B for 5 min, increasing to 45% B over 35 min, 
maintained at 45% for 10 min, increasing to 100% B over 5 min; FR = 20 mL/min, UV 
detection 210-500 nm]. Fractions were combined peak wise. The organic solvent was 
evaporated from the fractions after addition of toluene and the water layer was extracted with 
ethyl acetate yielding compound 34c (Rt = 7 min, 3.3 mg), 34b (Rt = 19 min, 7.1 mg) and 34a 
(Rt = 29 min, 59.6 mg). 
Isolation of p-hydroxyacetophenone amide 34d: Fraction 2 (221.2 mg) from the silica gel 
flash chromatography was separated by preparative RP-HPLC in 5 batches [column 250×21 
mm, Nuleodur 100 EC (10 µm, C18) (Macherey-Nagel); solvent A: methanol/H2O 10/90 + 
0.01% acetic acid, solvent B: methanol/H2O 90/10 + 0.01% acetic acid; gradient 25% B for 5 
min, increasing to 35% B in 25 min, increasing to 100% B in 1 minutes maintained at 100% B 
for 20 minutes; FR = 20 mL/min, UV detection at 210-500 nm]. Compound 34d (6.9 mg) 
eluted at Rt = 38 min. 
Isolation of p-hydroxyacetophenone amide 34e and 34f: 4.4 g of the methanol extract were 
subjected to silica gel flash chromatography (300 g silica gel 60, particle size 0.063-0.200 
mm, Merck) and eluted stepwise with ethyl acetate/DCM/n-heptane (3/3/4) (3 L) and ethyl 
acetate (6 L). 15 fractions were collected and dried in vacuo according to TLC analyses. 
Fraction 5 (48.6 mg) was further separated in 3 batches by preparative RP-HPLC [column 
250×21 mm, Nuleodur 100 EC (10 µm, C18) (Macherey-Nagel); gradient 37% B for 30 min, 
increasing to 100% B over 20 min; solvent A: methanol/H2O (10/90), solvent B: methanol; 
FR = 20 mL/min, UV detection 210-500 nm]. Compound 34e eluted at 33.5 min (0.8 mg). 
Fraction 9 (314 mg) of the silica gel chromatography was separated by preparative RP-MPLC 
[column 480×30 mm, ODS-AQ, 120 Å, S 16 µm, C-18 (Macherey-Nagel); solvent A:  
H2O/methanol (90/10), solvent B: methanol, gradient: 35% B to 38% B in 3 h, to 100% B in 
30 min, isocratic 30 min; FR = 30 mL/min, UV detection 280 nm). 11 fractions were 
collected and evaporated. The remaining aqueous layers were extracted with ethyl acetate. 
Compound 34f (1.1 mg) eluted at Rt = 185 min. 
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p-Hydroxyacetophenone iso-butanamide (34a): white needles; mp 188°C; analytical TLC: Rf 
= 0.07; UV (methanol): λmax (lg ε) = 202 (4.864), 218 (4.724), 278 (4.893) nm; IR (KBr): ν = 
3356, 3195, 2960, 1649, 1577, 1546, 1245, 1170 cm-1; NMR (CD3OD): Table 10; HRESIMS 
m/z: calcd. for C13H18NO3 236.1281, found: 236.1287. 
p-Hydroxyacetophenone n-butanamide (34b): white needles; mp 184°C; analytical TLC: Rf = 
0.05. UV (methanol): λmax (lg ε) = 201 (4.736), 219 (4.553), 278 (4.721) nm; IR (KBr): ν = 
3358, 3101, 2962, 1633, 1581, 1519, 1243, 1174 cm-1; NMR (CD3OD): Table 11; HRESIMS 
m/z: calcd. for C12H16NO3 222.1125, found 222.1125. 
p-Hyroxyacetophenone acetamide (34c): white needles; mp 187°C; analytical TLC: Rf = 0.02; 
UV (methanol): λmax (lg ε) = 201 (4.363), 219 (4.211), 278 (4.396) nm; IR (KBr): ν = 3344, 
3200, 2931, 1652, 1577, 1548, 1243, 1170 cm-1; NMR (CD3OD): Table 11; HRESIMS m/z: 
calcd. for C10H12NO3 194.0812, found 194.0809. 
p-Hydroxyethenphenyl iso-butanamide (34d): oil; analytical TLC: Rf = 0.24; UV (methanol): 
λmax (lg ε) = 200 (4.330), 219 (4.454), 285 (4.747) nm; IR (KBr): ν = 3289, 3074, 2969, 1670, 
1539, 1228, 1170 cm-1; NMR (CD3OD): Table 12; HRESIMS m/z: calcd. for C13H18NO2 
220.1332, found 220.1331. 
p-Hyrdoxyacetophenone iso-pentanamide (34e): analytical TLC: Rf = 0.07; UV (ethanol) λmax 
(lg ε) = 219 nm (4.228), 279 nm (4.350), 331 nm (3.388); NMR (CD3OD): Table 13; (+)-
HRESIMS m/z: calcd. for C14H20NO3 250.1438, found 250.1447. 
p-Hydroxyacetophenone n-pentanamide (34f): analytical TLC: Rf = 0.09; UV (ethanol): 
λmax (lg ε) = 218 (4.021), 279 (4.111), 331 (3.150) nm; NMR (CD3OD): Table 13; HRESIMS 
m/z: calcd. For C14H20NO3 250.1438, found 250.1447. 
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4.3.3 Biosynthetic Studies of p-Hydroxyacetophenone Amide 34a by Feeding 
Experiments 
Three cultures (100 mL medium described above) were provided with XAD 16 resin (2 mL). 
The cultures were supplemented with [13CH3]-sodium methionine (50 mg, 98%, Cambridge 
Isotope Laboratories), [D10]-leucine (50 mg, 98%, Campro Scientific) or [13C9,15N]-tyrosine 
(50 mg, 98% 13C, 98% 15N, Campro Scientific). The cultures were incubated at 30°C with 
shaking at 180 rpm for 6 days. After sieving off the XAD resin, the resin was eluted with 
acetone (60 mL) for 16 h. The extracts were evaporated and re-dissolved in methanol (1 mL) 
for HPLC-HRESIMS or CD3OD for NMR spectroscopy analysis. 
p-Hydroxyacetophenone iso-butanamide (34a) from feeding [13C9,15N]-tyrosine: 13C NMR 
(CD3OD, 75.5 MHz): δ = 194.6 (m, 1 C, C-7, labelled, calculated 50% incorporation rate (ir)), 
176.0 (m, 0.16 C, C-9, labelled, 8% ir), 176.0 (s, 0.02 C, C-9, unlabelled), 164.2 (m, 0.93 C, 
C-1, labelled), 131.6 (m, 5.33 C, C-3,5, labelled), 128.0 (m, 3.02 C, C-4, labelled), 116.4 (m, 
5.63 C, C-2,6, labelled), 46.5 (m, 3.13 C, C-8,10, labelled), 27.4 (m, 0.86 C, C-11, labelled), 
22.8 (d, J = 34.9, 0.81 C, C-12,13, labelled, 7% ir), 22.8 (s, 0.11 C, C-12,13, unlabelled), % 
13C incorporation = 1.1 × (integrallabelled/integralunlabelled) - 1.1; 1H NMR 
([D3]trifluoroethanol/H2O 1/1, 600MHz): reference spectrum δ = 0.99 (d, J = 6.6 Hz, 6 H, H-
12,13) 2.08 (dq, J = 7.7, 6.6 Hz, 1 H, H-11) 2.23 (d, J = 7.7 Hz, 2 H, H-10) 4.68 (d, J = 5.0 
Hz, 2 H, H-8) 7.00 (d, J = 8.8 Hz, 2 H, H-2,6) 7.56 (t, J = 5.0 Hz, 1 H, N-H) 7.94 (d, J = 8.8 
Hz, 2 H, H-3,5); labelled spectrum δ = 7.00 (d, 8.8 Hz, 3.74 H, H-2,6, unlabelled), 7.00 (dm, J 
= 150 Hz, 3.81 H, H-2,6, labelled, 51% ir), 7.56 (m, 1.0 H, N-H, unlabelled), 7.56 (dm, J = 95 
Hz, 0.42 H, N-H, labelled, 30% ir), 7.94 (d, J = 8.8 Hz, 2.88 H, H-3,5, unlabelled), 7.94 (dm, 
J = 150 Hz, 3.22 H, H-3,5, labelled, 53% ir); (% ir = (integrallabelled/ (integrallabelled + 
integralunlabelled))× 100); (+)-HRESIMS: m/z (%) = 250.1677 (2), 249.1647 (14), 248.1663 
(11), 247.1584 (10), 246.1584 (9), 245.1515 (42), 244.1537 (51), 237.1272 (27), 236.127 
(94), 161.0938 (69), 160.0966 (70), 153.0688 (24), 152.0701 (100%). (% ir = intensitylabelled/ 
(intensitylabelled + intensityunlabelled) × 100) 
p-Hydroxyacetophenone iso-butanamide (34a) from feeding [D10]-leucine: 1H NMR (CD3OD, 
300 MHz): identified signals from the crude extract δ = 1.03 (d, J = 6.4 Hz, 2.2 H, H-12,13), 
4.66 (s, 2.0 H, H-8), 6.91 (d, J = 8.8 Hz, 2.0 H, H-2,6), 7.94 (d, J = 8.8 Hz, 1.9 H, H-3,5); (+)-
HRESIMS: m/z (%) = 245.1834 (100), 236.1268 (53). (% ir = %labelled / (%labelled + %unlabelled) × 
100) 
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4.4 Isolation of Sulfangolids 24a-d 
4.4.1 Isolation of Sulfangolid A (25a) 
Sulfangolid A (25a) was produced by the Sorangium cellulosum strain So ce666 in a 60 L 
fermentor at 30°C containing the following medium: Starch 6 g/L, soybean flour 2 g/L, skim 
milk 1 g/L, casitone 1 g/L, glucose × H2O 1 g/L, CaCl2 × 2 H2O 1 g/L, MgSO4 × 7 H2O 1 g/L, 
Na-Fe-EDTA 8 mg/L at pH 7.4 in the presence of 1 % of adsorber resin Amberlite XAD-16 
and 1-docosanol 55 mg/L. The pH was regulated between pH 7.0 and 7.8. After 14 days of 
cultivation, starch and glucose were used up and the culture broth was passed through a 
process filter to collect the absorber resin. Residual cells were floated from the XAD-16 resin 
with water. The resin was eluted with MeOH/acetone 1/1 (3 L) and acetone (4 L). The organic 
solvents were evaporated and the remaining water/oil mixture (350 mL) was extracted with 
ethyl acetate (5 portions of 500 mL) after addition of saturated NaCl solution (150 mL). The 
ethyl acetate-layer yielded 30.0 g crude extract after evaporation. A MeOH/n-heptane 
partition was carried out to remove 10.9 g lipophilic by-products in the n-heptane layer (4 
portions of 200 mL). The remaining methanol layer was evaporated and dissolved in Et2O 
(200 mL) and 2 M ammonia. The ammonia layer was extracted with Et2O (5 portions of 200 
mL) at 0°C (centrifugation at 0°C, 5 min, 3000 rpm). After evaporation the Et2O-layer yielded 
2.1 g of lipophilic material. The ammonia layer was acidified to pH 4 and extracted with Et2O 
(3 portions of 200 mL) to yield 18.5 g of crude extract after evaporation. The water layer was 
finally extracted with ethyl acetate (3 portions of 250 mL) to give 10.2 g. In order to remove 
format salts this fraction was partitioned between water and DCM to yield 5.3 g in the DCM 
layer. This fraction was purified by RP-MPLC [column 480×30 mm (Kronlab), RP-ODS-AQ 
C18 (Macherey-Nagel), solvent A: H2O/ACN 95/5 + 50 mM/L NH4Ac + 400 µL/L acetic 
acid; solvent B: H2O/ACN 5/95 + 10 mM/L NH4Ac + 80 µL/L acetic acid, gradient: 35% B 
for 20 min, increasing to 40% B in 80 min, maintaining for 60 min, FR = 20 mL/min, UV 
detection 278 nm]. The fractions at Rt = 44 min were combined and neutralized with 2 M 
ammonia before the organic solvent was evaporated. The water layer was passed through a 
strata-X cartridge (0.5 g). After washing with water, the product was eluted from the cartridge 
with methanol to give 74.8 mg of dried material, which was further purified by RP-HPLC 
[column 250×21 mm, 10 µm, C18 RP-Nucleodur 100-EC (Macherey-Nagel), solvent A: 
H2O/ACN 95/5 + 50 mM/L NH4Ac + 400 µL/L acetic acid; solvent B: H2O/ACN 5/95 + 10 
mM/L NH4Ac + 80 µL/L acetic acid, gradient: 35% B for 5 min, increasing to 40% B in 20 
min, maintaining for 40 min, FR = 20.0 mL/min, UV detection 278 nm]. Sulfangolid A (25a) 
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had a Rt = 36 min and yielded 2.8 mg as ammonium salt after work up analogously to the RP-
MPLC chromatography. 
Sulfangolid A (25a): yellowish oil; analytical TLC: DCM/MeOH 8.5/1.5: Rf = 0.16; [α]DRT = 
+ 74.3 (c = 0.7 in methanol); NMR data (1H 600 MHz, 13C 150 MHz, [D6]DMSO): Table 15; 
UV/Vis (methanol): λmax (lg ε) = 283 (4.462), 342 nm (4.435); IR (KBr): ν = 3431 (b, s), 2958 
(m), 2932 (m), 1704 (s), 1624 (m), 1252 (s), 1011 (s) cm-1; MS (DCI): reactant gas ammonia, 
m/z (%): 548 (25), 566 (100), 567 (35), 568 (10), 584 (15); HRESIMS m/z: for C35H51O10S 
calcd. 663.3208; found 663.3206. 
4.4.2 Isolation of Sulfangolid B (25b)  
Sulfangolid B (25b) was produced by strain So ce192 in a 100 L fermentor at 30°C in a 
medium consisting of starch 8 g/L, soybean meal 2 g/L, yeast extract 2 g/L, glucose × 2 H2O 
2 g/L, CaCl2× 2 H2O 1 g/L, MgSO4 × 7 H2O 1 g/L, Na-Fe-EDTA 8 mg/L at pH 7.4 in the 
presence of 2% Amberlite XAD-16 and 10 mL of tegosipon antifoam. The pH was regulated 
analogue to the sulfangolid A (25a) production. After 7 days of cultivation the culture broth 
was passed through a process filter to collect the absorber resin. Residual cells were floated 
from XAD-16 resin with water. The resin was eluted with MeOH/H2O 6/4 and MeOH (each 5 
L). The methanol layer was evaporated in vacuo to give 22.0 g of crude extract. Lipophilic 
by-products were removed by MeOH/n-heptane partition to give 20.0 g MeOH extract and 
1.0 g of by-products. The methanol extract was dissolved in DCM and filtered over celite 
before silica-gel-flash chromatography (column 80 mL). The silica gel chromatography was 
eluted step wise with DCM (yield 9.0 g), DCM/MeOH 19/1 (yield 6.65 g), DCM/MeOH 9/1 
(yield 0.72 g) and finally with MeOH (yield 0.22 g) (500 mL of each solvent). The 
DCM/MeOH 9/1 extract was further purified by silica-flash chromatography [column 37×420 
mm HD-Sil 15µ, 60Å (Macherey-Nagel), gradient: 10 min with petroleum ether/DCM/MeOH 
50/48/2, increasing the MeOH proportion to 4% in 120 min, maintaining 4% for 30 min, 
increasing to 5% MeOH in 30 min, maintaining 5% for 30 min, rinsing the column with 
DCM/MeOH 7/3, FR = 35 mL/min, UV detection 278 nm]. The sulfangolid B (25b) 
containing fraction had a Rt of 124 min and a dry weight of 114 mg after evaporation. This 
fraction was further purified by RP-HPLC chromatography [column 20.5×250 mm Nucleosil 
100-7 C18 (Macherey-Nagel), 65% MeOH isocratic, FR = 18 mL/min, UV detection 278 
nm]. Sulfangolid B (25b) (8 mg) was isolated at Rt = 11 min. 
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Sulfangolid B (25b): yellowish oil, analytical TLC: DCM/MeOH 8.5/1.5: Rf = 0.16; NMR 
data (1H 600 MHz, 13C 150 MHz, CD3OD): Table 16; HRESIMS m/z: calcd. for C36H53O11S 
693.3314, found 693.3308. 
4.4.3 Isolation of Sulfangolid C (25c)  
Sulfangolid C (25c) was produced by Sorangium cellulosum strain So ce12 in the same 
medium as So ce192, supplemented with fructose 1 g/L and KNO3 1 g/L. Two fermentors 
with 70 L media each were performed. They were supplemented with 1% of adsorber resin 
XAD-16 and 100 mg/L 1-docosanol. The pH was regulated between pH 7.0 and 7.8. After 9 
days the culture broths were passed through a process filters. Residual cells of the combined 
XAD-16 resin were floated with water. The absorber resin was then eluted with MeOH/H2O 
1/1 (3.5 L) and MeOH (4.5 L). The organic solvent was evaporated from the layers in vacuo 
and the water layers of each fraction were extracted with ethyl acetate (5 portions of 250 mL) 
after addition of saturated NaCl solution (150 mL). The layers were combined and the solvent 
was evaporated in vacuo to give 33.8 g of crude extract. Lipophilic by-products were 
extracted by MeOH/n-heptane partition to yield 22.5 g methanol extract and 1.8 g n-heptane 
extract. The methanol extract was dissolved in Et2O (250 mL) and 2 M ammonia (125 mL). 
The Et2O-layer was extracted with 2 M ammonia (3 portions of 300 mL). The Et2O-layer 
yielded 11.8 g non-polar compounds. The combined ammonia layers were neutralized with 
formic acid to pH 7 and then extracted with Et2O (3 portions of 300 mL), yielding 6.2 g 
residue after evaporation. The water layer was further extracted with ethyl acetate (3 portions 
of 300 mL), yielding 5.9 g of enriched sulfangolid C (25c). This crude extract was dissolved 
in Et2O and H2O and acidified with formic acid to pH 4 to be extracted with Et2O (3 portions 
of 150 mL) at 0°C (centrifugation at 0°C, 8 min, 3000 rpm), yielding 2.6 g of the enriched 
carboxylic acid sorangicin A (13). The water layer was neutralized with 2M ammonia and 
extracted with ethyl acetate (3 portions of 200 mL) under the addition of saturated NaCl 
solution (80 mL). The ethyl acetate extract was evaporated in vacuo to yield 1.4 g enriched 
sulfangolid C (25c). This fraction was further purified by LH-20 chromatography (50×1000 
mm column, solvent: MeOH, FR = 4.0 mL/min, UV detection 278 nm) in 3 batches. The 
fractions were combined according to the UV-chromatogram and fraction 7 at Rt = 560 min 
with 85 mg product contained the highest concentration of sulfangolid C (25c). This fraction 
was further purified by RP-HPLC in three batches [column 250×21 mm, 10 µm, C18 RP-
Nucleodur 100-EC (Macherey-Nagel), solvent A: H2O/ACN 95/5 + 50 mM/L NH4Ac + 400 
µL/L acetic acid; solvent B: H2O/ACN 5/95 + 10 mM/L NH4Ac + 80 µL/L acetic acid, 
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gradient: 25% B maintaining for 15 min, increasing to 50% B in 90 min, maintaining 15 min, 
FR = 20.0 mL/min, UV detection 278 nm]. The UV peak at Rt = 81 min was neutralized with 
2 M ammonia, the organic solvent was evaporated and the water layer passed through a strata-
X cartridge (0.5 g, Phenomenex). After washing with water the compound was eluted from 
the cartridge with methanol to yield 29.6 mg. Sulfangolid C (25c) was further purified by RP-
HPLC [column 250×21 mm, 10 µm, C18 RP-Nucleodur 100-EC (Macherey-Nagel), solvent 
A: H2O/ACN 95/5 + 50 mM/L NH4Ac + 400 µL/L acetic acid; solvent B: H2O/ACN 5/95 + 
10 mM/L NH4Ac + 80 µL/L acetic acid, gradient: 30% B maintaining for 5 min, increasing to 
40% B in 40 min, maintaining at 40% B for 20 min, FR = 20 mL/min, UV detection 278 nm]. 
Sulfangolid C (25c) had a Rt = 17 min and yielded 17.7 mg of the ammonium salt after work 
up by strata-X cartridge (1.0 g). 
Sulfangolid C (25c): yellowish oil; analytical TLC: DCM/MeOH 8.5/1.5, Rf = 0.15; [α]DRT = 
+ 153.3 (c = 0.5 in methanol); NMR data (1H 600 MHz, 13C 150 MHz, [D6]DMSO): Table 
17; UV/Vis (methanol): λmax (lg ε) = 288 nm (4.446); IR (KBr): ν = 3421 (b, s), 2957 (s), 
2931 (s), 1705 (s), 1616 (m), 1255 (s), 1006 (s) cm-1; HRESIMS m/z: calcd. for C35H53O11S 
681.3314, found 681.3317. 
4.4.4 Isolation of Sulfangolid D (25d)  
Sulfangolid D (25d) was produced by Sorangium cellulosum, strain So ce1375, in a 70 L 
fermentor at 30°C with medium consisting of soybean meal 5 g/L, glucose × H2O 1 g/L, 
starch 10 g/L, CaCl2 × 2 H2O 1 g/L, MgSO4 × 7 H2O 1 g/L, NaNO3 80 mg/L and Na-Fe-
EDTA 8 mg/L at pH 7.2. The fermentor was additionally supplemented with 0.1% of 
Amberlite XAD-16 resin and 100 mg/L 1-docosanol. The pH was regulated as described 
above. After 10 days the resin was collected by sieving in a process filter. The recovered 
XAD resin containing residual cells (3.25 kg) was stirred for 1 h in methanol (15 L) before 
the organic solvent was passed through a celite filter. The organic solvent was evaporated and 
the water was extracted with ethyl acetate to yield 21.5 g of crude extract, which was 
dissolved in methanol and partitioned between methanol and n-heptane to remove 8.7 g 
lipophilic by-products. The methanol layer yielded 12.1 g after evaporation. The methanol 
extract was separated by silica gel chromatography (1.2 L silica gel 60 (Merck)) and stepwise 
eluted with DCM (2 L), DCM + 10% methanol (2.5 L) and DCM + 20% methanol. 
Sulfangolid D (25d) eluted in the last fraction to give 1.6 g of residue after evaporation. The 
extract was further purified by silica gel MPLC in two batches [column 500×70 mm HD-Sil 
18-20-60, MeOH/H2O (85/15) supplemented with 50 mM/L NH4Ac, FR = 8 mL/min, UV 
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detection 365 nm]. Sulfangolid A (25a) was recovered at Rt = 105 min (yield 566 mg) and 
Sulfangolid D (25d) at Rt = 210 min (yield 281 mg) as ammonium salts. 
Sulfangolid D (25d): yellowish oil; TLC: DCM/MeOH (85/15): Rf = 0.27; NMR data (1H 300 
MHz, 13C 75 MHz, CD3OD): Table 18; UV/Vis (methanol): λmax (lg ε) = 237 (3.954), 339 nm 
(5.741); IR (KBr): ν = 3447 (b, s), 2959 (s), 2935 (s), 1704 (s), 1617 (m), 1597 (s), 1457 (m), 
1256 (s), 1227 (s), 1165 (m), 1124 (m), 1079 (m), 1045 (m), 1008 (s), 980 (m), 922 (m) cm-1; 
HRESIMS m/z: calcd. for C36H53O10S 677.3365, found 677.3343. 
4.4.5 Fermentation of So ce757 for the Production Kinetics of Sulfangolid C (25c) 
Sorangium cellulosum strain So ce757 inoculated a 70 L fermentor at 30°C containing the 
following medium: starch 10 g/L, soybean meal 2 g/L, skim milk 2 g/L, glycerine (87%) 1 
g/L, CaCl2 × 2 H2O 1 g/L, MgSO4 × 7 H2O 1 g/L, glucose × 2 H2O 0.5 g/L, Na-Fe-EDTA 8 
mg/L at pH 7.8, supplemented with 1% Amberlite XAD-16. The pH was regulated between 
pH 7.0 and 7.8. A sample of about 100 mL culture was taken on day 2, 4, 6, 7, 8 and 9, the 
glucose concentration of the supernatant was tested with Diabur-Test 5000 (Roche), the 
XAD-16 was eluted twice with methanol and twice with acetone. The organic layers of each 
sample were combined and the solvent evaporated. The residue was concentrated 1:100 and 
analysed for the sulfangolid C (25c) concentration by HPLC. The XAD-resin was harvested 
on day 9 of cultivation. 
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4.4.6 Biosynthetic Studies of Sulfangolid C (25c) by Feeding Experiments  
Sorangium cellulosum strain So ce757 producing 19 mg/L sulfangolid C (25c) was used in the 
feeding experiments with the following medium: starch 10 g/L, soybean meal 2 g/L, milk 
powder 2 g/L, glycerine 87% 1 g/L, CaCl2× 2 H2O 1 g/L, MgSO4 × 7 H2O 1 g/L, glucose × 
H2O 0.5 g/L, Na-Fe-EDTA 8 mg/L at pH 7.8 and Amberlite XAD 16 resin 10 g/L. For the 
13C-labelled acetate and [D10]-leucine 4 Erlenmeyer flasks with 350 mL medium and for 
propionate a 700 mL culture were provided. As the strain grew in lumps, start of the 
cultivation with an exact inoculum was not possible. Alternatively, the kinetic of the 
production was correlated with the glucose content of the medium. Feeding was started with 
the beginning of the production at a glucose concentration of 0.25%. During 4 days the 
precursors were added in equal portions with a final amount of 252 mg [1-13C]-sodium acetate 
(99%), 251 mg of [2-13C-D3]-sodium acetate (99%, 98%), 250 mg [1,2-13C]-sodium acetate 
(99%), 504 mg [1-13C]-sodium propionate (97%) (Cambridge Isotope Laboratories) and 253 
mg [D10]-leucine (98%, Campro Scientific, under the addition of HCl). The XAD resin of 
each culture was harvested after starch and glucose consumption by sieving and then eluted 
with methanol and acetone. The extracts of each experiment were combined and partitioned 
between methanol and n-heptane. The methanol layers were further purified by RP-HPLC 
[column 250×21 mm, 10 µm, C18 RP–Nucleodur 100-EC (Macherey-Nagel), solvent A: 95/5 
H2O/ACN + 50 mM/L + 400 µL/L acetic acid, solvent B: 5/95 H2O/ACN + 10 mM/L + 80 
µL/L acetic acid, gradient: 10% B in 60 min to 65% B, FR = 20 mL/min, UV detection 287 
nm] and 3 was recovered at a Rt = 45 min. After evaporation of the organic solvent the water 
layers were extracted with ethyl acetate. Yields: [1-13C]-acetate labelled 25c 5.4 mg, [2-13C-
D3]-acetate labelled 25c 2.6 mg, [1,2-13C]-acetate labelled 25c 3.6 mg, [1-13C]-propionate 
labelled 25c 7.3 mg and [D10]-leucine labelled 25c 9.5 mg. The summarized NMR data are 
presented in Table 21. In addition, strain So ce757 was transferred to an analogous but 
sulfate-free medium and the sulfangolid C (25c) production decreased from 19 mg/L to 2 
mg/L after two passages. 
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6 Appendix 
6.1 Author´s Effort in Publication 
Roimatacene, a Polyunsaturated Carboxylic Acid from Cystobacter ferrugineus Cb G35 
WZ monitored the production of roimatacene (26) during all fermentations, developed the 
isolation strategie, as well as planed and carried out all derivatization experiments. The 
molecular modelling was done by R. Jansen, while the complete structure elucidation and the 
comparison of the modelling results were done by WZ. The feeding experiments were done 
by K. I. Mohr, while the isolation and analyses was done by WZ. The antimicrobial screening 
was conducted by K. I. Mohr and the proliferation assays in the lab of Florenz Sasse. WZ 
wrote the manuscript. 
Six p-Hydroxyacetophenone Amides from Cystobacter ferrugineus Cb G35 
The secondary metabolite production during fermentation was monitored by WZ. The 
isolation and the structure elucidation, as well as planning and analysing the feeding 
experiments were done by the author. WZ wrote the manuscript. 
Sulfangolids, Macrolide Sulfate Esters from Sorangium cellulosum 
The fermentation of strain So ce666 (sulfangolid A), So ce192 (sulfangolid B) and So ce12 
(sulfangolid C) were done by H. Irschik. The fermentation of So ce1375 was carried out by K. 
Gerth. The isolation of sulfangolid B was done by R. Jansen and of sulfangolid D by M. 
Herrmann. The isolation of sulfangolid A and C as it is presented here and in the manuscript 
was planned by R. Jansen and carried out by WZ during the Diploma Thesis. The verification 
of the proposed structures of 25a-d by NMR data and the presented NMR tables were done by 
the author. The relative configuration was done by WZ and extensively discussed with R. 
Jansen. The molecular modelling was done by R. Jansen. The feeding experiments were 
carried out and analysed by WZ. The manuscript was written by WZ. 
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6.2 Spectra 
6.2.1 Spectra of Roimatacene (26) 
 
 
Spectrum 1:   UV spectrum of roimatacene (26) in methanol (c = 0.5 mg/100 mL). 
 
Spectrum 2:   1H NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 3:   13C NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 4:   13C DEPT NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 5:   13C DEPT NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 6:   1H,13C HMQC NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 7:   1H,1H COSY NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 8:   1H,13C HMBC NMR spectrum of roimatacene (26) (1H 600MHz, 13C 150 MHz, [D6]DMSO). 
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Spectrum 9:   1H NMR spectrum of roimatacene (26) after H/D exchange (1H 600 MHz,13C 150 MHz, 
[D6]DMSO).  
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Spectrum 10:  13C NMR spectrum of roimatacene (26) after H/D exchange (13C 150 MHz, [D6]DMSO).  
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Spectrum 11:   13C DEPT NMR spectrum of roimatacene (26) after H/D exchange (13C 150 MHz, 
[D6]DMSO).  
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Spectrum 12:   13C DEPT NMR spectrum of roimatacene (26) after H/D exchange (13C 150 MHz, 
[D6]DMSO).  
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Spectrum 13:   13C APT spectrum of roimatacene (26) after H/D exchange (13C 100 MHz, [D6]DMSO). 
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Spectrum 14:   1H,13C HSQC NMR spectrum of roimatacene (26) after H/D exchange (1H 600 MHz,13C 150 
MHz, [D6]DMSO). 
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Spectrum 15:   1H,13C HMBC NMR spectrum of roimatacene (26) after H/D exchange (1H 600 MHz,13C 150 
MHz, [D6]DMSO). 
HMBC-roimataceneDMSOH2O.esp
6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
F2 Chemical  Shift (ppm )
8
16
24
32
40
48
56
64
72
80
88
96
104
112
120
128
136
144
152
160
168
F1
 
Ch
em
ic
al
 
Sh
ift
 
(pp
m
)
Appendix 
- 115 - 
 
Spectrum 16.   HPLC-HRESIMS chromatogram of the supernatant of the E. coli tolC MIC dilution assay after 
incubation, the supernatant was centrifuged (5 min, 3000 g) and 5 µL were analyzed. The peak 
at 10.3 min showed the roimatacene (26) characteristic chromophore and the mass spectrum 
represented the molecular ion of [M+Na]+ (calc. 539.2979). 
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6.2.2 Spectra of p-Hydroxyacetophenones (34a-f) 
 
Spectrum 17:   UV spectrum of p-hydroxyacetophenone iso-butanamide (34a) in methanol (c = 0.5 mg/100 
mL). 
 
Spectrum 18:   UV spectrum of p-hydroxyethenphenyl-iso-butanamide (34d) in methanol (c = 1 mg/100mL). 
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Spectrum 19:  IR spectrum of compound p-hydroxyacetophenone iso-butanamide (34a) (0.5 mg, KBr). 
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Spectrum 20:   1H NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (1H 400 MHz, CD3OD). 
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Spectrum 21:   13C NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (13C 100 MHz, CD3OD). 
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Spectrum 22:   DEPT NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (1H 400 MHz, 13C 100 
MHz, CD3OD). 
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Spectrum 23:   1H,13C HMQC NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 24:   1H,1H COSY NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 25:   1H,13C HMBC NMR spectrum of p-hydroxyacetophenone iso-butanamide (34a) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 26:   1H NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (1H 300 MHz, CD3OD). 
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Spectrum 27:   13C NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (13C 75 MHz, CD3OD). 
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Spectrum 28:   13DEPT NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (1H 300 MHz, 13C 75 
MHz, CD3OD). 
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Spectrum 29:   1H,13C HMQC NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (1H 300 MHz, 
13C 75 MHz, CD3OD). 
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Spectrum 30:   1H,1H COSY NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (1H 300 MHz, 
13C 75 MHz, CD3OD). 
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Spectrum 31:   1H,13C HMBC NMR spectrum of p-hydroxyacetophenone n-butanamide (34b) (1H 300 MHz, 
13C 75 MHz, CD3OD). 
Appendix 
- 127 - 
1H-cb83.2-MICZ4637.esp
8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical  Shift (ppm)
3.006.152.026.222.032.06
METHANOL-d4
7.
91 7
.
88
6.
88 6.
85
4.
84
4.
62
3.
32
3.
32
3.
31
3.
30
3.
30
2.
05
 
Spectrum 32:   1H NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 75 MHz, 
CD3OD). 
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Spectrum 33:   13C NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 75 MHz, 
CD3OD). 
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Spectrum 34:   13C DEPT NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 75 
MHz, CD3OD). 
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Spectrum 35:   1H,13C HMQC NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 
75 MHz, CD3OD). 
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Spectrum 36:   1H,1H COSY NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 
75 MHz, CD3OD). 
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Spectrum 37:   1H,13C HMBC NMR spectrum of p-hydroxyacetophenone acetamide (34c) (1H 300 MHz, 13C 
75 MHz, CD3OD). 
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Spectrum 38:   1H NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 13C 100 
MHz, CD3OD). 
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Spectrum 39:   13C NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 13C 100 
MHz, CD3OD). 
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Spectrum 40:   13C DEPT NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 13C 
100 MHz, CD3OD). 
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Spectrum 41:   1H,13C HMQC NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 42:   1H,1H COSY NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 43:   1H,13C HMBC NMR spectrum of p-hydroxyethenphenyl iso-butanamide (34d) (1H 400 MHz, 
13C 100 MHz, CD3OD). 
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Spectrum 44:   1H NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 MHz, 13C 
150 MHz, CD3OD). 
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Spectrum 45:   13C NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 MHz, 13C 
150 MHz, CD3OD). 
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Spectrum 46:   13C DEPT NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 MHz, 
13C 150 MHz, CD3OD). 
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Spectrum 47:   1H,13C HMQC NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 
MHz, 13C 150 MHz, CD3OD). 
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Spectrum 48:   1H,1H COSY NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 MHz, 
13C 150 MHz, CD3OD). 
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Spectrum 49:   1H,13C HMBC NMR spectrum of p-hydroxyacetophenone iso-pentanamide (34e) (1H 600 
MHz, 13C 150 MHz, CD3OD). 
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Spectrum 50:   1H NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 13C 150 
MHz, CD3OD). 
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Spectrum 51:   13C NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 13C 150 
MHz, CD3OD). 
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Spectrum 52:   13C DEPT NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 13C 
150 MHz, CD3OD). 
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Spectrum 53:   1H,13C HMQC NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 
13C 150 MHz, CD3OD). 
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Spectrum 54:   1H,1H COSY NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 
13C 150 MHz, CD3OD). 
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Spectrum 55:   1H,13C HMBC NMR spectrum of p-hydroxyacetophenone n-pentanamide (34f) (1H 600 MHz, 
13C 150 MHz, CD3OD). 
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Spectrum 56:   Comparison of 1H NMR signals of 34a unlabeled (above) and [13C,15N]-tyrosine labelled 
(below) (1H 600 MHz, TFE/H2O). 
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Spectrum 57:   13C NMR spectrum of [13C9,15N]- tyrosine labelled 34a (13C 75.5 MHz, CD3OD). 
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Spectrum 58:   1H NMR spectrum of [D10]-leucine labelled 34a in the crude extract (1H 300 MHz, CD3OD). 
 
 
Spectrum 59:   UV and HRESIMS spectrum of [D10]-leucine labelled 34a. 
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Spectrum 60:  UV and HRESIMS spectrum of [13C9,15N]-tyrosine labelled 34a. 
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6.2.3 Spectra of Sulfangolids 25a-d 
 
Spectrum 61:   UV-spectrum of sulfangolid A (25a) in methanol (2 mg/100 mL). 
 
 
Spectrum 62:   IR spectrum of sulfangolid A (25a) (KBr). 
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Spectrum 63:  UV spectrum of sulfangolid C (25c) in methanol (2mg/100 mL). 
 
 
Spectrum 64:   IR spectrum of sulfangolid C (25c) (KBr). 
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Spectrum 65:   UV spectrum from sulfangolid D (25d) in methanol. 
 
 
 
Spectrum 66:   IR spectrum from sulfangolid D (25d) (KBr). 
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Spectrum 67:   1H NMR spectrum of sulfangolid A (25a) (600 MHz, [D6]DMSO). 
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Spectrum 68:   1H NMR spectrum of sulfangolid A (25a) (600 MHz, [D6]DMSO after H/D exchange). 
Appendix 
- 154 - 
 
Spectrum 69:   simulated 1H NMR spectrum of sulfangolid A (25a) with ACD 11. 
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Spectrum 70:   13C NMR spectrum of sulfangolid A (25a) (13C 75 MHz, [D6]DMSO). 
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Spectrum 71:   13C DEPT NMR spectrum of sulfangolid A (25a) (13C 75 MHz, [D6]DMSO). 
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Spectrum 72:   1H,1H COSY NMR spectrum of sulfangolid A (25a) (1H 600 MHz, [D6]DMSO). 
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Spectrum 73:   1H,13C HSQC NMR spectrum of sulfangolid A (25a) (1H 600 MHz, 13C 150 MHz, 
[D6]DMSO). 
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Spectrum 74:   1H,13C HMBC NMR spectrum of sulfangolid A (25a) (1H 600 MHz, 13C 150 MHz, 
[D6]DMSO). 
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Spectrum 75:   1H,1H ROESY NMR spectrum of sulfangolid A (25a) (1H 600 MHz, [D6]DMSO). 
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Spectrum 76:   J-resolved NMR spectrum of sulfangolid A (25a) (1H 600 MHz, [D6]DMSO). 
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Spectrum 77:   1H NMR spectrum of sulfangolid B (25b) from 9.0 to 4.5 ppm (1H 600 MHz, CD3OD). 
 
Spectrum 78:  1H NMR spectrum of sulfangolid B (25b) 4.0 to 0.0 ppm (1H 600 MHz, CD3OD). 
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Spectrum 79:   13C NMR spectrum of sulfangolid B (25b) (13C 150 MHz, CD3OD). 
 
Spectrum 80:   13C- DEPT spectrum of sulfangolid B (25b) (150 MHz, CD3OD). 
Appendix 
- 163 - 
 
Spectrum 81:   Basic-HMQC spectrum of sulfangolid B (25b) (1H 600 MHz, 13C 150 MHz, CD3OD). 
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Spectrum 82:   1H,1H COSY spectrum of sulfangolid B (25b) (1H 600 MHz, CD3OD). 
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Spectrum 83:  1H,13C HMBC of sulfangolid B (25b) (1H 600 MHz; 13C 150 MHz, CD3OD).  
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Spectrum 84:   1H NMR spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO). 
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Spectrum 85:   1H NMR spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO after H/D exchange). 
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Spectrum 86:   13C NMR spectrum of sulfangolid C (25c) (13C 150 MHz, [D6]DMSO). 
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Spectrum 87:  1H,13C HSQC NMR spectrum of sulfangolid C (25c) (1H 600 MHz, 13C 150 MHz, 
[D6]DMSO). 
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Spectrum 88:   1H,1H COSY NMR spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO after H/D-
exchange). 
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Spectrum 89:   1H,13C HMBC NMR spectrum of sulfangolid C (25c) (1H 600 MHz, 13C 150 MHz, 
[D6]DMSO). 
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Spectrum 90:   1H,1H ROESY NMR spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO). 
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Spectrum 91:   J-resolved NMR spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO after H/D 
exchange). 
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Spectrum 92:   Partial view of J-resolved spectrum of sulfangolid C (25c) (1H 600 MHz, [D6]DMSO after H/D 
exchange). 
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Spectrum 93: 1H NMR spectrum of sulfangolid D (25d) (1H 300 MHz, CD3OD). 
 
13C-1375.444-HKAZ7032.esp
216 208 200 192 184 176 168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32 24 16 8
Chemical Shift (ppm)
METHANOL-d4
13
.
21
13
.
70
15
.
39
16
.
36
16
.
65
16
.
84
21
.
932
4.
10
26
.
10
28
.
68
30
.
54
30
.
83
34
.
19
36
.
17
37
.
44
40
.
30
47
.
17
72
.
53
76
.
61
77
.
14
78
.
98
80
.
61
83
.
09
10
3.
18
12
0.
85
12
1.
53
12
4.
08
12
7.
98
13
0.
45
13
1.
10
13
2.
94
13
3.
52
13
6.
15
13
6.
33
13
9.
19
14
0.
24
14
3.
32
14
4.
16
14
7.
00
14
7.
40
14
8.
72
16
8.
29
21
8.
29
 
Spectrum 94:  13C NMR spectrum of sulfangolid D (25d) (13C 75 MHz, CD3OD). 
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Spectrum 95:  13C DEPT NMR spectrum of sulfangolid D (25d) (13C 75 MHz, CD3OD). 
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Spectrum 96:   1H,13C HSQC spectrum of sulfangolid D (25d) (1H 300 MHz, 13C 75 MHz, CD3OD). 
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Spectrum 97:   1H,1H COSY spectrum of sulfangolid D (25d) (1H 300 MHz, CD3OD). 
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Spectrum 98:   1H,13C HMBC spectrum of sulfangolid D (25d) (1H 300 MHz, 13C 75 MHz, CD3OD). 
